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Abstract 
An active and co-ordinated immune response is required to protect the body from pathogens. 
However, an over-reactive, unregulated immune response can lead to a break down in self-
tolerance, which may lead to autoimmunity. Regulation of the immune response is therefore 
necessary to prevent a potentially devastating attack on self. On the other hand, excessive immune 
regulation can lead to the escape of pathogens and tumours from an effective immune attack. 
Control of immune regulation therefore needs to be balanced. 
 
Exposure to the ultraviolet (UV) component of sunlight suppresses the immune response. This so 
called “UV-immunosuppression” is a major contributor to skin carcinogenesis, but is also 
responsible for protecting the host from autoimmune disease, particularly multiple sclerosis (MS). 
Understanding the cellular and molecular mechanisms underlying UV-immunosuppression is 
therefore critical if we are to combat skin cancer, and develop new treatment options for MS 
patients. 
 
A major way in which UV suppresses immunity is via the activation of regulatory cells, with 
dermal mast cells and regulatory B cells playing a particularly important role. Indeed, following UV 
exposure to the skin, dermal mast cells encounter an IL-4-rich cutaneous environment and become 
activated. Within 24 hours, these IL-4-exposed mast cells are recruited to the skin-draining lymph 
nodes, where they preferentially home to B cell follicles. As UV is capable of activating a subset of 
regulatory B cells within skin-draining lymph nodes, my overall hypothesis is that the mast cells are 
capable of activating B cells to assume a regulatory phenotype. To that end, our laboratory has 
previously found mast cells treated with IL-4 in vitro to be capable of activating functionally 
suppressive B cells. Importantly, these mast cell-activated B cells had a similar phenotype to those 
B cells activated by UV in vivo. Subsequent investigations during my Honours found microvesicles 
from IL-4-treated mast cells were also capable of activating B cells. The data presented in this 
 XXXI 
thesis will reveal some of the ways in which mast cells are activating B cells; the potential 
mechanism by which these B cells suppress immunity; and that a similar event occurs in humans. 
 
Intracellular flow cytometry showed that IL-4-treated mast cells had upregulated IL-13 and EBI3 (a 
subunit which combines with p35 to form IL-35), as well as increased IL-10 and p35 after co-
culture with B cells. The fact that mast cells were being further influenced by B cells after co-
culture was surprising and suggested that a cross talk was occurring between these two cells. 
Contrary to my initial hypothesis, B cells did not show any mast cell-induced change in IL-10 or 
IL-13 production after co-culture. However, microvesicle-activated B cells were capable of 
suppressing a contact hypersensitivity response, possibly because these B cells are interacting with 
other, as yet unidentified mast cells in vivo. Furthermore, these microvesicle-activated B cells were 
capable of promoting mast cell production of IL-13, further suggesting an important cross talk 
occurs between mast cells and B cells to induce immune suppression. 
 
I also developed and deployed a similar assay to study human mast cell-B cell interactions. Mast 
cells were grown from CD34+ human peripheral blood stem cells and stimulated with IL-4 before 
co-culturing with autologous CD19-enriched B cells. Since there are no gold standard markers for 
regulatory B cells, I used mass cytometry to investigate up to 35 markers in a single panel. This in-
depth analysis provided evidence that IL-4-treated mast cells (and their microvesicles) 
preferentially targeted CD23+ CD38+/hi IgMhi transitional B cells, and promoted an 
immunoregulatory phenotype, including IL-10 production. Although there were upregulation of 
many activation markers which could be associated with immune suppression (including CD25 and 
CD274), these B cells were not able to inhibit bead-stimulated T cell proliferation. In fact, mast 
cell-activated B cells increased T cell proliferation. Despite this, an ELISA found IL-10 to be 
increased in the culture supernatant but only when microvesicle-activated B cells were co-cultured 
with T cells and mast cells, and not in the absence of mast cells. This further suggests that B cells 
require both mast cells and microvesicles to have a functional influence on T cells. 
 XXXII 
In conclusion, the results presented in this thesis demonstrate the ability of mast cells and their 
microvesicles to activate regulatory B cells. These B cells in turn enhance mast cell cytokine 
production. This may explain why, in mice, the migration of UV-activated dermal mast cells into 
the B cell follicles of skin-draining lymph nodes is critical in UV-immunosuppression. Whilst this 
phenomenon remains to be assessed in humans, these data highlight that human mast cells are also 
capable of activating B cells into a regulatory phenotype. Further investigations into how these 
B cells may be functionally suppressive in vivo will be important. This study has provided further 
insight into mast cell-B cell interactions, and their importance in regulating the immune response. 
This has great implications in the study of autoimmune disease and carcinogenesis. 
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Chapter 1 
 
INTRODUCTION 
 
 
 
Not all journeys have a defined start: you can’t always 
tell when it really began. This was the case for Josephine. It 
wasn’t clear how she got to where she was, but the bright 
white room with a giant creature looming over her triggered 
her primal instincts, with one clear message: Get out of here… 
 
  
 2 
Chapter 1: Introduction 
1.1 Immune suppression and regulation 
The immune system is a key driving force that defends our body from external foreign pathogens, 
as well as protecting us from ourselves. Pathogens use a multitude of mechanisms to suppress the 
immune system, allowing them to grow in our bodies. Many cancers develop evasive techniques to 
likewise proliferate and metastasise throughout the body. On the other hand, autoimmune diseases – 
where our immune system attacks our self – may arise when the immune system is not correctly 
regulated. For these reasons it is important to understand how the immune system may be regulated, 
so we may activate (during infections or cancers) or inhibit (during autoimmune diseases) the 
immune response. 
 
1.1.1 Ultraviolet (UV)-induced immune suppression 
The ultraviolet (UV) spectrum of sunlight includes two major wavebands: UVA (320-400 nm); and 
the shorter, more energetic UVB wavelengths (290-320 nm). UV is best known for its ability to 
cause skin cancer, in part through DNA damage (Agar et al., 2004). However, this carcinogenic 
effect is promoted through the suppression of the host anti-tumour immune response (Fisher and 
Kripke, 1977), in both mice (Byrne et al., 2002) and humans (Damian et al., 1999). This greatly 
affects the adaptive immune response, whereby there is suppression of the induction, effector and 
memory phases of CD8+ cytotoxic lymphocyte (CTL) responses (Rana et al., 2011), as well as 
CD4+ T helper cell (Th) type 1 (Th1) (Brown et al., 1995), Th2 (McGlade et al., 2007), Th17 
(Singh et al., 2010) and T follicular helper cell (Chacon-Salinas et al., 2011) responses. This makes 
solar UV an important ubiquitous carcinogen. 
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Although UV-induced immune suppression contributes to skin cancer, it may also play an 
important role in protection from autoimmunity. Autoimmune diseases are caused by a breakdown 
in self-tolerance, leading to an attack by the host’s immune cells against said host. Many 
autoimmune diseases have been identified, with both genetic and environmental factors 
contributing to the risk of development. To that end, a greater level of UV exposure from sunlight 
decreases the risk of developing a number of autoimmune diseases. This includes type I diabetes 
(Mohr et al., 2008), Sjögren’s syndrome (Shapira et al., 2010b), Crohn’s disease (Armitage et al., 
2004), as well as multiple sclerosis (Acheson et al., 1960, McMichael and Hall, 1997, van der Mei 
et al., 2003). 
 
1.1.2 Autoimmune diseases 
1.1.2.1 Multiple sclerosis (MS) 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), whereby 
destruction of myelin proteins occurs. The resulting inflammation and interference to nerve 
impulses severely impacts both physical (paralysis, fatigue, loss of hand-eye coordination) and 
mental (mood swings, short-term memory loss) parameters (MS Australia, 2012). With more than 
2,500,000 cases worldwide, and 23,000 Australians currently suffering from MS (MS Australia, 
2012), there is much interest in developing new treatment options. 
 
As mentioned, UV suppresses cell-mediated immune responses. This is of importance, as the 
International Multiple Sclerosis Genetics Consortium showed MS is primarily caused by a 
breakdown in the cell-mediated response (Sawcer et al., 2011), and higher levels of autoantibody-
producing B cells reactive to intracellular antigens are found in patients suffering from MS 
(Fraussen et al., 2013). It was Acheson et al. (1960) who first suggested UV decreased the risk of 
developing MS, with similar results observed in those with high levels of vitamin D (Munger et al., 
2006). McMichael and Hall (1997) showed that Australians living in Tasmania have a 6-fold 
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increase in the occurrence of MS compared to those living in North Queensland. This latitude 
effect, whereby populations closer to the equator have a decreased risk of developing MS, has been 
found in both the northern and southern hemispheres, including Scotland (Handel et al., 2011), 
Sweden (Ahlgren et al., 2011), Latin America (Risco et al., 2011), North America (Beretich and 
Beretich, 2009), USA (Noonan et al., 2010), Canada (Sloka et al., 2008), Ireland (McGuigan et al., 
2004), Sardinia (Rosati et al., 1978), as well as the UK, Atlantic and Central Europe, with an 
opposite effect in Italy and Scandinavia (Simpson et al., 2011). These data support the theory that 
higher levels of UV exposure reduce the risk of developing MS (van der Mei et al., 2003), but the 
contradictory observation for Italy and Scandinavia may be attributed to their diet, as fatty fish 
intake has been found to protect from MS (Baarnhielm et al., 2014). However, the exact molecular 
and cellular mechanisms initiated following UV to grant protection are not yet known. I hypothesise 
it is through the activation of regulatory cells that suppress the immune response, thereby 
decreasing the risk of developing MS. 
 
1.1.2.2 Experimental autoimmune encephalomyelitis (EAE) 
To study the immunological effects that occur during MS, the animal model experimental 
autoimmune encephalomyelitis (EAE) is commonly used. Similar to MS, mice induced with EAE 
undergo demyelination due to marked cellular infiltration within the CNS (Olitsky and Yager, 
1949). EAE has hence previously been used as a pre-clinical model for testing MS treatments 
(Shapira et al., 2010a), and many current therapies were pioneered using EAE, including IFN-β 
(Abreu, 1982, Aritake et al., 2010), glatiramer acetate (Teitelbaum et al., 1971, Johnson et al., 
1995) and fingolimod (Fujino et al., 2003, Cohen et al., 2010). 
 
Induction of EAE in C57BL/6 mice usually involves subcutaneous injection of myelin-derived 
peptides (most commonly myelin oligodendrocyte glycoprotein: MOG) together with complete 
Freund’s adjuvant. The immune system becomes sensitised to the myelin proteins, whereby an 
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immune response develops against the myelin sheaths, leading to their destruction. Pathogenesis of 
EAE is driven by the activation of CD4+ T helper cells specific for defined epitopes of various 
myelin autoantigens (Pettinelli and McFarlin, 1981, Zamvil et al., 1986, Martin and McFarland, 
1995), primarily Th1 and Th17 cells (Domingues et al., 2010). 
 
UV has been found to grant protection from EAE (Hauser et al., 1984), with a shift from a Th1 to a 
Th2 cell response (Araneo et al., 1989). The exact molecular and cellular mechanisms, however, are 
not yet known. Earlier studies investigating vitamin D3 have shown that administration prevents the 
development of EAE (Cantorna et al., 1996, Nashold et al., 2000), although the doses required for 
protection are supraphysiological and can be toxic in humans. As previous data have found that UV 
can prevent EAE pathogenesis independently of vitamin D3 production (Becklund et al., 2010, 
Wang et al., 2013), my studies did not include any vitamin D3 work. Additionally, recent data 
published by our laboratory has shown adoptive transfer of B cells from UV-exposed mice can 
prevent the development of EAE in recipient mice (Kok et al., 2016), indicating that UV may grant 
protection from EAE in a B cell-dependent manner. 
 
1.1.3 Cancer 
UV radiation is most well-known for its contribution to cancer by directly damaging DNA within 
skin (Agar et al., 2004). Fisher and Kripke (1977) found adoptive transfer of cells from mice 
exposed to UV into recipient mice (which had their bone marrow ablated by X-rays) rendered the 
recipients unable to reject transplanted tumours. In other words, UV can promote cancer 
development via the suppression of the immune system. This phenomenon is not limited to UV, as 
other cancers activate immune suppression to promote carcinogenesis and metastasis (Olkhanud et 
al., 2011, Affara et al., 2014, Bodogai et al., 2015). Understanding the molecular and cellular 
mechanisms that suppress the immune system to promote carcinogenesis will allow for the 
development of new therapies designed to treat cancer. 
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1.1.4 Molecules that influence the immune system 
1.1.4.1 Interleukin-4 (IL-4) 
Interleukin-4 (IL-4) was first identified for its capacity to promote IgM-induced B cell proliferation 
(Howard et al., 1982). Since then, IL-4 has been found to play an important role in T cell-induced 
B cell growth (Swain and Dutton, 1982), stimulating eosinophils (Sanderson et al., 1985), as well as 
promoting growth of T helper cells (Fernandez-Botran et al., 1986). Interestingly, UVB-induced 
systemic immune suppression could not be achieved in IL-4–/– mice, nor UV-exposed wild type 
mice treated with anti-IL-4 antibodies (Shreedhar et al., 1998a). Furthermore, IL-4 has been found 
to have an important role in the activation and maturation of functional mast cells, as mast cells fail 
to degranulate following UVB exposure in IL-4-deficient mice (Hart et al., 2000). These coinciding 
events suggest that UV-induced IL-4 is important for the maturation and or activation of 
immunoregulatory mast cells following UV.  
1.1.4.2 Interleukin-10 (IL-10) 
Interleukin-10 (IL-10) is the most well-known immunomodulatory cytokine, due to its ability to 
induce anergy in self-reactive T cells (Groux et al., 1996). A role for IL-10 in mediating UVB-
induced immune suppression is also firmly established (Rivas and Ullrich, 1992, Rivas and Ullrich, 
1994, Kang et al., 1994, Shreedhar et al., 1998a, Barr et al., 1999, Alard et al., 2001, Piskin et al., 
2005, Matsumura et al., 2006, Grimbaldeston et al., 2007, Toichi et al., 2008, Chacon-Salinas et 
al., 2011), whereby mice deficient of IL-10 are completely resistant to both UVB-induced 
immunosuppression (Beissert et al., 1996) and carcinogenesis (Loser et al., 2007). UVB exposure 
results in a cascade of molecular and cellular events that ultimately raise serum IL-10 levels (Hart et 
al., 2000). Sources of UV-induced IL-10 include mast cells (Chacon-Salinas et al., 2011), T cells 
(Rivas and Ullrich, 1992) and B cells (Matsumura et al., 2006). The UVB-induced upregulation of 
IL-10 is particularly relevant in the context of autoimmune diseases such as MS due to its ability to 
maintain peripheral tolerance. 
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B cells have been found to be the most abundant source of IL-10 (Madan et al., 2009) in mice. 
Indeed, mice deficient in B cell-derived IL-10 could not recover from EAE (Fillatreau et al., 2002). 
Furthermore, MS patients have been reported to have decreased levels of B cell derived IL-10 
(Duddy et al., 2007, Knippenberg et al., 2011). Fingolimod is a well-established treatment option of 
MS patients (Cohen et al., 2010, Kappos et al., 2010), which is capable of promoting B cell 
production of IL-10 (Blumenfeld et al., 2016). The relevance of B cell-derived IL-10 will be 
covered in Section 1.3. 
 
1.1.4.3 Interleukin-13 (IL-13) 
Interleukin-13 (IL-13) is capable of suppressing Th1 and Th17 inflammation by regulating the 
synthesis of tumour necrosis factor (TNF), IL-6 (Minty et al., 1993) and IL-17-driven 
autoimmunity (Newcomb et al., 2009), the latter independently of IL-10 (Newcomb et al., 2012). It 
can be induced in mast cells following stimulation from IL-33 (Sarchio et al., 2012), which is 
produced by dermal fibroblasts following UVB exposure (Byrne et al., 2011). IL-13 can enhance 
FcεRII (CD23) and MHCII on resting B cells from human tonsils (Defrance et al., 1994), although 
in mice it did not affect B cell proliferation or the expression of CD23, unlike IL-4 (Lai and 
Mosmann, 1999). The drive towards a Th2 cell response and mast cell-activation makes this an 
interesting cytokine to investigate in my studies. 
 
1.1.4.4 Interleukin-35 (IL-35) 
Although so far there have not been any studies investigating interleukin-35 (IL-35) in the context 
of UV, IL-35 has become accepted as another potent immunosuppressive cytokine. IL-35 was first 
found within human trophoblasts, as a heterodimer made up of p35 and EBI3 (Devergne et al., 
1997). It was theorised to be immunomodulatory due to its location, and has since been identified 
within regulatory T cells as an important immunosuppressive cytokine (Niedbala et al., 2007, 
Collison et al., 2007). Like IL-10, there is precedence within the literature for IL-35 to be an 
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important B cell-derived cytokine as a means of protection from EAE. Shen et al. (2014) found 
mice deficient of B cell-derived IL-35 developed more severe EAE, and had higher activation of 
macrophages and inflammatory T cells. Mice induced with experimental autoimmune uveitis were 
protected from disease when treated with recombinant IL-35, and this protection was likewise 
found when they were injected with B cells pre-treated with recombinant IL-35 (Wang et al., 2014). 
 
1.1.4.5 Platelet-activating factor (PAF) and serotonin receptor agonists 
Please note: The following section(s) of this chapter is a modified version of a previously 
published first author book chapter (Marsh-Wakefield & Byrne. 2015. Photoimmunology and 
Multiple Sclerosis. Curr Top Behav Neurosci: Vol 26: “Emerging and Evolving Topics in Multiple 
Sclerosis Pathogenesis and Treatments” pages 117-141. Edited by A. C. La Flamme and J. M. 
Orian. Published by Springer International Publishing, Gewerbestrasse. 
 
While it is now appreciated that UVB suppresses immunity in internal organs as well as the skin 
(McGlade et al., 2007, Rana et al., 2011), the trigger must have a cutaneous origin as UVB does not 
penetrate deep enough to reach internal organs. Two early molecular events following UVB 
exposure is the release of platelet-activating factor (PAF) from keratinocytes (Barber et al., 1998, 
Alappatt et al., 2000) and the isomerisation of epidermal trans-urocanic acid (UCA) to cis-UCA 
(Anglin et al., 1961, Pascher, 1962). These are important and relevant because both PAF 
(Walterscheid et al., 2002) and cis-UCA (De Fabo and Noonan, 1983) are potent mediators of UVB 
immunosuppression. 
 
Normal skin has abundant levels of trans-UCA, which is a UVB photoreceptor that is isomerised to 
cis-UCA following exposure to UVB (Anglin et al., 1961, Pascher, 1962, Kammeyer et al., 1997). 
By signalling through the serotonin receptor 5-HT2A (Walterscheid et al., 2006), cis-UCA causes a 
defect in antigen presentation (Noonan et al., 1988), ultimately leading to systemic suppression of 
the adaptive immune response (De Fabo and Noonan, 1983, El-Ghorr and Norval, 1995). While it 
remains to be determined whether UVB-induced cis-UCA is involved in protection from MS, the 
fact that patients with relapsing remitting MS have lower plasma levels of cis-UCA compared to 
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healthy controls (Correale and Farez, 2013) may indicate a relationship between these two events. 
 
PAF is a plasma membrane phospholipid first discovered in 1972 by studying its influence on the 
immune system, where it aggregated platelets to release histamine (Benveniste et al., 1972). PAF 
itself is a phospholipid, which can be derived from the plasma membrane of cells (Chilton et al., 
1984), including human keratinocytes (Travers et al., 1996). Exposure to UVB causes PAF and 
other photo-oxidised cellular phospholipids to be almost immediately released from keratinocytes 
(Barber et al., 1998, Alappatt et al., 2000). The generation of these PAF receptor agonists (Travers 
et al., 2010) leads to a positive amplification loop of PAF synthesis and ultimately apoptosis 
(Marathe et al., 2005, Pei et al., 1998). This cascade of events in turn suppresses the adaptive 
immune response (Rola-Pleszczynski et al., 1988, Walterscheid et al., 2002). Many immune cells, 
including keratinocytes (Travers et al., 1995) and B cells (Travers et al., 1989, Nguer et al., 1992, 
Bastien et al., 1999), express PAF receptor. Mice treated with PAF receptor antagonists 
(Walterscheid et al., 2002) or mice deficient in PAF receptors (Wolf et al., 2006) are resistant to 
UVB-induced immunosuppression. One mechanism may involve PAF binding to its receptor on 
keratinocytes leading to the release of TNF that in turn triggers Langerhans cell migration to the 
local draining lymph nodes (Fukunaga et al., 2010). Another possibility is that PAF targets PAF 
receptor-expressing bone marrow-derived cells to upregulate IL-10 through COX-2-generated 
prostaglandins (Zhang et al., 2008). More recently, PAF was shown to target dermal mast cells, 
triggering upregulation of CXCR4 and their migration to CXCL12-expressing local draining lymph 
nodes (Chacon-Salinas et al., 2014). Using a combination of antagonists and receptor knockout 
mice it has been shown that PAF and serotonin receptor signalling were both required for the 
activation of UVB-induced regulatory B cells (Matsumura et al., 2006). Interestingly, a recent paper 
found UVB could promote microvesicle production in keratinocytes, but was blocked when cells 
were deficient of PAF receptors (Bihl et al., 2016). The potential for microvesicles to assist in 
cellular communication will be covered further in Section 1.4. 
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There are conflicting reports on the role of PAF and serotonin in CNS-targeted autoimmunity. 
While a pathogenic role for PAF in EAE has been proposed (Kihara et al., 2005), this analysis was 
restricted to the potential damage caused by PAF in the CNS and not its role in mediating systemic 
immune suppression. Meanwhile, contrasting studies used specific PAF receptor antagonists to rule 
out any role for PAF in mediating EAE (Vela et al., 1991). A pathogenic role for serotonin has also 
been proposed based on studies where serotonin receptor antagonists inhibited the development of 
EAE (Dietsch and Hinrichs, 1989). In contrast, efforts to pharmacologically boost available 
serotonin shows promise. One way to boost the levels of extracellular free serotonin is through the 
use of serotonin re-uptake inhibitors (antidepressants). This class of drug boosts IL-10 levels 
(Kubera et al., 2001) and reduces the formation of new lesions in MS patients (Mostert et al., 
2008). Antidepressants can also ameliorate the course of EAE (Vollmar et al., 2009). Whether 
UVB-induced signalling through PAF and/or serotonin receptors is involved in protection from 
CNS-targeted autoimmunity remains to be investigated. 
 
1.1.4.6 Tumour necrosis factor (TNF) 
Another early molecular event occurring in UVB-exposed skin is the release of tumour necrosis 
factor (TNF) (Skov et al., 1998), most likely produced by degranulating mast cells (Walsh et al., 
1991). Upregulation of TNF is a major trigger for Langerhans cell migration from the epidermis to 
the draining lymph node (Moodycliffe et al., 1994) and is required for UVB suppression of skin 
immunity (Rivas and Ullrich, 1994). TNF may be pathogenic in the context of CNS-targeted 
autoimmunity, as TNF-expressing mast cells are responsible for recruiting neutrophils into the 
meninges, which in turn alter vascular permeability (Christy et al., 2013). MS patients also have 
increased levels of TNF within the CNS and cerebrospinal fluid (Hauser et al., 1990), which 
correlates with disease severity (Sharief and Hentges, 1991). Disappointingly, early therapeutic 
interventions to neutralise TNF in MS patients had to be terminated due to disease exacerbation 
(Group, 1999). These apparent contradictions may be explained in a number of ways including the 
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possibility that TNF has different effects depending on its source and site of production (i.e. skin vs. 
CNS). Another important consideration is the fact that TNF exerts its effects on target cells by 
binding to two receptors: TNFR1 (CD120a, originally TNFR60), which is predominantly activated 
by soluble TNF; and TNFR2 (CD120b, originally TNFR80), which is preferentially activated by 
membrane bound TNF (Grell et al., 1995). Activation of CD120a has proinflammatory effects in 
MS patients (Akassoglou et al., 1998), whereas CD120b activation promotes both remyelination 
and neuroprotection (Arnett et al., 2001, Fontaine et al., 2002). Indeed, it has been empirically 
confirmed that selective antagonism of CD120a receptors attenuates EAE (Williams et al., 2014). 
This, together with the fact that UVB selectively decreases CD120a expression but increases 
CD120b expression in human skin (Barr et al., 1999), suggests that UVB-induced TNF may be 
promoting remyelination and neuroprotection. This intriguing possibility remains to be explored. 
 
1.1.5 Immunosuppressive cells 
1.1.5.1 Cellular effects of UV 
The cascade of molecular events triggered by exposure to UVB leads to suppression of the 
induction, effector and memory phases of both cell-mediated and humoral immune responses. UVB 
affects CD8+ CTL responses (Rana et al., 2011), as well as suppressing Th1 (Brown et al., 1995), 
Th2 (McGlade et al., 2007) and Th17 (Singh et al., 2010) responses. UVB suppression of the T cell 
response is likely to be important in protection from MS because CTL (Mars et al., 2011) as well as 
Th1 and Th17 responses are strong drivers of CNS-targeted autoimmunity (Zamvil et al., 1986, 
Lock et al., 2002, Langrish et al., 2005, Tzartos et al., 2008, Yang et al., 2008, Sweeney et al., 
2011, Inoue et al., 2012). T follicular helper cell responses are also significantly suppressed by 
UVB (Chacon-Salinas et al., 2011). The subsequent inhibition of germinal centre formation leads to 
significant decrease in high-affinity class-switched antibody production. While this suppression of 
humoral immunity impacts on the success of vaccination (Cooper et al., 1992, Sleijffers et al., 
2002), it may explain the protective effect of UVB in CNS-targeted autoimmunity because myelin-
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reactive autoantibodies are present in EAE mice (Matsushita et al., 2008) and MS patients (Genain 
et al., 1999). The broad spectrum of suppressive events initiated and maintained by sunlight makes 
therapeutic exposure to UVB an attractive option. This has prompted the Australian-based 
“PhoCIS” randomised controlled clinical trial which will explore whether narrowband UVB therapy 
decreases the risk of developing multiple sclerosis in patients with Clinically Isolated Syndrome 
(CIS; a “pre-MS” where patients have had their first demyelinating event) over a 12 month period 
from their first demyelinating event (ANZCTR ID:ACTRN12614000185662). 
 
1.1.5.2 Regulatory T cells 
Regulatory T cells were originally described as “suppressor T cells” in the 1970’s but are now 
commonly identified as CD4+ CD25+ cells (Sakaguchi et al., 1995) that express the transcription 
factor Foxp3 (Roncador et al., 2005). They are an important subset of CD4+ T cells responsible for 
suppressing immunity and maintaining peripheral self-tolerance (Groux et al., 1997). One of the 
earliest reports identifying regulatory cells was by Daynes and Spellman (1977), whereby 
lymphocytes from UV radiated mice could transferred UV-induced tumour susceptibility, 
suggesting UV activates regulatory cells that suppress the immune response, allowing tumour 
growth. Further work was done to identify UV-induced regulatory T cells (Elmets et al., 1983, 
Shreedhar et al., 1998b). They are relatively well characterised (Loser and Beissert, 2012), 
expressing CD4, CD25, CD62L and the transcription factor Foxp3 (Schwarz, 2008, Schwarz et al., 
2011), while expression of CD152 (CTLA-4) (Schwarz et al., 2000), GITR (Shimizu et al., 2002) 
and the putative regulatory T cell marker neuropilin-1 (nrp1) (Bruder et al., 2004) are required for 
their suppression of immunity. This is likely to be important for CNS-targeted autoimmunity 
because it has been shown that the adoptive transfer of wild type but not nrp1−/− regulatory T cells 
suppress EAE (Solomon et al., 2011). While the expression of these membrane bound molecules 
partly explains the mechanism of UV-induced regulatory T cell suppression, their ability to produce 
immune modulating cytokines, particularly IL-10 (Shreedhar et al., 1998b), is also involved. 
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There is a correlation between UV-induced protection from EAE and UV-induced regulatory 
T cells, which was likewise found in MS patients treated with UVB phototherapy (Breuer et al., 
2014). Although this study did not definitively show a dependence on regulatory T cells for UV-
induced protection, other studies in animal models (Stohlman et al., 1999) and MS patients 
(Tennakoon et al., 2006, Frisullo et al., 2010) have highlighted the important contribution 
regulatory T cells play in maintaining self-tolerance. Indeed, targeting regulatory T cells is a 
promising therapeutic strategy. IL-10-producing T cells have been successfully activated in vitro 
through the combination of vitamin D and dexamethasone in both humans and mice, which 
successfully prevented the induction of EAE (Barrat et al., 2002). Treatment of CD4+ T cells with a 
B7-H1(PD-L1)-Ig fusion protein in combination with anti-CD3 activates type 1 regulatory T cells, 
which suppressed the induction of EAE following adoptive transfer 3 days prior to MOG injection 
(active induction), as well as during co-injection with MOG-specific T cells (passive induction) 
(Ding et al., 2006). Indeed, adoptive transfer of freshly isolated CD4+ CD25+ T cells from the 
lymph nodes of mice were likewise able to prevent the induction of both active and passive forms 
of EAE, with normal Th1 cell levels but increased MOG-specific Th2 cells (Kohm et al., 2002). 
While targeting regulatory T cells for MS therapy shows much promise, it is complicated by the 
fact that a variety of subsets exist with different mechanisms of activation and suppression. Full 
utilisation of their therapeutic potential awaits further investigations into the most efficient way to 
activate and amplify regulatory T cells. 
 
1.2 Mast cells 
Mast cells are most commonly associated with their role in allergic reactions (Oyaizu et al., 1985) 
and inflammation (Lee et al., 2002). After first exposure to an allergen, IgE antibodies are produced 
against this allergen and the body becomes sensitised. Upon re-exposure a large and immediate 
response occurs. Mature mast cells express the immunoglobulin receptor for IgE, FcεRIα (Rottem 
et al., 1992), to allow high affinity binding with IgE (Keown et al., 1998) and in turn trigger 
 14 
degranulation, whereby there is secretion of many pre-formed molecules (Pfeiffer et al., 1985). The 
instant release of pre-formed molecules is hence an extremely rapid response by the immune 
system, as seen during anaphylactic reactions. 
 
Mast cells have also been reported to contribute to graft tolerance, quite possibly via an interaction 
with regulatory T cells (Lu et al., 2006). A similar suppressive role of mast cells has been found 
following UV-induced immune suppression (Hart et al., 1998). In this study, mast cell-deficient 
Wf/Wf mice did not have a suppressed contact hypersensitivity response following UV exposure. 
Immune suppression could however be restored through the addition of wild type mast cells. This 
was the first evidence that mast cells are capable of contributing to immune suppression. Work by 
Chacon-Salinas et al. (2011) demonstrated the importance of mast cell-derived IL-10, as UV-
induced immune suppression was not restored following reconstitution of mast cell-deficient mice 
with IL-10-knockout mast cells. The fact that mast cells can take on an immunoregulatory role is of 
particular interest as there is much controversy surrounding their contribution to pathogenesis of 
many diseases. 
 
1.2.1 Mast cells in autoimmune diseases 
The immunoregulatory role of mast cells following UV may play a role in autoimmune diseases. Li 
et al. (2011) found mast cell-deficient mice developed more severe EAE. As mast cells are well 
associated with allergies (Oyaizu et al., 1985), there is potential for this immunoregulatory role to 
decrease disease severity. Likewise, Safavi et al. (2015) found mice deficient of CD117 (the 
receptor of stem cell factor) could not recover from EAE. Gregory et al. (2005) found mast cell-
deficient mice have an attenuated Th1-driven response during EAE, which may explain the 
decrease in disease severity. On the other hand, mast cells have been identified within the plaques 
of MS patients (Olsson, 1974), and may promote disease pathogenesis through the production of 
tryptase within the cerebrospinal fluid (Rozniecki et al., 1995). Secor et al. (2000) even found a 
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decrease in EAE incidence, delayed EAE onset and decreased mean clinical scores in mast cell-
deficient mice. Thus, mast cells can have both detrimental and beneficial effects, meaning that the 
role of mast cells in MS and EAE is unresolved. 
 
1.2.2 Mast cells in cancer 
Mast cells also contribute to carcinogenesis. In fact, inhibiting UV-induced mast cell migration into 
and away from the skin to skin-draining lymph nodes prevents skin tumour development (Sarchio et 
al., 2014). Stem cell factor (SCF), a ligand for CD117 which is commonly expressed on mast cells, 
has been found to be within basal cell carcinomas, with increased mast cells in the surrounding 
tumour (Yamamoto et al., 1997, Humphreys et al., 2000). Similar results were found by Huang et 
al. (2008), whereby tumour-derived SCF attracted and activated mast cells, in turn producing 
proinflammatory IL-17 as well as increasing regulatory T cells. This may occur via an interaction 
with myeloid-derived suppressor cells (MDSC), which can be recruited by mast cells to produce 
IL-17, in turn indirectly attracting regulatory T cells (Yang et al., 2010). Interestingly, mast cells 
have been found to enhance both immunosuppressive and immunosupportive functions of MDSC 
(Saleem et al., 2012). Work by Danelli et al. (2015) found the CD40/CD40L cross-talk between 
cells to be important for both the pro- and anti-inflammatory response following mast cell-MDSC 
interaction. Mast cells have also been found to directly contribute to melanoma formation, as 
Jimenez-Andrade et al. (2013) found monomeric IgE (in the absence of antigen) could promote 
melanomas as well as increase mast cell production of vascular endothelial growth factor. In 
contrast, Siiskonen et al. (2015) recently showed that lower mast cell numbers in melanoma 
tumours is associated with reduced survival and more advanced stages of the disease. Thus, like 
autoimmunity, the role of mast cells in tumour immune evasion and cancer development is both 
controversial and unresolved. 
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1.2.3 Mast cell interaction with B cells 
Mast cells are well known to interact with B cells, promoting B cell proliferation, survival and 
differentiation into plasma cells (Merluzzi et al., 2010, Palm et al., 2016). Mast cell-derived CD40L 
(Pawankar et al., 1997) and CD1d (Hong et al., 2014) have been found to activate B cells. Tkaczyk 
et al. (1996) found the supernatant from mast cells could activate B cells, an event which could not 
be blocked with anti-IL-4 or anti-IL-6. In fact Mion et al. (2014) found mast cells could activate 
IL-10-producing B cells via the CD40/CD40L pathway. This last study is most interesting, as it 
may reflect what is occurring in vivo. Following UV exposure of the skin, mast cells migrate to the 
dermis, and are then recruited to the skin-draining inguinal lymph nodes where they target B cell 
follicles (Byrne et al., 2008). A subset of UV-induced regulatory B cells have also been identified 
following UV exposure (Byrne and Halliday, 2005). These cells are immunoregulatory, possibly 
through the production of IL-10 (Matsumura et al., 2006). It has also been shown that UV-exposed 
skin-draining lymph nodes are capable of “trapping” cells, with the effect only occurring after 
adoptive transfer of lymphocytes from UV radiated donors into recipient mice, suggesting a cellular 
mechanism by which this occurs (Spangrude et al., 1983). Work by Chung et al. (1986) found 
prostaglandin E2 plays a role in the blockade of cellular egression from lymph nodes following UV. 
 
Thus, mast cells are known to collaborate with many different cells types including regulatory 
T cells and MDSC. The nature of the interaction between mast cells and B cells and the resultant 
drive towards immune suppression is the focus of this thesis. 
 
1.3 Regulatory B cells 
B cells are most well known for their role in antibody production as a means of eliminating foreign 
antigens from the body (Harris et al., 1945, Bjorneboe et al., 1947, Fagraeus, 1947). Originating 
from haematopoietic stem cells, B cells develop within the bone marrow from pro-B cells to 
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pre-B cells to immature B cells (where they develop a mature B cell receptor), then move on to the 
periphery as transitional B cells to naïve B cells, then once exposed to their antigen they become 
mature B cells, where they can begin producing antibodies (as a plasma cell) or become a memory 
cell (Cambier et al., 2007). B cells can be activated by the B cell receptor complex by antibodies, 
which in turn can promote B cell survival (Lam et al., 1997) and/or proliferation (Fruman et al., 
1999). They are hence primarily considered pro-inflammatory, as they can further influence the 
immune system into targeting and neutralising foreign pathogens. What is not as well understood is 
their capability of suppressing the immune system, particularly through the production of the anti-
inflammatory cytokine IL-10. 
 
1.3.1 Origin of regulatory B cells 
Regulatory B cells (at the time dubbed “suppressor B cells”) were first identified by Katz et al. 
(1974), whereby isolated B cells were demonstrated to be capable of suppressing a delayed 
hypersensitivity response against ovalbumin. It was later found by O'Garra et al. (1990) that normal 
murine B cells (as well as certain B cell lymphomas) were capable of producing IL-10. Mizoguchi 
et al. (2002) was the first to introduce the term “regulatory B cells”, a subset which likewise were 
found to produce IL-10. The most well-known subset today are B10 cells, which were first 
identified within the spleen of naïve mice (Yanaba et al., 2008). These have been found to be 
antigen specific, with a direct effect on T cell activation and inflammatory response through their 
production of IL-10 (Yanaba et al., 2009). In most contexts, regulatory B cells have been theorised 
to limit inflammation. This may in fact include skin, as Geherin et al. (2016) found B1 cells 
migrated to the skin after innate stimulation (like LPS) and in turn produced IL-10 to try to control 
the driven inflammation. The ability of B cells to suppress the immune system within skin is of 
particular relevance when we consider the immunoregulatory effects of UV. 
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1.3.2 UV-induced activation of B cells 
In addition to UVB-induced regulatory T cells (Ullrich and Kripke, 1984), dendritic cells (Ng et al., 
2013) and mast cells (Grimbaldeston et al., 2007, Byrne et al., 2008, Biggs et al., 2010, Chacon-
Salinas et al., 2011), we were the first group to demonstrate that a major way UVB causes immune 
suppression is via the activation of an IL-10-secreting regulatory B cell. We call these MHCIIhi 
B220hi cells, UV-induced regulatory B cells (Byrne and Halliday, 2005, Byrne et al., 2005, 
Matsumura et al., 2006). Although IL-10 can be produced by mast cells and UV-induced regulatory 
T cells, B cells have been shown to be the most abundant source of this anti-inflammatory cytokine 
(Madan et al., 2009). Indeed, UV-activated B cells are phenotypically distinct, as they are CD1dlow 
CD5– (Kok et al., 2016), when compared with CD1dhi CD5+ B10 cells (Yanaba et al., 2008). When 
these UV-activated B cells were transferred into mice induced with EAE, they prevented 
development of disease (Kok et al., 2016). In any event, targeting UV-induced regulatory B cells is 
an attractive proposition because regulatory T cell therapy has currently only been shown to prevent 
EAE induction (Roncarolo and Battaglia, 2007). Similarly, UV-induced regulatory T cells only 
suppress the induction of immunity (Glass et al., 1990) and need to be “re-programmed” to 
suppress established cutaneous responses (Schwarz et al., 2011). In fact, while B cells were EAE 
protective, the transfer of splenic CD4+ T cells from EAE-regressed donors actually exacerbated 
EAE (McGeachy et al., 2005). In contrast, artificially induced regulatory B cells suppress both EAE 
induction and progression of established disease (Rafei et al., 2009, Sun et al., 2012). It is hence 
relevant to further consider regulatory B cells in the context of autoimmune diseases. 
 
1.3.3 Regulatory B cells in autoimmune diseases 
The importance of regulatory B cells in disease is well highlighted during EAE, an animal model of 
MS. Our lab has most recently found adoptive transfer of B cells from mice exposed to UV could 
delay induction and limit severity of EAE in non-exposed recipients (Kok et al., 2016). B cell-
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deficient mice do not enter remission during EAE (Wolf et al., 1996), whilst mice deficient of 
IL-10-producing B cells have been found to have worsened EAE (Fillatreau et al., 2002). 
Supporting the pioneering studies of Wolf et al. (1996), depleting B cells prior to induction of EAE 
worsens disease, but if depleted after disease induction, EAE is less severe (Matsushita et al., 
2008), suggesting B cells can be protective against the induction of disease, but may contribute to 
later pathogenesis. Similar results were found by Matsushita et al. (2010), whereby adoptive 
transfer of B10 cells reduced EAE initiation, but not ongoing disease (while regulatory T cell 
depletion worsened late-phase disease). This effect can partly be explained by the influence B cells 
have over T cell responses, as mice with defective IL-10-producing B cells have an increase in Th1 
and Th17 cells, but a decrease in regulatory T cells (Carter et al., 2011). B cells have also been 
suggested to trap autoreactive T cells within lymph nodes to prevent migration into the CNS 
(Korniotis et al., 2016). This group found TLR9-induced activation of B cells (using CpG) drove 
pro-B cells into a regulatory role that could protect mice from EAE in a CCL19-, IL-10- and IFN-γ-
dependent manner. 
 
There is evidence regulatory B cells may complement regulatory T cells during EAE. Oestrogen has 
been previously shown to protect mice from EAE (Jansson et al., 1994), and Subramanian et al. 
(2011) subsequently tested to see whether this protection depended on the function of regulatory 
T cells during disease. By targeted deletion they ablated Foxp3 expression (and hence regulatory 
T cells), yet found mice were still protected from EAE with oestrogen independently of regulatory 
T cells. In fact, B cells were being activated with regulatory function, suggesting this complements 
regulatory T cells. Benedek et al. (2016) linked oestrogen-dependent protection to an increase in 
regulatory B cell frequency within the CNS. Very late antigen-4 (VLA-4) expression on B cells has 
also been found to be important in the protection of EAE disease initiation, as mice deficient of 
VLA-4-expressing B cells developed worsened disease with virtual absence of regulatory B cells 
within the CNS (Lehmann-Horn et al., 2016). This is in contrast to the effectiveness of 
natalizumab, a monoclonal anti-VLA-4, which is a well-established treatment option for patients 
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with MS (Tubridy et al., 1999). These studies suggest both encephalitogenic and protective immune 
cells require VLA-4 expression to enter the CNS to affect the environment. 
 
The role of regulatory B cells has also been highlighted in other similar animal models of 
autoimmune diseases. In fact, IL-10-producing B10 cells decrease proliferation of Th17 cells 
in vitro and in vivo, and could even suppress collagen-induced arthritis (Yang et al., 2012), whilst 
mice lacking IL-10-producing B cells develop more severe collagen-induced arthritis (Carter et al., 
2012). IL-33-treatment has been found to protect mice from inflammatory bowel disease 
(dependent on IL-10), as well as being capable of activating regulatory B cells that in turn following 
adoptive transfer could protect IL-10-deficient mice from inflammatory bowel disease (Sattler et 
al., 2014). Adoptive transfer of CD5+ B cells have been found to be protective against chemically-
induced colitis (Chao et al., 2016). Thus, regulatory B cells play an important role in autoimmune 
diseases.  
 
1.3.4 Regulatory B cells in murine cancers 
Adoptive transfer of B10 cells into mice treated with anti-CD20 prevents B cell depletion, as well 
as lymphoma deletion (Horikawa et al., 2011). These B10 cells inhibited activation and effect 
functions of monocytes in an IL-10-dependent manner. IgM–/– mice, which are devoid of mature 
B cells, have spontaneous regression of EL4 thymoma and MC38 colon carcinoma. This tumour 
eradication could be ablated via adoptive transfer of B cells, confirming a role for B cells in tumour 
immune evasion and carcinogenesis (Shah et al., 2005). Murine tumour-evoked regulatory B cells 
have been found to be enriched following anti-CD20 treatment as they express low levels of CD20, 
whereby administration of anti-CD20 promotes metastasis (Bodogai et al., 2013). These regulatory 
B cells are also CD1dlow CD5–, making them phenotypically distinct to B10 cells (Yanaba et al., 
2008), but phenotypically similar to those activated following UV (Kok et al., 2016). Interestingly, 
B cell production of TNF in mice may be important in the generation and/or accumulation of 
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regulatory B cells during cancer (Schioppa et al., 2011). This is intriguing as UVB can increase 
TNF within human skin (Skov et al., 1998), quite possibly from mast cells (Walsh, 1995), 
promoting the migration of Langerhans cells to the lymph node in mice (Moodycliffe et al., 1994), 
as well as being responsible for UV-induced immunosuppression of a contact hypersensitivity 
response (Rivas and Ullrich, 1994). B cell-deficient mice failed to support orthotopic squamous cell 
carcinoma tumour growth (a human papillomavirus model), whereby anti-CD20 treatment 
concurrent with squamous cell carcinoma implantation significantly slowed tumour growth (Affara 
et al., 2014). However, if anti-CD20 were administered after tumours were apparent this did not 
occur, despite an increase in the percentage of CD8+ T cells infiltrating the tumours. In a 
subcutaneous prostate model, elimination of immunosuppressive B cells (IL-10+ CD5–) allowed 
CTL-dependent eradication of oxaplatin-treated tumours, whilst oxiplatin (an immunogenic 
chemotherapeutic agent) treatment greatly increased intratumoural B220+ CD19+ B cells (Shalapour 
et al., 2015). 
 
1.3.5 Phenotyping of murine regulatory B cells 
It is important to note that there are various phenotypic subsets of regulatory B cells, 
distinguishable from the original CD1dhi CD5+ B10 cells (Nishimura et al., 2013, Kok et al., 2016). 
This is perhaps not that surprising considering that a recent phenotypic analysis of human 
regulatory T cells by mass cytometry found 22 distinct subsets (Mason et al., 2015). In relation to 
our lab's previous work, the most relevant may be tumour-evoked regulatory B cells, which have 
been found to be activated by leukotriene B4 (LTB4) (Wejksza et al., 2013). These B cells have a 
similar CD1dlow CD5– phenotype of those studied by our lab, and appear to be a different subset to 
that of the B10 cells (Kok et al., 2016). As UV can induce LTB4 within human fibroblasts in vitro 
(Yan et al., 2006) and PAF can promote LTB4 in human polymophonuclear leukocytes (Moilanen 
et al., 1993), the regulatory B cells activated following UV may be of the same subset as tumour-
evoked regulatory B cells. It is also important to note that a phenotypically similar subset of B cells 
 22 
have been identified by Moshkani et al. (2012), although these B cells were found to play a role in 
inflammation during a TNF-transgenic mouse model of rheumatoid arthritis. This suggests the 
function of these B cells may be context-dependent and possibly disease-specific. 
 
Mice deficient of IL-6 receptor on B cells have reduced IL-10-producing B cells and worsened 
antigen-induced arthritis (Rosser et al., 2014). This becomes of more interest when considering 
UVB radiation can increase IL-6 serum levels in B6J/129Sv mice (Nishimura et al., 1999). The 
same study found IL-6–/– mice exposed to UV had no increase in IL-10 serum levels, but could be 
restored with recombinant IL-6. It hence may be UV-induced IL-6 is promoting IL-10 levels within 
the serum via B cells. 
 
It is also possible to identify regulatory B cells independent of IL-10 production, as shown by Khan 
et al. (2015), where B cells with high expression of PD-L1 were found to prevent the development 
of EAE. Our EAE-protecting, UV-activated B cells likewise express high levels of PD-L1 (Kok et 
al., 2016). There have also been studies into sex hormones, and how they may contribute to 
protection from disease, as low dose 17β-estradiol has been found to protect mice from EAE (Bebo 
et al., 2001). It is hence interesting that IL-10-producing B cells have also been found to play a role 
in 17β-estradiol-mediated protection against EAE via PD-L1 (Zhang et al., 2015). There are many 
phenotypic surface and intracellular markers used for the identification of regulatory B cells, but 
unlike regulatory T cells, which are mostly CD4+ CD25+ Foxp3+ CD127low, there is no standard set 
of markers that can be used for routine regulatory B cell identification. 
 
1.3.6 Other cytokines produced by regulatory B cells 
IL-10 is not the only immunoregulatory cytokine that has been found to be important in regulatory 
B cell function. As covered in Section 1.1.4.4, IL-35 is another important regulator of the immune 
system (Niedbala et al., 2007, Collison et al., 2007). Mice with B cells deficient in IL-35 
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production develop more severe EAE, but have greater protection from intracellular bacterial 
pathogens (Shen et al., 2014). It has even been found that adoptive transfer of CD1dhi CD5+ B cells 
could restore pancreatic neoplasm growth in B cell-deficient µMT mice, but not if the B cells were 
from il-12a (gene for p35, which forms IL-35 with EBI3) knockout mice. As they also found Ebi3 
mRNA to be upregulated in these B cells, it strongly suggests this pro-tumourgenic effect is 
dependent on B cell production of IL-35 (Pylayeva-Gupta et al., 2015). The adoptive transfer of 
B cells treated with recombinant IL-35 were able to grant protection from experimental 
autoimmune uveitis, with decreased Th1 and Th17 cells in lymph nodes but increased IL-10+ B220+ 
B cells and IL-35+ B cells in the spleen (Wang et al., 2014). 
 
Adoptive transfer of CpG-treated pro-B cells were found to be protective of type 1 diabetes through 
upregulation of Fas ligand (FasL), whilst blockade of IL-10 receptor could not prevent suppression 
of effector T cells (Montandon et al., 2013). Human B cells have even been found to constitutively 
produce MHCII+ FasL+ exosomes, which in turn have been demonstrated to induce apoptosis in 
CD4+ T cells in vitro, suggesting another mechanism by which B cells may regulate the immune 
system (Klinker et al., 2014). Transforming growth factor-β1 (TGF-β1) production by B cells has 
been found to be another important cytokine involved with regulatory B cell function (Kessel et al., 
2012). In fact, mice with B cells deficient of TGF-β1 had worsened EAE disease with an increase in 
T cell production of IFN-γ and IL-17 within the spinal cord (Bjarnadottir et al., 2016). It has been 
suggested the ratio of IL-10/TNF production by B cells is more important than IL-10 levels alone, 
and when looking at the ratio in human B cell subsets it was possible to further distinguish between 
these subsets (Cherukuri et al., 2014). B cells have recently been found to produce the peptide 
PEPITEM, which binds to cadherin-15 on endothelial cells to promote S1P synthesis and release, in 
turn inhibiting T cell trafficking with no effect on other leukocytes (Chimen et al., 2015). 
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Together, these studies highlight the many varied ways of identifying B cells with regulatory 
functions, as well as providing alternative mechanisms by which they can act on the immune 
system. 
 
1.3.7 Regulatory B cells in humans 
Regulatory B cells in humans do not yet have a defined phenotype (unlike regulatory T cells). As 
such, regulatory B cells have been identified and defined by their production of IL-10, as found by 
Duddy et al. (2004). Table 1.1 summarises what is currently known about the various subsets of 
human regulatory B cells. Of particular interest are the differences in phenotype of various 
regulatory B cell subsets, including evidence of both naïve (CD27–) and memory (CD27+) B cells 
being suppressive. An equivalent human subset of murine B10 cells capable of producing IL-10 
(also CD24hi CD27+) have been identified (Iwata et al., 2011), whilst Kessel et al. (2012) have even 
successfully isolated human regulatory B cells (CD25hi) using magnetic beads, and these B cells in 
turn could decrease T cell proliferation and activate regulatory T cells in vitro. Regulatory B cells 
within systemic lupus erythematosus patients have even been found to have a decreased regulatory 
capacity, further highlighting the importance of these cells within autoimmune diseases (Blair et al., 
2010). A more recent study found MS treatment with atacicept (depletes BAFF and APRIL, which 
are cytokines necessary for B cell survival; depletes more mature B cells than anti-CD20) had 
worsened disease (Kappos et al., 2014). This adverse event may be due to the inadvertent deletion 
of MS-protecting B cells because IL-10-producing B cells rely on APRIL for their induction (Hua 
et al., 2016). Patients with allergic asthma have been found to have a reduced number of CD24hi 
CD27+ memory B cells, as well as a decreased level of IL-10 production following LPS treatment 
(van der Vlugt et al., 2014). Patients suffering from common variable immunodeficiency (whereby 
there is a deficiency in serum immunoglobulins) have a decreased level of IL-10 production by 
CD19+ CD24hi CD38hi B cells, with increased numbers of IFN-γ+ TNF+ CD4+ T cells that 
contribute to the disease (Vlkova et al., 2015). 
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Stanic et al. (2015) had an interesting way of phenotyping, where they transfected human peripheral 
blood B cells with human IL-10 to make them overexpress IL-10 and investigate changes in 
phenotype. They found a decrease in anti-inflammatory cytokines (including TNF), with increased 
CD25, CD274, GARP, CD38 and IgD expression but decreased CD19, CD27, CD80 and IgM. 
Previously, the same group were able to isolate out the IL-10-producing population of B cells to 
analyse their expression of several markers, and found it was the CD25+ CD71+ CD73– population 
that was responsible for IL-10 production, which was also the source of IgG4 (van de Veen et al., 
2013). B cells from human peripheral blood have been found to express Foxp3, a marker commonly 
used to identify regulatory T cells (Noh et al., 2010). IL-21 has been found to activate human 
regulatory B cells that were capable of suppressing T cell proliferation, and even produced 
granzyme B (particularly CD5+ B cells) (Lindner et al., 2013). Human B cells expressing high 
levels of CD39 (ectonucleoside triphosphate diphosphohydrolase-1) after stimulation with CD40L 
and IL-4 were found to produce more IL-10 and adenosine, which in turn could suppress T effector 
cell proliferation and activation in vitro compared to CD39– and CD39mid B cells (Figueiro et al., 
2016). In mice, CD39 and CD73 are important for the production of adenosine, with IL-10–/– 
B cells with reduced CD73 expression (Kaku et al., 2014). Human expression of PD-L1 on B cells 
can be important for regulating circulating T follicular helper cells, which correlated with BAFF 
receptor expression, and a naïve-like phenotype (CD19+ CD10– CD21+ CD27–). Even patients with 
severe acute pancreatitis have fewer IL-10-producing B cells, with similar findings in an animal 
model of severe acute pancreatitis, which was worse in mice depleted of B cells but could be 
restored by adoptive transfer of IL-10-producing B cells (Qiu et al., 2016). It is also worth noting 
the effect of aging on IL-10-producing B cells. Kalampokis et al. (2016) found a greater level of 
B10 cells within children compared to adults, whilst children suffering from an autoimmune disease 
(including juvenile idiopathic arthritis, juvenile dermatomyositis, systemic lupus erythematosus and 
mixed connective tissue disease) had a lower frequency and number compared to their healthy 
counterparts. TIM-1+ B cells have been found to be functionally suppressive against CD4+ T cell 
cytokine production, which is impaired in patients suffering from systemic sclerosis (Aravena et al., 
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2017). Needless to say, regulatory B cells in humans appear to have a role in multiple diseases, 
possibly with more diverse subsets than those found in mice. 
 
1.3.8 Regulatory B cells in MS 
The role of regulatory B cells in disease is of particular relevance in the context of MS, as patients 
have decreased levels of IL-10 from B cells (Duddy et al., 2007). The fact that there are differences 
in B cell phenotypes between MS patients and healthy controls (including within the cerebrospinal 
fluid itself as well as peripheral blood, with MS patients having increased CD80+ and CD86+ 
B cells within the cerebrospinal fluid compared to the blood) suggests B cells may play a larger role 
in MS than previously thought (Corcione et al., 2004). Gadolinium-enhancing lesions in MS 
patients are an indicator of blood-brain barrier breakdown. It is hence interesting MS patients 
treated with rituximab (a monoclonal antibody that selectively targets and depletes CD20+ B cells) 
have less total gadolinium-enhancing lesions and are less likely to relapse, with no effect on 
immunoglobulin levels (Hauser et al., 2008). Rituximab has also been identified to reduce the 
levels of both B and T cells within the cerebrospinal fluid of MS patients (Cross et al., 2006). 
Similar results were found by Kappos et al. (2011), whereby the monoclonal antibody ocrelizumab 
(also targets CD20) reduced gadolinium-enhancing lesions within the CNS of MS patients 
compared to placebo and IFN-β1a treatment. These results were recently repeated and confirmed by 
(Montalban et al., 2017). Direct treatment of human peripheral blood mononuclear cells with 
IFN-β1a enhanced IL-10 production by B cells (Huang et al., 2013). 
 
Fingolimod is another common drug for treatment against MS, and it has recently been found to 
have a direct effect on B cell migration through the blood-brain barrier, as well as increasing their 
ability to produce IL-10 (Grutzke et al., 2015). MS patients have been found to have increased 
levels of CD19+ B cells within blood, as well as increased “naïve regulatory B cells”, identified as 
CD19+ CD1d+ CD5+ CD27– IgD+ (Habib et al., 2015). Similar results were found by Knippenberg 
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et al. (2011), whereby relapsing MS patients had a decreased level of CD27– IL-10-producting 
B cells, which was restored during remission. In fact, B cells from MS patients have an increased 
GM-CSF/IL-10 ratio, pushing the B cells into a more pro-inflammatory state (Li et al., 2015a). 
Another interesting observation is the decreased level of B cell-derived microvesicles in untreated 
MS patients compared to healthy controls, which was restored in MS patients treated with the S1P 
agonist fingolimod (Zinger et al., 2016). The effect of fingolimod therapy on B cells is further 
highlighted by Blumenfeld et al. (2016), with an increased naïve/memory B cell ratio, as well as 
increased IL-10+ B cells. These studies highlight the important role regulatory B cells play during 
MS, and by furthering our understanding we may be able to develop new therapeutics as a means of 
treatment. 
 
1.3.9 Regulatory B cells in human cancers 
CD5+ chronic lymphocytic leukemia cells produce large quantities of IL-10 ex vivo, with greater 
serum IL-10 levels in CLL patients (DiLillo et al., 2013). Saulep-Easton et al. (2016) more recently 
identified the ligand BAFF and its receptor TACI as being required for B cell production of IL-10. 
The tumour-evoked regulatory B cells as previously mentioned were first identified in tumours 
(Olkhanud et al., 2011). Melanoma patients have more transitional B cells (CD24hi CD38hi CD19+ 
CD27–) in their peripheral blood compared to healthy controls, suggesting an important shift in 
B cell levels/subsets (Soldevila et al., 2013). PD-1hi B cells were found to play a pro-tumourogenic 
role during advanced stage human hepatocellular carcinoma, by interacting with PD-L1+ cells to 
suppress tumour-specific T cells via IL-10 (Xiao et al., 2016). Furthermore in invasive breast 
cancer, CD19+ B cells were found in high density and could be activated by PD-L1hi cancer cells to 
become CD19+ CD24+ CD38+ and produce IL-10 (Guan et al., 2016). They also found these B cells 
from cancer patients could induce formation of regulatory T cells, adding another mechanism of 
immunosuppression. These studies further emphasise the important role regulatory B cells are 
playing in cancers, as well as the diverse means they may interact with other cells. 
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1.3.10 Cell-cell interactions 
A major way in which B cells are likely to exert their immune regulatory functions is via cell-cell 
interactions. IL-10-producing CD5+ B cells from mice tolerised against the allergen casein were 
capable of preventing a casein-induced allergic response following adoptive transfer, but required 
Foxp3+ regulatory T cells to do so (Kim et al., 2016). On the other hand, Huarte et al. (2016) found 
IL-10-producing B220+ CD5+ BTLA+ B cells to be important in revitalising regulatory T cells to 
protect mice from EAE. These studies demonstrate the interplay between regulatory B and T cells 
in a disease setting. 
 
There is also evidence of regulatory B cells interacting with MDSC. The aforementioned tumour-
evoked regulatory B cells have been found to activate regulatory functions of MDSC, which 
contribute to pro-carcinogenic effects of B cells in vivo (Bodogai et al., 2015). Tolerogenic 
dendritic cells in non-obese diabetic mice can increase the frequency and number of IL-10-
producing B cells both in vitro and in vivo, through the proliferation of existing regulatory B cells, 
and also the conversion from non-regulatory B cells (Di Caro et al., 2014). In turn, influencing 
dendritic cell activation of immune responses is also a major way in which UV-activated B cells 
suppress immunity (Byrne and Halliday, 2005). Plasmacytoid dendritic cells (pDC) have been 
found to activate IL-10-producing CD24+ CD38hi B cells in healthy patients via IFN-γ and CD40 
engagement, which in turn suppressed pDC IFN-γ production (Menon et al., 2016). Interestingly, 
patients with systemic lupus erythmatosus had an impaired pDC-induced activation of regulatory 
B cells, indicating the importance of DC-B cell interactions in regulating the immune system. 
 
Hong et al. (2014) have shown that murine CD1d on mast cells is important for activation of 
B cells. Tkaczyk et al. (1996) found supernatant from mast cells could activate B cells (based on an 
increase in cell size, MHCII and B220 expression), an event that could not be prevented by anti-
IL-4 or IL-6 treatment. Bone marrow-derived mast cells, activated by IgE cross-linking of 
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FcH receptors, have been found to activate effector B cells as seen through upregulation of CD19, 
MHCII, and CD86 on B cells and class switching to IgG after co-culture (Palm et al., 2016). 
Indeed, our laboratory found murine IL-4-treated mast cells capable of activating B cells that could 
suppress a contact hypersensitivity response (Leighton, 2009). These last few studies are of 
particular relevance to the results presented in this thesis. 
 
  
Table 1.1 – Review of human regulatory B cells. The colours represent areas covered in each paper, including IL-10 (purple), transitional B cells (red), activation of 
regulatory T cells (blue), CD274/CD275 pathway (green), suppression of T cell proliferation (magenta), and suppression of T cell cytokine production (orange). Note the 
data summarised is based only off human B cells (no murine work presented).
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Phenotype Functional assay Tissue Disease Reference
Decreased T cell production of IFN-  and TNF
Could block inhibition with anti-IL-10, anti-CD80, anti-CD86 either separately or together
CD19 + CD24hi  CD38hi  B cells produce more IL-10 than CD19+ CD24hi  CD38– and CD19+ CD24int  CD38int
Stimulated peripheral blood monocytes with anti-CD3, promoting IL-10 by CD19 + CD24hi  CD38hi  B cells
Decreased TNF+ IFN- + CD4+ T cells in an IL-10/IL-10 receptor-dependent manner
PD-L1 hi  cell line MDA-MB231 promoted CD19+ CD24+ CD38+ B cells, as well as their production of IL-10
Decreased T cell production of IFN-  and TNF (healthy and rheumatoid arthritis patients)
Convert effector T cells into regulatory T cells (healthy but not rheumatoid arthritis patients)
Decreased CD4+ and CD8 + T cell proliferation
Increased Foxp3 expression on CD4 + T cells
Decreased CD4+ T cell proliferation
Enchanced regulatory T cell Foxp3 and CTLA-4 expression
Anti-PD-1 promotes PD-1 hi  tumour-derived (but not blood-derived) B cell production of IL-10
CD19 + B cells treated with IL-21 inhibit CD4 + T cell proliferation
IL-21 and anti-BCR increase B cell production of granzyme B
CD19 + CD10– CD21+ CD27–
PD-L1 hi  BAFF-receptor hi
None
Isolated CD19+ B cells from 
peripheral blood
Ex vivo  use of Rituximab (anti-CD20) did not deplete 
CD19 + PD-L1hi  B cells
Khan et al. , 2015
CD1d + CD19+ CD25+ CD38+ CD147+ 
IgM + IL-10 + granzyme B+ IDO +
Isolated CD19+ B cells from 
peripheral blood
Granzyme B+ B cells and IL-21-producing T cells 
infiltrate solid tumours (breast, ovarian, cervical)
Lindner et al. , 2013
CD1d hi  CD25hi  CD27hi
CD86 hi  IL-10 hi  TGF- hi
Isolated CD25hi  B cells from 
peripheral blood
None Kessel et al. , 2012
CD5 hi  CD24–/+  CD27+/hi
CD38 dim PD-1 hi
Isolated B cells by cell 
sorting from hepatocellular 
carcinoma tumours
Hepatocellular carcinoma tumours contain a large 
proportion of PD-Lhi  B cells
Xiao et al. , 2016CD5 hi  tumour-derived B cells in the presence of anti-PD-1 inhibit PD-1 – T cell producion of IFN- , and decrease 
granzyme B and perforin production in PD-1– CD8+ T cells, both dependent on IL-10 receptor
CD19 + CD24hi  CD38hi
Isolated B cells by cell 
sorting from peripheral 
Decreased in rheumatoid arthritis patients Flores-Borja et al. , 2013
CD20 low
(possibly CD19+ CD25+ CD81hi )
Isolated B cells using 
negative selection from 
peripheral blood
Rituximab (anti-CD20) selected for CD20 low B cells 
capable of suppressing T cell proliferation
Bodogai et al. , 2013
CD19 + CD24hi  CD38hi  IL-10 +
Plasmacytoid dendritic cells promote CD19+ CD24hi  CD38hi  B cells into IL-10-producing CD24 + CD38hi  B cells that 
inhibit CD4+ T cell production of TNF and IFN-
Isolated B cells by cell 
sorting from peripheral 
Plasmacytoid dendritic cells from systemic lupus 
erythematosus patients can not activate regulatory B cells
Menon et al. , 2016
CD19 + CD24+ CD38+
Isolated CD19+ B cells from 
peripheral blood
Co-localisation of CD19 and IL-10 in invasive carcinoma 
of breast tumours
Guan et al. , 2016Invasive carcinoma of breast patients have greater level of CD19+ CD24+ CD38+ within blood, with greater IL-10 
production, and could promote regulatory T cell differentiation (further promoted when first cultured with PD-L1 hi  cells)
CD1d hi  CD5+ CD10+ CD19+ CD20+ 
CD24 hi  CD27– CD38 hi  IgDhi  IgMhi
Isolated B cells by cell 
sorting from peripheral blood 
CD19 + CD24hi  CD38hi  B cells from systemic lupus 
erythematosus patients could not suppress T cell cytokine 
production
Blair et al. , 2010
CD19 + CD24hi  CD38hi  IL-10 +
Isolated CD25hi  B cells from 
peripheral blood
CD19 + CD24hi  CD38hi  B cells from common variable 
immune deficiency patients produced less IL-10 but had 
more TNF+ IFN- + CD4+ T cells
Vlkova et al. , 2015
CD19 + CD10– CD20+ CD24+ CD27– None Peripheral blood
Fingolimod (S1P agonist) treatment increases 
"regulatory" B cells in MS patients and increases all B 
cell production of IL-10
Grützke et al. , 2015
CD19 + IL-10 + None Peripheral blood
Severe acute pancreatitis patients have fewer IL-10-
producing B cells
Qiu et al. , 2016
CD24 hi  CD27+ Decreased monocyte production of TNF in an IL-10-dependent manner
Isolated B cells by cell 
sorting from peripheral 
blood
Autoimmune disease patients (systemic lupus 
erythematosus, rheumatoid arthritis, Sjögren syndrome, 
blistering skin disease, multiple sclerosis) had an increase 
in B10 + progenitor B10 cells
Iwata et al. , 2011
CD25 + CD71– CD73+ IL-10 hi
(possibly IgG4hi )
Inhibited CD4+ T cell proliferation when added to peripheral blood monocytes stimulated with purified protein 
derivative in an IL-10 receptor-independent manner
Isolated B cells by cell 
sorting from peripheral blood 
Allergen-specific B cells from allergic patients after 
specific immunotherapy have increased IL-10 and IgG 4
van de Veen et al. , 2013
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1.4 Microvesicles 
Microvesicles, also referred to as microparticles, are derived from the plasma membrane of cells 
through the coordinated action of the enzymes flippase, floppase and scramblase (Daleke, 2003, 
Dignat-George and Boulanger, 2011). Preliminary Figure 1.1 highlights some basic differences 
between the types of extracellular vesicles. Exosomes are smaller than microvesicles, and are 
formed by multivesicular bodies (which contain endosomes) that then fuse with the plasma 
membrane to release the endosomes as exosomes (Antonyak and Cerione, 2015). A series of 
centrifugations is commonly used for differentiating such extracellular vesicles (Crescitelli et al., 
2013). Microvesicles can be actively formed by many different cell types, and have been found to 
package cytokines (Kunder et al., 2009), receptors (Combes et al., 1999) and mRNA (Deregibus et 
al., 2007) for specific target cells. As a result, microvesicles are capable of both activating (Curtis et 
al., 2009) and inhibiting (Perez-Casal et al., 2009) the immune response. For example, platelet-
derived microvesicles in humans have been found to block the differentiation of regulatory T cells 
into IL-17 and IFN-γ-producing cells, through P-selectin-dependent binding (Dinkla et al., 2016). 
They even found ~8 % of regulatory T cells in healthy patients to be P-selectin+, as well as platelet-
specific marker CD41+, providing evidence this is a relevant mechanism used in vivo. It should be 
noted that although there have not been any cells that do not produce microvesicles, signals can 
influence the rate of production. Akuthota et al. (2016) found TNF and CCL11 could promote 
human eosinophil production of microvesicles. Microvesicles have even been located at the 
immunological synapse between T cells and antigen-presenting cells (Choudhuri et al., 2014). 
However the relevance of this has not yet been established. 
 
Our laboratory has observed an upregulation in mRNA for ATP-binding cassette (ABC) transporter 
A-1 (ABCA-1) in murine skin following exposure to UV (Preliminary Figure 1.2). As ABCA-1 is 
part of a particularly important group of floppases required for the formation of microvesicles 
(Hamon et al., 2000), UV may be encouraging the formation of microvesicles. More recently, Bihl 
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et al. (2016) found HaCat cells (the well documented human keratinocyte-derived cell line) exposed 
to UVB or carbamyl-PAF produced more microvesicles. In fact, they also found cells lacking the 
PAF receptor were inhibited of UVB-induced microvesicle formation. Thus, UV is able to 
upregulate MV production, although the functional consequence of this is not yet clear. 
 
1.4.1 Vesicles in autoimmune diseases 
Significant increases in the level of circulating microvesicles has been observed in many diseases, 
including MS. Indeed, MS patients display greater levels of endothelial-derived microvesicles 
(Minagar et al., 2001, Jy et al., 2004, Zinger et al., 2016), but interestingly, not those derived from 
B cells. Similarly, type 1 diabetics have been found to have more circulating microvesicles than 
those with type 2 diabetes (Chiva-Blanch et al., 2016). For MS patients, an increase in 
microvesicles may be associated with negative disease outcomes, with the exception of B cell-
derived microvesicles which are decreased is MS patients but can be restored following fingolimod 
treatment (Zinger et al., 2016). It may be B cell-derived microvesicles are protective. 
 
TNF plays a particularly important role in modulating microvesicle production. This pro-
inflammatory cytokine increases endothelial-derived microvesicles in vivo in mice, with similar 
results when treating human umbilical vein endothelial cells via CD120a (Lee et al., 2014). This 
may be due to the ability of TNF to alter specific miRNA levels (Alexy et al., 2014). As selective 
inhibition of CD120a attenuates EAE (Williams et al., 2014), it may be acting against TNF-induced 
microvesicle production. In contrast, microvesicle uptake can be blocked using anti-Del-1 
(developmental endothelial locus-1) antibodies in human endothelial cells, with similar results in 
mice deficient of Del-1 (Dasgupta et al., 2012). As Del-1-deficient mice have a greater EAE 
severity (Choi et al., 2015), it may be inhibiting the uptake of protective microvesicles. 
Furthermore, exosomes derived from serum were able to suppress T cell activation, as well as 
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decrease severity of established EAE (Williams et al., 2013). These studies highlight the strong 
effect microvesicles can have during EAE, as both pathogenic and protective. 
 
Plasma from relapsing MS patients could promote in vitro endothelial microvesicle production 
(compared to remitting MS patients or healthy controls), as well as promoting transendothelial 
migration of monocytes (Jimenez et al., 2005). MS patients likewise have a greater number of 
microvesicles within the cerebrospinal fluid, similar to what is observed in animals with EAE 
(Verderio et al., 2012). Interestingly, they found fingolimod treatment decreased this number in 
mice. This links to the finding that fingolimod could inhibit acid sphingomyelinase (Dawson and 
Qin, 2011), which contributes to microvesicle formation (Bianco et al., 2009). As previously 
mentioned, B cell-derived microvesicles in untreated MS patients is decreased compared to healthy 
controls, which was restored in MS patients treated with fingolimod (Zinger et al., 2016). Even 
though other microvesicles increase during MS (Minagar et al., 2001, Jy et al., 2004, Zinger et al., 
2016), it is particularly interesting that this is not the case with B cells, suggesting they may be 
protective. 
 
Cell-derived vesicles, including microvesicles and exosomes, are an attractive option for therapy, as 
they allow packaging of specific molecules (including proteins, receptors, mRNA) that can target 
and influence specific cells. Exosomes from IL-10-treated dendritic cells for example, can prevent 
the development of collagen-induced arthritis in C57BL/6 mice (Kim et al., 2005). Similarly, 
exosomes from TGF-β1 gene-modified dendritic cells attenuate Th17-mediated inflammatory 
autoimmune disease through regulatory T cell activation (Cai et al., 2012). Even dendritic cell-
derived exosomes with membrane-associated TGF-β1 can inhibit the development and progression 
of EAE in C57BL/6 mice (Yu et al., 2013). With the recent discovery that exposure to UV 
modulates the production of microvesicles, it will be important to ascertain whether this process is 
involved in UV protection from EAE. 
  
Preliminary Figure 1.1 – Differentiation of extracellular vesicles. Extracellular vesicles 
differ in size, and can be separated by using a series of centrifugations. The order of 
separation is from top to bottom.
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Preliminary Figure 1.2 — UV upregulates mRNA for ABCA-1. The mRNA level of 
ATP-binding cassette (ABC) transporter A-1 (ABCA-1) was measured within the murine 
skin after 24 or 48 hr of UV. No UV group did not receive UV. Mean and S.E.M. shown.
n = 3, Kruskal-Wallis ANOVA (Dunn’s multiple comparisons post test). ns not significant. 
Data courtesy of Scott Byrne, Cellular Photoimmunology Group, Infectious Diseases & 
Immunology, University of Sydney.
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1.4.2 Vesicles in cancer 
Microvesicles have also been found to contribute to carcinogenesis. Ma et al. (2016) showed 
microvesicles emanating from tumour cells irradiated with UV in vitro could promote macrophage 
differentiation into a M2 phenotype. This in turn promoted tumour growth and metastasis in vivo. 
Another example of microvesicles aiding cancer growth was found by (Bebawy et al., 2009), who 
showed that microvesicles transported the plasma membrane multidrug efflux transporter 
P-glycoprotein, which in turn contributed to cancer drug resistance. Supporting this evidence, 
microvesicles have been found to be responsible for human pancreatic cell line resistance to anti-
cancer drugs, whereby they helped remove uptaken drug from the cells, as well as capturing the 
drug in the microenvironment (Muralidharan-Chari et al., 2016). Conversely, Tang et al. (2012) 
found microvesicles from murine tumour cell lines first treated with chemotherapeutic drugs in 
vitro were able to kill untreated tumour cells in vivo, without the side effects of the drugs tested. 
Work by Zhuang et al. (2011) found intranasal injection of tumour cell-derived microvesicles 
migrated towards lung and intestines, as opposed to exosomes which targeted the brain. Together 
these highlight the potential use of microvesicles as a means to target specific locations as well as 
cells. 
 
1.4.3 Mast cells and vesicles 
Kunder et al. (2009) found mast cells could produce microvesicles following stimulation with 
compound 48/80 (a well-established polymer that stimulates mast cells), as well as showing the 
capability of microvesicles to traverse the body via the lymphatics system. Human PMA-activated 
T cells have been found to produce microvesicles capable of promoting mast cell activity (Shefler et 
al., 2010), including production of IL-24 (Shefler et al., 2014). Murine platelet-derived 
microvesicles can likewise promote mast cell production of the inflammation-resolving lipid 
mediator lipoxin A4 in vitro (Tang et al., 2010). In addition, direct injection of these platelet-
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derived microvesicles into mice resulted in protection from dextran sulphate sodium-induced 
colitis.  
 
Conversely, bone marrow-derived mast cells have been found to actively produce exosomes after 
IL-4 treatment to stimulate B and T cells (Skokos et al., 2001). This study even found these 
exosomes to express MHCII, CD86, LFA-1, ICAM1, CD40 and CD40L, suggesting multiple 
different potential mechanisms to communicate with cells. In fact exosomes from bone marrow-
derived mast cells could also upregulate MHCII, CD80, CD86 and CD40 on immature dendritic 
cells, as well as increase their antigen-presenting cell function (Skokos et al., 2003), further 
highlighting the importance of mast cell-derived vesicles in activating the immune response. This is 
again highlighted by Li et al. (2016), whereby bone marrow-derived mast cells constitutively 
released CD63+ OX40+ exosomes, which enhanced differentiation of naïve CD4+ T cells to 
Th2 cells. Exosomes from human mast cell line HMC-1 have been found to contain mRNA that 
could be transported into target cells yet still be functional (Valadi et al., 2007, Ekstrom et al., 
2012). My Honours work found microvesicles from murine IL-4-treated mast cells could activate 
B cells (Marsh-Wakefield, 2012). Thus, the ability of mast cells to produce immunomodulatory 
vesicles (in particular microvesicles) could play an important role during UV-induced immune 
suppression. By understanding how these microvesicles are acting and what they contain, we could 
develop therapies to inhibit this mechanism as a means of treatment against UV-induced 
carcinogenesis, or promote it in the context of autoimmune diseases. 
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1.5 Summary, hypotheses and aims 
The available evidence suggests that mast cells could be responsible for the activation of regulatory 
B cells in vivo following UV exposure. Our lab has previously found IL-4-treated mast cells are 
capable of activating B cells (O'Sullivan, 2008) that in turn were functionally suppressive 
(Leighton, 2009). These mast cell-activated B cells are phenotypically similar to those activated by 
UV in vivo (Gillis, 2010, Kok et al., 2016). Furthermore, during my Honours, I discovered that 
microvesicles from IL-4-treated mast cells were capable of activating B cells (Marsh-Wakefield, 
2012). This thesis aims to investigate the nature of mast cell-B cell interactions in mice and 
humans. 
 
My hypothesis is that mast cells and B cells engage in a cellular cross-talk that leads to the 
generation of cells and molecules that could result in immune suppression rather than activation. 
More specifically, I hypothesise that this interaction involves the immunomodulatory cytokines 
IL-10, IL-13 and IL-35. Furthermore, I hypothesise human IL-4-treated mast cells are capable of 
activating phenotypically and functionally suppressive B cells. 
 
The following aims will address these hypotheses: 
 
Aim 1: To investigate the effect of IL-4 and B cells on murine mast cell phenotype and 
cytokine production. 
Aim 2: To interrogate the nature of the interaction between murine mast cells, their 
microvesicles and B cells in relation to the production of immunomodulatory 
cytokines. 
Aim 3: To determine, using mass cytometry, whether human IL-4-treated mast cells (and their 
microvesicles) influence the activation of B cells. 
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Chapter 2 
 
MATERIALS AND METHODS 
 
 
 
The needle was sharp, but the hands were faster; it was 
all over before Josephine could make a sound. Her sister was 
likewise in shock, saying “Surely there’s a reason for all this”. 
That was exactly what Josephine was worried about… 
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Chapter 2: Materials and Methods 
2.1 Mice 
Female C57BL/6 mice (Animal Resource Centre, Perth, Australia) between 6-9 weeks were used 
for all experiments. Mice were housed in wire-topped plastic boxes in groups of 2-6, at the 
Blackburn Animal House (University of Sydney, Australia) or the Charles Perkins Centre Animal 
House (University of Sydney, Australia). Mice were kept under specific pathogen free conditions in 
accordance with the monitoring standards of the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes (NHMRC, 2004), and monitored routinely for signs of sickness 
or distress. γ-Irradiated rat and mouse cubes (Specialty Feeds, Glen Forest, Australia) and water 
were provided ad libitum by the animal house staff. Mice were euthanased by cervical dislocation. 
Mice used for contact hypersensitivity tests were monitored daily following challenge, alongside 
ear measurements. All experiments were endorsed by the Sydney University Animal Ethics 
Committee (AEC project codes K14/5-2010/3/5306, K14/5-2010/3/5336, K14/7-2013/3/6020). 
 
2.2 Bone marrow-derived mast cells 
2.2.1 Isolation from bone marrow 
Female C57BL/6 mice were euthanised, followed by femur extraction and transfer to a sterile 
biosafety cabinet. Epiphyses were cut off with scissors to allow a 23-gauge needle (Terumo 
Medical Corporation, Somerset, USA) to be inserted into the bone. Bone marrow cells were then 
gently flushed out using cold 50 % foetal bovine serum (FBS; In vitro technologies, Nobel Park, 
Australia; Sigma, St. Louis, USA) in PBS. Cells were then filtered through a 70 µm sieve (BD; 
Miltenyi Biotec, Bergisch, Germany) into a conical tube and centrifuged at 300xg, 20 °C for 7 min. 
Cells were then resuspended in “BMMC media”, consisting of RPMI 1640 + GlutaMAX (RPMI; 
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Gibco, Carlsbad, USA), with 10 % (v/v) FBS, 10 ng mL–1 stem cell factor (SCF; PeproTech, Rocky 
Hill, NJ, USA), 10 ng mL–1 interleukin-3 (IL-3; Peprotech), 50 µM 2-mercaptoethanol (Sigma-
Aldrich), 1 % (v/v) penicillin and streptomycin (PenStrep; Gibco). Both IL-3 and SCF are 
necessary for selection of connective tissue-type mast cells (Tsai et al., 1991, Haig et al., 1994). 
Cells were counted before being incubated at 37 °C with 5 % CO2 in vented tissue culture flasks at 
a density of 1 x 106 cells mL–1. Cells were passaged twice each week and resuspended in 1 part old 
and 2 part fresh BMMC media at 1 x 106 cells mL–1. Bone marrow-derived mast cells were then 
used for experiments between 5-10 weeks of age. Note that the purity of mast cells (as being 
CD117+ FcεRIα+) was 90-95 %, and remained consistent between 5-10 weeks of age as most 
changes happen earlier on. 
 
2.2.2 IL-4 treatment of mast cells 
Mast cells cultured between 5-10 weeks were treated with 0.4 µg mL–1 interleukin-4 (IL-4; 
PeproTech) at 1 x 106 cells mL–1. This treatment lasted 48 hr at 37 °C with 5 % CO2. 
 
2.2.3 B cell isolation and co-culture with mast cells 
In a biosafety hood, spleens from C57BL/6 mice were extracted and gently forced through a 70 µm 
sieve with the back of a syringe in autoMACS running buffer (Miltenyi Biotec). Cells were 
centrifuged (300xg, 4 °C, 7 min) and then resuspended in red cell lysis buffer (4 mL/spleen; Sigma) 
and left to sit at room temperature (20-24 °C) for 10 min. Four times the volume of cold cRPMI 
(RPMI 1640 + GlutaMAX, 10 % (v/v) FBS, 1 % (v/v) PenStrep, 50 µM 2-mercaptoethanol) was 
added to cells to quench the lysis buffer. Cells were centrifuged at a slower rate to remove red blood 
cells (200xg, 4 °C, 10 min). Cells were then resuspended in 1 µL MACS® CD19-Microbeads 
(10 % (v/v) in autoMACS running buffer; Miltenyi Biotec) per 1 x 106 cells on ice shielded from 
light for 20 min. Cells were washed with autoMACS running buffer and centrifuged (300xg, 4 °C, 
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10 min) before running a positive selection (using “Possel” program) for CD19-labelled B cells on 
an autoMACS pro separator (Miltenyi Biotec) under sterile conditions. B cell purity was 90-95 %. 
 
The IL-4-treated bone marrow-derived mast cells were washed twice with cRPMI and centrifuged 
(300xg, 4 °C, 10 min). This was important as it removes any residual cytokines (i.e. IL-3, SCF and 
IL-4). Mast cells were then co-cultured with B cells at a 1:10 ratio for 48 hr in cRPMI at 1 x 106 
cells mL–1, at 37 °C with 5 % (v/v) CO2. 
 
2.3 Flow cytometry 
2.3.1 Surface staining 
To prepare for flow staining, cells were spun down (300xg, 4 °C, 5 min) and aliquoted to wells of a 
96-well v-bottom plate. Cells were stained with antibodies for 20 min on ice (conventional 1:100 
dilution), shielded from light. 150 µL FACS buffer (4 mM EDTA, 0.75 % (v/v) bovine serum 
albumin (BSA; Miltenyi Biotec), PBS) was added to cells and centrifuged (300xg, 4 ° C, 5 min). 
Wash was repeated with 200 µL FACS buffer. Cells were then resuspended in 100 µL FACS buffer 
and filtered through 70 µm gauze into FACS tubes to be run on a BD LSRII or BD LSRFortessa 
X-20. As cells were run immediately after staining, no fixation was required. 
 
2.3.2 Intracellular staining 
Cells were pre-incubated with 50 ng mL–1 phorbol 12-myristate 13-acetate (PMA; Sigma), 
0.5 µg mL–1 ionomycin (Sigma), 10 µg mL–1 lipopolysaccharide (LPS; Sigma), 2 µM monensin 
(Sigma) for 5 hr prior to the end of the 48 hr co-culture. For IL-10 staining, 10 µg mL–1 anti-CD40 
(BD) and 15 µg mL–1 anti-kappa (Abcam, Cambridge, UK) were also included in this pre-
incubation. Cells were then washed twice in FACS buffer and centrifuged (300xg, 4 °C, 5min). 
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They were then stained with anti-mouse CD16/32 (Fc block; 1:100 dilution; BioLegend, San Diego, 
USA) and live/dead dye-UV (1:1,000 dilution; Invitrogen, Carlsbad, USA) for 20 min on ice, 
shielded from light. Cells were washed again with FACS buffer and transferred to wells of a 
96-well v-bottom plate and centrifuged (300xg, 4 °C, 5 min.), then repeated. Cells were then stained 
with antibodies against surface markers for 20 min on ice, shielded from light. They were then 
washed with FACS buffer and centrifuged (300xg, 4 °C, 5 min) twice. Cells were then resuspended 
in 250 µL of fixation buffer (BioLegend) and left to sit at room temperature for 20 min, shielded 
from light. Cells were washed twice with permeabilisation wash buffer (PWB; BioLegend) and 
centrifuged (300xg, 20 °C, 5 min), then left in PWB for 10 min at room temperature, shielded from 
light. Following centrifugation (300xg, 20 °C, 5 min), cells were resuspended in PWB containing 
antibodies against intracellular markers (conventional 1:50 dilution) at room temperature for 
20 min, shielded from light. Only one intracellular antibody was included in each stain (hence many 
PE-conjugated antibodies in Table 2.1). Samples were washed with PWB and centrifuged (300xg, 
20 °C, 5 min), then resuspended in 200 µL PWB and left to sit at room temperature for 30 min, 
shielded from light, and this step was then repeated. Cells were then resuspended in cell staining 
buffer (BioLegend) and filtered through 70 µm gauze (Sefar Filter Specialists, Huntingwood, 
Australia) into FACS tubes to be run on a BD LSRII or BD LSRFortessa X-20. 
 
 
 
 
 
 
 
 
 
 
 44 
Table 2.1 – Antibodies used for intracellular flow cytometry. 
Target Fluorochrome Clone Isotype Company Dilution 
CD86* APC GL-1 Rat IgG2a BioLegend 1/100 
MHCII* FITC M5/114.15.2 Rat IgG2b BioLegend 1/100 
EBI3 PE 355022 Rat IgG2a R&D Systems 1/50 
IL-10 PE JES5-16E3 Rat IgG2b BioLegend 1/50 
IL-13 PE eBio13A Rat IgG1 eBioscience 1/50 
p28 PE MM27-7B1 Mouse IgG2a BioLegend 1/50 
p35 eFluor® 660 4D10p35 Rat IgG2a eBioscience 1/50 
p40 PE C15.6 Rat IgG1 BD 1/50 
 
*Surface markers included for mast cell-B cell differentiation and analysis purposes 
 
2.3.3 Analysis 
All flow cytometry data acquired was analysed using FlowJo software v10.0.8r1 (Treestar Inc., 
Ashland, USA). 
 
Appendix A shows the initial gating steps performed on all flow cytometry data for analysing single 
cells. Further gating is shown in the relevant chapters. For intracellular stains, gating was done 
based on the relevant isotype control. Ideally, knock-out mice would be used as controls for non-
specific antibody binding, but these were not available for my experiments. Furthermore, human 
cells do not have this luxury, so isotype controls were deemed most appropriate. The mean 
fluorescent intensity was taken as higher expressing cells that further increase their expression 
would not alter the median. 
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2.4 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software version 7.0a. A p value less than 
0.05 was considered statistically significant. Statistical advice was sought from my supervisor 
(A/Prof Scott Byrne) and co-supervisor (Prof Gary Halliday), and was informed that for all 
experiments with an n value of less than 20 a non-parametric test should be used, as normal 
distribution cannot be assumed with lower n values. Dr Alan Pope provided advice for experiments 
involving human cells. For experiments comparing between two groups, an unpaired Mann-
Whitney two-tailed t-test was performed. For experiments with 3 or more groups to compare, a 
Kruskell-Wallis one-way analysis of variance (ANOVA) was used to compare selected controls and 
samples using a Dunn’s Post test. For comparison between similar samples (e.g. same donors) 
between two groups, a paired Wilcoxon two-tailed t-test was performed. When comparing 3 or 
more groups, a Friedman one-way analysis of variance (ANOVA) was used to compare selected 
controls and samples using a Dunn’s Post test. For some of the human T cell assays, a 2-way 
ANOVA with Turkey’s multiple comparison test was used. This was used as each division acted as 
time, and examined the overall expression of CD69 or S1P1 over each division. For murine mast 
cell-B cell co-cultures, each n value represents a different mast cell culture from, with each mast 
cell culture from a single mouse.  
 46 
Chapter 3 
 
IL-4 AND B CELLS ALTER 
MAST CELL PHENOTYPE AND 
CYTOKINE PRODUCTION 
 
 
The mind is capable of creating the unimaginable, the 
unexplainable, or even the unobtainable. But this just makes 
nightmares that much worse. It was the waiting that hurt 
Josephine most of all: knowing that something was about to 
happen, and letting her imagination get the best of her. But 
after seeing her sister’s wait come to an end, no one could 
blame Josephine for her fears. It was time to act on her primal 
instincts… 
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Chapter 3: IL-4 and B cells alter mast cell phenotype and 
cytokine production 
3.1 Introduction 
Mast cells play complex and varied roles in both the promotion and protection from disease. 
Manipulating mast cells and their products to protect from cancer and autoimmune diseases like 
multiple sclerosis requires an understanding of how mast cells can be activated (whether through 
cytokines or other cells), and the consequences of this activation for the immune system more 
widely. 
 
Interleukin-4 (IL-4) plays an important role in the activation and maturation of functional mast 
cells, particularly in the context of UV-immune suppression because mast cells fail to degranulate 
following UVB exposure in IL-4-deficient mice (Hart et al., 2000). Consequently, UVB-induced 
systemic immune suppression could not be achieved in IL-4–/– mice, nor UV-exposed wild type 
mice treated with anti-IL-4 antibodies (Shreedhar et al., 1998a). These coinciding events suggest 
that UV-induced IL-4 is important for the maturation and or activation of immunoregulatory mast 
cells following UV. 
 
Exposing the skin to UV results in a significant increase in dermal mast cells (Byrne et al., 2008) 
and a large dermal influx of IL-4-producing neutrophils (Teunissen et al., 2002). It is possible that 
these concomitant UV-triggered events are where mast cells are first exposed and modulated by 
IL-4. These IL-4-activated dermal mast cells then migrate to the B cell follicles of skin-draining 
lymph nodes (Byrne et al., 2008). The newly arrived mast cells are likely to encounter an IL-4-rich 
lymph node environment because UV-induced NKT cells produce significant amounts of IL-4 
(Fukunaga et al., 2010).  
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Our laboratory has already confirmed that bone marrow-derived mast cells incubated with IL-4 can 
activate B cells (O'Sullivan, 2008) and that these mast cell-activated B cells assume a phenotype 
that is similar to B cells found in the draining lymph nodes of UV-exposed, immune suppressed 
mice (Gillis, 2010). Furthermore, when these mast cell-activated B cells were transferred into naïve 
recipient mice, they could suppress the induction of a contact hypersensitivity response (Leighton, 
2009). 
 
In vitro studies support a role for IL-4 in human mast cell maturation and activation because 
exposing human mast cells to IL-4 decreases expression of CD117 in both primary mast cells 
(Nilsson et al., 1994, Lahm et al., 1995) as well as mast cell cell-lines (Sillaber et al., 1991). 
Similarly, FcεRI expression is downregulated on human (Toru et al., 1996) and murine (Ryan et al., 
1998) mast cells cultured in the presence of IL-4. Additional studies have found IL-4 can 
downregulate IL-13 mRNA in murine mast cells (Mirmonsef et al., 1999), whilst Kaur et al. (2006) 
have found IL-13 itself to upregulate FcεRI on human mast cells. The first aim of this chapter was 
to determine whether similar events were occurring within our mast cell system, by investigating 
their phenotype and cytokine production. In turn, we then wanted to establish whether these 
changes could explain how our mast cells are able to activate phenotypically and functionally 
suppressive B cells. We hypothesise IL-4 is altering the phenotype of the mast cells for maturation 
purposes, which would then promote the production of cytokines that can influence B cells or 
themselves in an autocrine manner (including IL-10, IL-13, and IL-35). 
 
Once mast cells have undergone changes in phenotype or cytokine production, it is worthwhile to 
consider how these mast cells can then influence other immune cells. One such molecule by which 
these cellular interactions could occur is MHCII, due to its role in antigen presentation to T cells. 
Although there is conflicting data whether mast cells constitutively express MHCII (Frandji et al., 
1993, Warbrick et al., 1995, Love et al., 1996, Dimitriadou et al., 1998, Poncet et al., 1999) or not 
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(Lipski et al., 1996, Grabbe et al., 1997, Kambayashi et al., 2009), most studies agree mast cells 
can be induced to express (or increase expression) of MHCII (Banovac et al., 1989, Frandji et al., 
1993, Frandji et al., 1995, Warbrick et al., 1995, Love et al., 1996, Grabbe et al., 1997, Poncet et 
al., 1999, Tkaczyk et al., 1999, Kambayashi et al., 2009, Ito et al., 2015). Expression of MHCII on 
mast cells has been found to enhance their interaction with T cells (Dimitriadou et al., 1998, Ito et 
al., 2015). For these reasons, it was of interest to determine whether IL-4 or B cells could influence 
mast cell expression of MHCII. 
 
In the context of UV, mast cells have been found to play a pivotal role during UV-induced immune 
suppression (Hart et al., 1998). In fact, mast cell-derived IL-10 has been found to be responsible for 
suppressing T follicular helper cell responses following UV exposure (Chacon-Salinas et al., 2011). 
Following UV exposure mast cells are recruited to the dermis, and then migrate to the skin-draining 
lymph nodes where they preferentially target the B cell follicles (Byrne et al., 2008). Our laboratory 
has previously highlighted the importance of UV-induced mast cell migration, as inhibiting mast 
cell migration to the lymph nodes prevents formation of UV-induced skin tumours (Sarchio et al., 
2014). It is hence important to consider what may be occurring to the mast cells within lymph nodes 
after they have migrated to this location. Due to the preferential migration of mast cells to the B cell 
follicles, the second aim of this chapter was to determine whether B cells have any effect on the 
mast cells after co-culture. Much like IL-4 treatment of mast cells, we hypothesise that B cells are 
further altering both mast cell phenotype and cytokine production. B cell-induced mast cell-derived 
cytokines in turn may act in an autocrine or paracrine manner, contributing to immune suppression. 
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3.2 Materials and methods specific to this chapter 
3.2.1 Surface staining of mast cells for flow cytometry 
Bone marrow-derived mast cells (BMMC) were treated (or not) with 0.4 µg mL–1 IL-4 in BMMC 
media for 48 hr (as described in Section 2.2.2). Following treatment, BMMC were washed, 
centrifuged (300xg, 4 °C, 5 min) and counted, then 0.1 x 106 cells were added to wells of a 96-well 
plate. BMMC were incubated with the antibody cocktail outlined in Table 3.1 for 20 min on ice, 
shielded from light. Note anti-CXCR4, anti-CD25 and anti-MHCII were included in separate 
antibody cocktails, each alongside CD117 and FcεRIα. 150 µL FACS buffer (4 mM EDTA, 0.75 % 
(v/v) BSA, PBS) was added to the cells and centrifuged (300xg, 4 ° C, 5 min), followed by a second 
wash with 200 µL FACS buffer. Antibody-stained BMMC were then resuspended in 100 µL FACS 
buffer and transferred through 70 µm gauze into FACS tubes to be run on a BD LSRII or BD 
LSRFortessa X-20. 
 
For mast cell-B cell co-cultures, the gating strategy to differentiate between mast cells and B cells is 
shown in Figure 3.1. MHCII and live/dead staining were used to separate mast cells and B cells so 
they could then be analysed for individual surface expression (as well as intracellular cytokines 
from Section 3.2.2). 
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Table 3.1 – Antibodies used for surface staining of mast cells by flow cytometry. 
Target Fluorochrome Clone Isotype Company Dilution 
CD117 PE-Cy7 ACK2 Rat IgG2b BioLegend 1/100 
FcεRIα APC MAR-1 Armenian 
Hamster IgG 
BioLegend 1/100 
CXCR4 PE L276F12 Rat IgG2b BioLegend 1/50 
CD25 PE PC61 Rat IgG1 BD 1/50 
MHCII FITC M5/114.15.2 Rat IgG2b BioLegend 1/100 
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Figure 3.1 – Gating strategy used to differentiate between mast cells and B cells. 
After gating on time, total cells and single cells (Appendix A), B cells were differentitated 
from mast cells using MHCII-FITC and Live/dead dye-UV staining (representative plots are 
shown).
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3.3 Results 
3.3.1 IL-4 treatment of bone marrow-derived mast cells modulates CD117 and 
FcεRIα surface expression but not CD25 or CXCR4 
Unlike other immune cells, it can be difficult to differentiate mast cell subsets based solely on their 
phenotype (Dwyer et al., 2016). This endeavour is complicated by the fact that the tissue 
(connective or mucosal) in which mast cells reside significantly impacts on their differentiation and 
function. Bone marrow-derived stem cells cultured in the presence of IL-3 alone differentiate into 
mucosal mast cells (Guy-Grand et al., 1984). Adding stem cell factor (SCF) to the culture 
conditions allows for their development into cells that resemble connective tissue mast cells like 
those found in the skin (Tsai et al., 1991, Haig et al., 1994). These bone marrow-derived mast cells 
(BMMC) can be identified by flow cytometry through their high expression of both CD117 (c-Kit) 
and FcεRIα (the high-affinity IgE receptor). Consistent with what has been shown by others 
(Mirmonsef et al., 1999), and as can be seen in Figure 3.2, IL-4 treatment significantly decreased 
CD117 expression on BMMC (Figure 3.2C). However, the same treatment with IL-4 increased 
FcεRIα expression on BMMC (Figure 3.2D). In contrast, IL-4 treatment had no significant effect on 
the constitutive level of CD25 (Figure 3.3A and 3.3C) or CXCR4 expression by mast cells (Figure 
3.3B and 3.3D). 
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Figure 3.2 – IL-4 treatment of bone marrow-derived mast cells alters surface marker 
expression of CD117 and FcεRIα. Mast cells were treated with 0.4 µg mL–1 IL-4 for 48 hr 
at 1 x 106 cells mL–1. (A and B) shows the relative expression of CD117-PE-Cy7 (A) or
FcεRIα-APC (B) on unstained (grey), untreated (dotted line) and IL-4-treated (unbroken 
line) mast cells. (C and D) shows the mean fluorescent intensity of untreated (open 
triangles) to IL-4-treated (closed triangles) mast cells for CD117 (C) or FcεRIα (D).
n = 9-14 from 8-14 independent experiments, where pairs represent the same culture; 
Wilcoxon test.
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Figure 3.3 – Constitutive expression of CD25 and CXCR4 on bone marrow-derived 
mast cells is not altered by IL-4 treatment. Mast cells were treated with 0.4 µg mL–1 IL-4 
for 48 hr at 1 x 106 cells mL–1. (A and B) shows the relative expression of CD25-PE (A) or 
CXCR4-PE (B) on unstained (grey), untreated (dotted line) and IL-4-treated (unbroken 
line) mast cells. (C and D) shows the mean fluorescent intensity of untreated (open 
triangles) to IL-4-treated (closed triangles) mast cells for CD25 (C) or CXCR4 (D). n = 6-13 
from 6-11 independent experiments, where pairs represent the same culture; Wilcoxon 
test; ns not significant (CD25 p value = 0.3125; CXCR4 p value = 0.1909).
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3.3.2 IL-4 treatment of bone marrow-derived mast cells modulates the 
expression of immune regulatory cytokines  
3.3.2.1 IL-13 but not IL-10 production is increased by IL-4 
UV is known to activate mast cells to produce the immune regulatory cytokine IL-10 
(Grimbaldeston et al., 2007). Indeed, UV is unable to suppress the immune response in mice whose 
mast cells fail to produce IL-10 (Chacon-Salinas et al., 2011). UV-induced inflammatory mediators 
like platelet activating factor (PAF) (Chacon-Salinas et al., 2014), IL-33 (Byrne et al., 2011) and 
Vitamin D (Biggs et al., 2010) are all known triggers of mast cell-derived IL-10. To test whether 
IL-4 could also induce IL-10 in mast cells, IL-4-stimulated mast cells were stained for IL-10 by 
intracellular flow cytometry. A minority of BMMC (~10% of cells) produced IL-10 (Figure 3.4A), 
the expression of which was unaltered by IL-4 stimulation. In contrast, there was a significant 
increase (a doubling from ~10% to ~20%) in the percentage of mast cells producing IL-13 
(Figure 3.4B): another well-known immunoregulatory cytokine that can activate B cells (Defrance 
et al., 1994). 
 
3.3.2.2 IL-4 treatment of bone marrow-derived mast cells increases the expression of the IL-35 
and IL-27 subunit EBI3  
Next I tested whether IL-4 was upregulating any other novel cytokines that might explain how mast 
cells could modulate immunity. The immunosuppressive cytokine IL-35 was first found within 
human trophoblasts, as a heterodimer of p35 and EBI3 (Devergne et al., 1997). IL-35 was theorised 
to be immunomodulatory due to its location, and has since been identified within regulatory T cells 
as an important immunosuppressive cytokine (Niedbala et al., 2007, Collison et al., 2007). IL-35 is 
also produced by B cells, which in turn are responsible for protecting mice from autoimmune 
diseases. Shen et al. (2014) found mice deficient in B cell-derived IL-35 developed more severe 
EAE, with higher activation of macrophages and inflammatory T cells. Recombinant IL-35 can also 
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directly activate regulatory B cells (Wang et al., 2014), which protected mice from experimental 
autoimmune uveitis. Whether mast cells can be activated to produce IL-35 is not known. 
 
When quantifying IL-35, it is important to analyse its two subunits EBI3 and p35 (Devergne et al., 
1997). However, EBI3 and p35 are not exclusive to IL-35, as EBI3 can bind with p28 to form IL-27 
(Pflanz et al., 2002) and p35 can bind with p40 to form IL-12 (Kobayashi et al., 1989). Due to the 
fact that there is no antibody that can recognise IL-35 specifically, I analysed the expression of all 
four subunits of these 3 cytokines: EBI3, p28, p35 and p40. Figure 3.5 shows that IL-4 significantly 
upregulated mast cell production of EBI3. 
 
3.3.2.3 IL-4 treatment of bone marrow-derived mast cells has no effect on mast cell production of 
subunits p28, p40 or p35 
Staining for the two subunits that can join with EBI3 to make either IL-27 (p28) or IL-35 (p35) 
revealed that BMMC do not express p28 (Figure 3.6A and Appendix B), as the level of isotype 
staining was greater than the staining for p28 itself for all 3 culture repeats, but they do express p35 
(Figure 3.6C). For p40, which can combine with p35 to make IL-12, there was no change in the 
level of p40 production by BMMC after IL-4 treatment (Figure 3.6B). It should be noted that p40 
staining was greater than the staining than the isotype, meaning that mast cells can produce p40. 
Thus, mast cells have the capacity to produce IL-35 and IL-12 but not IL-27, and IL-4 activation of 
BMMC increases this capacity for IL-35 production. 
  
Figure 3.4 – IL-4 treatment upregulates mast cell production of IL-13 but has no 
effect on IL-10. Bone marrow-derived mast cells were first treated (or not) with 0.4 µg 
mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. They were then stimulated with PMA (50 ng mL–1), 
ionomycin (500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM) 5 hr prior to conclusion 
of culture. Samples were then stained with (A) anti-IL-10-PE or (B) anti-IL-13-PE for 
intracellular flow cytometry (representative flow plots are shown of IL-4-treated mast cells). 
Dotted verticle lines represent the median of the isotype control across all groups and 
experiments, whereby anything less than this would be considered as negative for the 
cytokine of interest. n = 3-4 from 3-4 independent experiments; Mann-Whitney test, 
median shown; ns not significant.
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Figure 3.5 – IL-4 treatment promotes mast cell production of the IL-35 and IL-27 
subunit EBI3. Bone marrow-derived mast cells were first treated (or not) with 0.4 µg mL–1 
IL-4 for 48 hr at 1 x 106 cells mL–1. They were then stimulated with PMA (50 ng mL–1), 
ionomycin (500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM) 5 hr prior to conclusion 
of culture. Samples were stained with antibodies specific for EBI3-PE by intracellular flow 
cytometry (representative flow plots are shown; numbers report the mean fluorescent 
intensity and interquarile range of anti-EBI3 staining). Dotted verticle lines represent the 
median of the isotype control across all groups and experiments, whereby anything less 
than this would be considered as negative for EBI3. n = 7 from 7 independent 
experiments; Mann-Whitney test, median shown.
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Figure 3.6 – IL-4 treatment has no effect on p28, p35 or p40 production by mast 
cells. Bone marrow-derived mast cells were first treated with 0.4 µg mL–1 IL-4 for 48 hr at 
1 x 106 cells mL–1. They were then stimulated with PMA (50 ng mL–1), ionomycin
(500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM) 5 hr prior to conclusion of culture. 
Samples were then stained with (A) anti-p28-PE, (B) anti-p40-PE or (C) anti-p35-eFluor 
660 by intracellular flow cytometry (representative plots are shown in Appendix B). Dotted 
verticle lines represent the median of the isotype control across all groups and 
experiments, whereby anything less than this would be considered as negative for the 
subunit of interest. n = 3 from 3 independent experiments; Mann-Whitney test, median 
shown; ns not significant.
Note for all 3 individual repeats, p28 staining was less than the isotype control.
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3.3.3 B cells influence IL-4-treated mast cell phenotype and cytokine 
production 
3.3.3.1 IL-4-treated bone marrow-derived mast cells upregulate MHCII only after co-culture with 
B cells 
To further investigate the potential of B cells to in turn influence mast cells after co-culture, the 
level of MHCII expression on mast cells was investigated. MHCII can be expressed on murine mast 
cells, and is required for their ability to present externally acquired antigens (Frandji et al., 1993). 
IL-4 treated mast cells were either stained immediately for MHCII (Figure 3.7A and 3.7C) or 
cultured with B cells for a further 48 hr prior to staining for MHC II (Figure 3.7B and 3.7D). While 
the IL-4 treatment by itself had no effect on mast cell MHCII (Figure 3.7C), there was a significant 
and consistent upregulation of MHC II on the IL-4-treated mast cells after co-culture with B cells 
(Figure 3.7D). Figure 3.1 shows the gating used to differentiate mast cells and B cells. 
 
3.3.3.2 B cells promote IL-4-treated mast cell production of immune regulatory cytokines 
Because IL-4 could promote mast cell production of IL-13 but not IL-10, we then wanted to 
determine whether these changes were further altered following co-culture with B cells. 
Intracellular flow cytometry was performed, and as can be seen in Figure 3.8, the percentage of 
mast cells producing IL-10 (Figure 3.8A) and IL-13 (Figure 3.8B) were significantly upregulated 
following co-culture with B cells. 
 
Furthermore, IL-4 could promote mast cell production of the IL-35 and IL-27 subunit EBI3. Similar 
to the effect of B cells on mast cell IL-10 and IL-13, there was a significant upregulation of EBI3 
production by IL-4-treated mast cells after co-culture with B cells (Figure 3.9). 
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To distinguish between IL-12, IL-27 and IL-35, it was important to consider the other subunits that 
make up these cytokines. As can be seen in Figure 3.10 there was no B cell-driven change in the 
percentage of mast cells producing p28 (Figure 3.10A) or p40 (Figure 3.10B). However, there was a 
significant upregulation of p35 in the IL-4-treated mast cells after co-culture with B cells 
(Figure 3.10C). 
  
Figure 3.7 – IL-4 treatment of bone marrow-derived mast cells increase MHCII 
expression only after co-culture with B cells. Mast cells were treated (or not) with
0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. (A and C) shows the mean fluorescent 
intensity of MHCII-FITC on untreated (open triangles) or IL-4-treated (closed triangles).
(B and D) shows mast cells after a 48 hr co-culture with B cells at a 1:10 ratio
(mast cells:B cells). n = 5-6 from 5-6 independent experiments, where pairs represent the 
same culture; Wilcoxon test; ns not significant.
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Figure 3.8 – IL-4-treated mast cells have upregulated IL-10 and IL-13 production after 
co-culture with B cells. Bone marrow-derived mast cells were first treated (or not) with 
0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. These were then co-cultured at a 1:10 ratio 
with isolated splenic B cells for 48 hr. They were then stimulated with PMA (50 ng mL–1), 
ionomycin (500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM) 5 hr prior to conclusion 
of culture. Anti-CD40 (10 µg mL–1) and anti-kappa (15 µg mL–1) were also included for 
IL-10 staining. Samples were then stained with (A) anti-IL-10-PE or (B) anti-IL-13-PE for 
intracellular flow cytometry (representative flow plots are shown of IL-4-treated mast cells). 
Dotted verticle lines represent the median of the isotype control across all groups and 
experiments, whereby anything less than this would be considered as negative for the 
cytokine of interest. n = 6 from 6 independent experiments; Mann-Whitney test, median 
shown.
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Figure 3.9 – IL-4-treated mast cells have upregulated EBI3 production after 
co-culture with B cells. Bone marrow-derived mast cells were first treated with 0.4 µg 
mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. These were then co-cultured at a 1:10 ratio with 
isolated splenic B cells for 48 hr. They were then stimulated with PMA (50 ng mL–1), 
ionomycin (500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM) 5 hr prior to conclusion 
of co-culture. Samples were stained with antibodies specific for EBI3-PE by intracellular 
flow cytometry (representative flow plots are shown; numbers report the mean fluorescent 
intensity and interquarile range of anti-EBI3 staining). Dotted verticle lines represent the 
median of the isotype control across all groups and experiments, whereby anything less 
than this would be considered as negative for EBI3. n = 6 from 6 independent 
experiments; Mann-Whitney test, median shown.
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Figure 3.10 – IL-4-treated mast cells have upregulated p35 production after 
co-culture with B cells, but no change in p28 nor p40. Bone marrow-derived mast cells 
were first treated with 0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. BMMC were then 
co-cultured at a 1:10 ratio with purified splenic B cells for 48 hr. Cells were then stimulated 
with PMA (50 ng mL–1), ionomycin (500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM)
5 hr prior to conclusion of co-culture. Finally, samples were then stained with (A) 
anti-p28-PE, (B) anti-p40-PE or (C) anti-p35-eFluor 660 antibodies for intracellular flow 
cytometry (representative plots are shown in Appendix C). Dotted verticle lines represent 
the median of the isotype control across all groups and experiments, whereby anything 
less than this would be considered as negative for the subunit of interest. n = 3-5 from 3-5 
independent experiments; Mann-Whitney test, median shown; ns not significant.
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3.4 Discussion 
IL-4-treatment of bone marrow derived mast cells resulted in changes to the expression of key 
surface and intracellular markers. Some of these changes may pre-dispose mast cells to become 
immunoregulatory, partially explaining their ability to activate regulatory B cells (O'Sullivan, 2008, 
Leighton, 2009, Gillis, 2010). 
 
The surface expression of CD117 was significantly downregulated by IL-4 (Figure 3.2B and 3.2C). 
CD117 (receptor for SCF) is highly expressed on mature murine mast cells (Katayama et al., 1993, 
Dvorak et al., 1994) and is already known to be downregulated on murine mast cells by IL-4 
(dependent on STAT6 and PI3K). Similar results have been found in primary human mast cells 
(Nilsson et al., 1994) and human mast cell cell-lines (Sillaber et al., 1991, Lahm et al., 1995). 
IL-10, working independently of, or synergistically with, IL-4 also downregulates CD117 
(Mirmonsef et al., 1999). My results indicate that IL-4-treated mast cells are not a likely source of 
this IL-10 (Figure 3.3A). While these experiments did not explore the effect of IL-10 on mast cell 
phenotype, keratinocytes release IL-10 following UV exposure (Shreedhar et al., 1998a), which 
could accentuate the effects of UV-induced IL-4 on dermal mast cells. 
 
A change in CD117 expression can in turn affect mast cell activity. It has been shown previously in 
humans that mutations in the CD117 gene KIT resulting in a loss of function of CD117 contributes 
to spontaneous activation of mast cells (Longley et al., 1999). In our context of decreased CD117 
expression, it may also assist in mast cell activation. In contrast, an increase in KIT expression has 
been observed in some melanoma patients, but only those with chronic sun damage (Curtin et al., 
2006). As these papers did not look at KIT levels in mast cells specifically, the changes in CD117 
may not be on mast cells themselves. Although the functional outcome of the decrease in CD117 
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expression after IL-4 treatment may not be fully clear, it is reaffirming that other groups have found 
similar results. 
 
In contrast to CD117, FcεRIα (the high affinity IgE receptor) was found to be increased on mast 
cells after IL-4 treatment. This appears to be in contrast to the work of Ryan et al. (1998), who 
showed that IL-4 decreased murine mast cell expression of FcεRIα. One possible explanation for 
this discrepancy may be the fact that bone marrow-derived mast cells used by Ryan et al. (1998) 
were grown in IL-3 alone (in the absence of SCF). These culture conditions are known to promote 
mucosal mast cells that are functionally different from the connective tissue mast cells used in my 
experiments (Guy-Grand et al., 1984). It should also be noted Ryan et al. (1998) were able to get 
FcεRIα inhibition with as little as 20 ng mL–1 IL-4, with a dose response up to 20 mg mL–1. Our 
mast cells were treated with 0.4 µg mL–1, suggesting dose is not responsible for this difference. 
Ryan et al. (1998) also used the same strain of C57BL/6 mice, although they did use adult rather 
than young mice, which may explain our contrasting results. However, similar to what was found in 
this results chapter, IL-4 also upregulates FcεRIα on human mast cells (Toru et al., 1996, Babina et 
al., 2016). The level of FcεRIα expression on mast cells is traditionally associated with allergic 
diseases. Indeed, patients with perennial allergic rhinitis have tissue resident nasal mast cells that 
express higher levels of FcεRI (Pawankar et al., 1997). Similar results are found in asthmatic 
patients (Andersson et al., 2011), although these authors found FcεRI expression to be low in 
alveolar mast cells in healthy and allergic rhinitis patients. In the context of my results, the IL-4-
mediated upregulation of mast cell FcεRIα may increase the sensitivity of mast cells to further 
activation signals. Indeed, our laboratory has previously shown that IgE-cross linking of 
Fcε receptors on BMMC activates the cells to upregulate CXCR4 (Byrne et al., 2008). This may be 
important in the context of UV-induced skin cancer because monomeric IgE (even in the absence of 
antigen) binding to Fcε receptors can promote melanoma growth (Jimenez-Andrade et al., 2013). 
This enhanced tumour growth was mast cell-dependent and involved, at least in part, mast cell 
production of vascular endothelial growth factor. In this way, via an antigen-independent IL-4-
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driven mechanism, UV may upregulate FcεRIα on mast cells that in turn could allow them to 
interact with monomeric IgE and contribute to melanoma development via angiogenesis. 
 
Recently, Deho et al. (2014) showed that two distinct subsets of BMMC exist that can be 
differentiated based on their expression of CD25, the high affinity receptor for IL-2 (IL-2RD). 
CD25 is upregulated on activated T cells and is a marker known to be expressed constitutively by 
some regulatory T cells (Sakaguchi et al., 1995). Compared to CD25+ BMMC, CD25– cells 
proliferated more in response to IL-3 and SCF, and when IgE-activated, the CD25– BMMC 
produced more IL-6, IL-10, IL-13 and TNF. In contrast, CD25+ BMMC produced significantly 
more IL-2, which correlated with their ability to protect from excessive cutaneous inflammation 
(Deho et al., 2014). Together, these data suggest that CD25 may be a useful marker to identify 
subsets of mast cells that perform different functions in vivo. However, all of the BMMC expressed 
CD25 and this expression was not affected by IL-4 stimulation in vitro (Figure 3.3A). Although 
mast cells grown from healthy humans are mostly CD25– (Schernthaner et al., 2005), some patients 
with systemic mastocytosis have elevated levels of CD25 (Valent et al., 2010). In any event, it is 
unlikely that IL-4 stimulated murine BMMC mediate B cell activation or immune regulation via 
CD25 expression. 
 
Similar to the results obtained for CD25, IL-4 treatment of mast cells did not increase surface 
expression of CXCR4. Interestingly, unstimulated BMMC constitutively expressed CXCR4, which 
is in contrast to that found previously by our group (Byrne et al., 2008). One possible explanation 
for the differences between the two studies is that the earlier work used the anti-CXCR4 clone 2B11 
whilst in my work it was clone L276F12. Clone 2B11 has previously been found to bind differently 
to CXCR4 when compared to another clone, 12G5 (Huskens et al., 2007). It may be a section of 
CXCR4 becomes exposed once mast cells are activated that the 2B11 clone can only recognise once 
exposed, so for future experiments it may be worthwhile to test the two clones side by side. CXCR4 
can be induced by UV-induced PAF on murine (Chacon-Salinas et al., 2014) and human (Damiani 
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et al., 2015) mast cells, which is required for their migration from the skin to the draining lymph 
nodes following UV radiation (Byrne et al., 2008, Sarchio et al., 2014). Indeed, blocking CXCR4 
with the antagonist AMD3100 prevented this UV-induced mast cell migration, inhibiting UV-
induced immune suppression (Byrne et al., 2008) and carcinogenesis (Sarchio et al., 2014). 
However, because IL-4 treatment does not influence mast cell CXCR4 expression, this does not 
appear to be a mechanism involved in B cell activation or immune regulation.   
While it is already known that IL-4-treated mast cells can activate functionally suppressive B cells 
(Leighton, 2009), the mechanism is unknown. Because cell-to-cell contact is not required for IL-4-
treated mast cell activation of B cells (Gillis, 2010), we hypothesised that mast cell-derived 
cytokines may be responsible. Our laboratory has already shown by ELISA that IL-4-treated mast 
cells do not produce the well known B cell activating cytokines IL-10, IL-21 or BAFF (Gillis, 
2010). My results for IL-10 support these earlier studies (Figure 3.3A). Our consistent findings that 
IL-4-treated mast cells do not increase their production of IL-10 was somewhat surprising because, 
at least in the context of UV-induced inflammation (Grimbaldeston et al., 2007) and immune 
suppression (Chacon-Salinas et al., 2011), mast cell-derived IL-10 is a key cytokine. However, 
IL-4-treated mast cells can and do upregulate IL-10, but only after they have been co-cultured with 
B cells (Figure 3.8A), which will be discussed later. 
 
IL-4 stimulation of BMMC did result in an increase in IL-13 production (Figure 3.3B). IL-13 is a 
potent B cell activating cytokine (Defrance et al., 1994) that has been shown to promote B cell 
antibody production (Mckenzie et al., 1993, Lai and Mosmann, 1999). IgE-activated mast cells are 
already known to produce IL-13 (Burd et al., 1995), which may provide positive feedback in an 
autocrine and/or paracrine manner to promote FcεRIα expression on mast cells (Kaur et al., 2006). 
TLR4 agonists such as LPS can also stimulate human mast cells to produce IL-13 (Varadaradjalou 
et al., 2003). In contrast to my findings, Mirmonsef et al. (1999) found that stimulating mast cells 
 71 
with IL-4 decreased IL-13 mRNA levels. However as already discussed in the context of changes in 
BMMC CD117 levels, these studies used mucosal rather than connective tissue mast cells, which 
may explain the discrepancies, as both these cell type are grown in slightly different conditions that 
may affect overall function (Guy-Grand et al., 1984, Tsai et al., 1991, Haig et al., 1994). Mast cell 
production of IL-13 may be involved in B cell activation as IL-13 has been found to induce IgG4 
and IgE synthesis in human B cells independently of IL-4 (Punnonen et al., 1993). If mast cells 
have upregulated FcεRIα following IL-4, they may be more prone to activation, at the same time 
producing IL-13 to promote B cell synthesis of IgE which amplifies the cascade. To determine the 
role of IL-13 within this context, neutralising anti-IL-13 antibodies could be included in the co-
culture. If B cells are no longer being activated, it would strongly suggest IL-13 is important in this 
context. IL-13 can also suppress Th1 and Th17-driven inflammation (Minty et al., 1993, Newcomb 
et al., 2009, Newcomb et al., 2012). This may be particularly relevant in the context of UV-
protection from autoimmune diseases like multiple sclerosis (MS) because experimental 
autoimmune encephalomyelitis (EAE), an animal model of MS, is primarily driven by a Th1 and 
Th17 response (Pettinelli and McFarlin, 1981). Indeed, our laboratory recently discovered that a 
major way in which UV protects from EAE is via the activation of regulatory B cells (Kok et al., 
2016) so these two events may be linked. Whether mast cell-derived IL-13 is responsible for this 
protection remains to be determined.  
Recently, the anti-inflammatory and immune suppressive cytokine IL-35 was shown to be able to 
directly activate regulatory B cells (Wang et al., 2014). My results show that IL-4-treatment of mast 
cells increases their expression of EBI3, one of the subunits of IL-35. BMMC also expressed p35 
and p40, but not p28, suggesting that mast cells might be capable of producing IL-35 (made up of 
EBI3 and p35), which in turn might explain their ability to activate immune regulatory B cells. 
Unfortunately there is no way to determine from these experiments whether mast cell EBI3 is 
forming IL-35 (by combining with p35), IL-27 (by combining with p28) or is free floating. To 
address this, a capture antibody could be used to bind to any released EBI3 or p35 on the cell, and 
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then come in with a second antibody against the other dimer, showing a release of IL-35. Note that 
simply staining against EBI3 and p35 with different fluorochromes would determine which cells 
contain both EBI3 and p35, but not necessarily whether they are forming IL-35. Indeed, EBI3 can 
act independently of both p28 and p35 to protect the skin of mice from fibrosis (Kudo et al., 2015). 
In patients suffering from systemic sclerosis, EBI3 levels within keratinocytes (in the epidermis) 
and regulatory T cells (in the dermis) is significantly lower (Kudo et al., 2015). What makes this 
observation both interesting and relevant is that systemic sclerosis patients also have a larger 
number of cutaneous mast cells (Seibold et al., 1990), and low dose UVA1-phototherapy is an 
effective treatment option (Kreuter et al., 2004). Whether phototherapy is activating the dermal 
mast cells to produce protective EBI3 in these patients is not known. However, it is an intriguing 
possibility, especially considering that dermal mast cells have recently been shown by members of 
our laboratory to be a major target for effective phototherapy in both mice (Schweintzger et al., 
2015) and humans (Wolf et al., 2014). 
 
When we consider Figure 3.6, there is no change in production of any subunit. It is important to 
note that for p28 (Figure 3.6A), the percentages shown were less than their isotype control in each 
experiment, so it is believed mast cells are not producing p28. As such, this also rules out the 
possibility of IL-27 playing a role in activation of B cells. From here, we must then consider the 
effects B cells may be having on mast cells after their co-culture. 
 
MHCII is most well known for its expression on antigen-presenting cells. It can be expressed on 
murine mast cells and is required for their APC ability (Dimitriadou et al., 1998). Human mast cells 
have likewise been found to express MHCII constitutively (Poncet et al., 1999, Love et al., 1996), 
whilst other groups suggest it is only expressed when stimulated, particularly with IFN-γ (Grabbe et 
al., 1997). Vincent-Schneider et al. (2001) found the rat mast cell line RBL-2H3 transfected to 
express MHCII had high levels within secretory granules, which could be activated to express 
MHCII. The build-up of immature MHCII was due to low cathepsin S activity, which is involved in 
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the degradation of the invariant chain (Villadangos et al., 1997). As cathepsin S activity can be 
increased through IFN-γ treatment of murine macrophages (Beers et al., 2003), this may explain 
how IFN-γ can increase MHCII in mast cells. Differences aside, I found my murine mast cells to 
express low levels of MHCII (Figure 3.7), with no change when receiving IL-4 alone (Figure 3.7C). 
It should be noted though that mast cells still had a much lower level of MHCII expression when 
compared to B cells (Figure 3.1). However, when mast cells were then co-cultured with B cells, 
MHCII expression on the mast cells was increased (Figure 3.7D). Frandji et al. (1995) found IFN-γ 
almost completely inhibited bone marrow-derived mast cell antigen-presenting cell function, 
regardless of the upregulated MHCII. To complicate things further, activation of FcεRI in mast 
cells was able to restore the lost antigen-presenting cell function from IFN-γ treatment (Tkaczyk et 
al., 1999). MHCII upregulation may involve the protein Notch, as mast cells constitutively express 
Notch1 and Notch2 (Nakano et al., 2009). Indeed, activation of mast cells using Notch ligand-
expressing cells together with IgE cross-linking of Fcε receptors increased mast cell expression of 
MHCII. Mast cells activated in this way also upregulated TNF, IL-4, IL-6 and IL-13. Despite the 
fact that resting B cells fail to express some Notch ligands (Moriyama et al., 2008), these ligands 
have been reported to be upregulated on activated B cells (Elyaman et al., 2007). Human B cells 
may also alter their expression of Notch receptors and ligands during maturation (Bertrand et al., 
2000), which in turn may be a mechanism by which B cells influence the phenotype of mast cells. 
Nakano et al. (2009) also found BMMC (after co-culture with cells expressing Notch ligands) to 
promote CD4+ T cell proliferation, and preferentially differentiated them into Th2 cells. Hence in 
my context, it may be these mast cells in turn are interacting with T cells to influence the immune 
system. Interestingly, IL-33, which is upregulated in UV-exposed skin (Byrne et al., 2011), has 
recently been found to induce MHCII in BMMC (Ito et al., 2015). Furthermore, mast cells have 
been found to play an important role in suppressing the T follicular helper cell response following 
UV exposure (Chacon-Salinas et al., 2011). Kambayashi et al. (2009) found bone marrow-derived 
mast cells capable of expressing MHCII preferentially expanded antigen-specific regulatory T cells 
over naïve T cells. Indeed, mast cells have previously been highlighted as important instigators of 
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regulatory T cell activity (Lu et al., 2006), quite possibly via TGF-β1 (Zhang et al., 2010). 
However, FcεRIhi MHCII+ but not FcεRIlow MHCII– bone marrow-derived mast cells could act as 
antigen-presenting cells (Gong et al., 2010). The IL-4-induced upregulation of FcεRI on mast cells, 
alongside the MHCII after co-culture with B cells, promotes the hypothesis these mast cells may be 
able to directly interact with T cells. 
 
When considering how UV can activate regulatory B (Byrne and Halliday, 2005) and T (Shreedhar 
et al., 1998b) cells, as well as the role of mast cells in suppressing the immune system (Hart et al., 
1998), it is tempting to speculate that mast cells exposed to UV-induced IL-4 precipitate immune 
suppression. As UV induces IL-4 production from neutrophils within the dermis (Teunissen et al., 
2002), followed by recruitment of mast cells (Byrne et al., 2008), this may be the first point of 
activation of mast cells. In turn, mast cells are then recruited to the skin-draining lymph nodes 
where they preferentially target B cell follicles (Byrne et al., 2008). This migration is dependent on 
CXCR4 (Sarchio et al., 2014), but may also involve PAF (Nilsson et al., 2000). Once the mast cells 
are present, they may be able to interact with B cells that increase mast cell expression of MHCII, 
such that mast cells can then act on T cells. At the same time, Langerhans cells are recruited to skin-
draining lymph nodes after UV, whereby they activate NKT cells to produce large quantities of 
IL-4 (Fukunaga et al., 2010). This in turn may further influence mast cells within the lymph nodes, 
further driving the activation of B cells. 
 
IL-4 alone could upregulate mast cell IL-13 and EBI3 (subunit of IL-27 and -35) production. While 
IL-13 and EBI3 remained elevated, co-culture with B cells led to an increase in mast-derived IL-10 
and p35. Because no p28 or p40 was produced, this suggests that following co-culture with B cells, 
mast cells are unlikely to produce IL-12 or IL-27, but rather IL-35. The next chapter will determine 
whether IL-35 is present within the co-cultures. 
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As human B cells have been found to constitutively express both IL-27 receptor complexes IL-27R 
and gp130 (Larousserie et al., 2006b), when considering the upregulated EBI3 this may be a 
mechanism by which the IL-4-treated mast cells are activating B cells. Alternatively, mast cells 
have also been found to constitutively express suppressor of cytokine signalling 3 (SOCS3) (Traum 
et al., 2012), a negative regulator of the IL-6 family (such as IL-27 and IL-35) receptor gp130 
(Yasukawa et al., 2003). This prevents the expression of gp130 on mast cells, making them 
unresponsive to IL-27 (Traum et al., 2012). This group did find however that IL-10 treatment of 
mast cells allowed expression of gp130. In my context, it may be the IL-10 is working in an 
autocrine manner to allow the IL-4-treated mast cells (after interacting with B cells) to be 
responsive to the upregulated EBI3. So rather than possible IL-35 activating regulatory B cells, 
these subunits may be acting on the mast cells instead. 
 
The increase in IL-10 from the IL-4-treated mast cells only after co-culture with B cells was quite 
surprising, as we expected B cells to be the major source of this anti-inflammatory cytokine. 
Although IL-10 has been found to downregulate bone marrow-derived mast cell CD117 expression 
independently of IL-4 (Mirmonsef et al., 1999), we have found that IL-4 alone decreases mast cell 
CD117, and it is only after co-culture with B cells that IL-10 production was induced in the mast 
cells. The importance of mast cell production of IL-10 in suppressing the immune system is now 
well established (Chacon-Salinas et al., 2011). The results presented in this chapter suggest that 
there may be cross talk occurring between the mast cells and B cells. This is further highlighted by 
the increase in MHCII expression by the mast cells following co-culture with B cells. In addition, 
there was an increase in p35, a subunit of IL-12 and -35. Although this does not prove there was an 
increase in IL-35, the fact that both subunits (EBI3 and p35) increased suggest there is an increase 
in IL-35. As summarised in Figure 3.11, I propose that IL-4 prepares mast cells for further 
activation, as there is an increase in EBI3 and IL-13. When they come in contact with B cells, they 
in turn are activated and promote mast cell production of p35. Due to the preformed EBI3, the mast 
cells only need to increase their p35 expression in order to upregulate IL-35. This would be 
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important for downstream immune suppression because recombinant IL-35 has been found to 
activate regulatory B cells (Wang et al., 2014). Similar results in human palatine tonsil-derived 
mesenchymal stem cells were very recently found whereby EBI3 from these cells was able to 
promote B cell production of IL-10 (Cho et al., 2017). Together, they highlight the possibility of 
mast cells activating regulatory B cells via EBI3, possibly with p35 and IL-35. 
 
This chapter focused on changes that are occurring in the mast cells, but it is equally important to 
consider the effects that are occurring in the B cells. Our lab has previously shown IL-4-treated 
mast cells shift B cells to become phenotypically (Gillis, 2010) and functionally (Leighton, 2009) 
regulatory. In fact during my Honours I found microvesicles could activate B cells (Marsh-
Wakefield, 2012), but it was never tested whether they were functionally suppressive. It is also 
important to address whether IL-35 is physically present, rather than just its two subunits EBI3 and 
p35. These questions were hence addressed in Chapter 4. 
  
??
Figure 3.11 – Proposed action of IL-4-treated mast cells when interacting with
B cells. (1) Mast cells are first treated with IL-4. (2) IL-4-treated mast cells increase 
production of IL-13 and EBI3. There is a reservoir of EBI3. (3) IL-4-treated mast cells 
interact with B cells. (4) B cells promote mast cell production of IL-10 and p35 (while 
maintaining IL-4-induced production of IL-13 and EBI3 from mast cells). (5) The increased 
p35 production interacts with the reservoir of EBI3, forming IL-35. (6) Mast cell-derived 
IL-35 will then directly activate regulatory B cells or directly suppress the immune system. 
Whether the produced cytokines act in an autocrine manner is still unknown.
IL-4-treated
mast cell
IL-4
EBI3
p35
IL-10
IL-13
Immune
suppression
B cells
IL-35
EBI3
EBI3
IL-13
IL-13
1
2
3
p35
p35 IL-10IL-10
4
IL-13
IL-13
IL-13
EBI3
EBI3
EBI3
5
6
p35EBI3
Regulatory
B cells
77
 78 
Chapter 4 
IL-4-TREATED MAST CELL-
DERIVED MICROVESICLES 
ALTER B CELL FUNCTION AND 
CYTOKINE PRODUCTION 
 
 
 
How can I fly if I have no wings? This thought drove 
Josephine to the brink of her limit, but it was here she realised 
no single entity can do everything: it is through cooperation 
and collaboration that the greatest goals can be achieved. This 
however did not make it easy for her, because she now needed 
to visit The Owlsmith… 
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Chapter 4: IL-4-treated mast cell-derived microvesicles 
alter B cell function and cytokine production 
4.1 Introduction 
Following UV exposure to the skin, dermal mast cells are activated to migrate preferentially to the 
B cell follicles of skin-draining inguinal lymph nodes (Byrne et al., 2008). Conspicuously, a subset 
of UV-induced regulatory B cells that produce IL-10 (Matsumura et al., 2006) are activated in these 
same skin-draining lymph nodes following UV exposure (Byrne and Halliday, 2005, Kok et al., 
2016). This coincidental mast cell-B cell interaction suggests that UV-activated migrating dermal 
mast cells might influence the activation of lymph node-derived B cells. 
 
The interaction between mast cells and B cells has been studied previously. Mast cells, possibly 
through their expression of CD1d (Hong et al., 2014) or CD40L (Pawankar et al., 1997), can 
promote B cell proliferation, survival, production of IL-10 (Mion et al., 2014) and differentiation 
into plasma cells (Merluzzi et al., 2010, Palm et al., 2016). In 1996, Tkaczyk et al. (1996) found 
that the supernatant from mast cells grown in IL-4 and IL-3 could promote B cell proliferation and 
expression of IgM. This mast cell-driven activation of B cells could not be blocked with anti-IL-4 
or anti-IL-6, suggesting that another mast cell-derived soluble product, or possibly even a 
subcellular vesicle was responsible for B cell activation.  
 
Bone marrow-derived mast cells (BMMC) have been found to actively produce exosomes, which 
are small cell-derived vesicles that are exocytosed from cells, with a diameter less than 0.1 µm. 
IL-4-treated BMMC can produce exosomes that promote splenocyte proliferation and blast 
formation (Skokos et al., 2001). Furthermore, this study found these exosomes to express MHCII, 
CD86, LFA-1, ICAM1, CD40 and CD40L, suggesting multiple different potential mechanisms to 
communicate with cells. In fact, BMMC-derived exosomes could also upregulate MHCII, CD80, 
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CD86 and CD40 on immature dendritic cells, as well as increase their ability to present antigens 
(Skokos et al., 2003), further highlighting the importance of mast cell-derived vesicles in activating 
the immune response. This is again highlighted by Li et al. (2016), whereby BMMC constitutively 
released CD63+ OX40+ exosomes, which enhanced differentiation of naïve CD4+ T cells to 
Th2 cells. Exosomes from the human mast cell line HMC-1 have been found to contain up to 121 
different miRNA’s that could be transported into target cells, to then produce proteins encoded by 
the miRNA (Valadi et al., 2007, Ekstrom et al., 2012). Together, these studies highlight the 
capabilities of mast cell-derived exosomes to provide activating signals to other immune cells. 
 
Another well-known subset of cell-derived vesicles are microvesicles (also referred to as 
microparticles). Microvesicles are derived from the plasma membrane of cells, through the 
coordinated action of flippase, floppase and scramblase (Daleke, 2003, Dignat-George and 
Boulanger, 2011). These hence differ from exosomes, which are exocytosed from inside the cell, as 
well as microvesicles being larger (0.1 – 1 µm diameter; exosomes are generally < 0.1 µm 
diameter). Apoptotic bodies on the other hand are generally larger (0.8 –5 µm diameter), which are 
released by cells undergoing programmed cell death. Following stimulation with compound 48/80, 
mast cells produce microvesicles (Kunder et al., 2009). This study also found their microvesicles 
could traverse the lymphatics, allowing a wide range of communication that may be relevant in the 
context of UV. 
 
Many studies have focused on mast cell-derived exosomes, but for my work I am interested in 
whether mast cell-derived microvesicles are capable of activating B cells that are functionally 
suppressive. During my Honours I found microvesicles from IL-4-treated mast cells were capable 
of activating B cells, as observed by an increase in MHCII and B220 expression (Marsh-Wakefield, 
2012). As well as this, some of the aforementioned studies did not separate out microvesicles from 
their exosomes (Skokos et al., 2001, Skokos et al., 2003), so it may be the observed activation of 
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cells is via mast cell-derived microvesicles rather than exosomes. It was hence of interest to 
determine whether these microvesicle-activated B cells in turn could suppress the immune system. 
 
Furthermore, platelet-activating factor (PAF) receptor and the serotonin receptor 5-HT2A have been 
shown to be required for the activation of B cells following UV exposure (Matsumura et al., 2006). 
This study used antagonists against PAF and 5-HT2A receptors (CV 3988 and ketanserin 
respectively) to inhibit B cell activation. Likewise during my Honours I found these antagonists 
could prevent the activation of B cells by mast cells (Marsh-Wakefield, 2012). It was then of 
interest for me to investigate the levels of PAF within mast cells and their microvesicles, and 
whether IL-4 treatment could in turn affect PAF production. 
 
Hence the aim of this chapter was to determine whether microvesicles from IL-4-treated mast cells 
could activate functionally suppressive B cells. An additional aim was to investigate whether IL-4-
treated mast cells or their microvesicles could alter their production of anti-inflammatory cytokines. 
We hypothesised that microvesicle-activated B cells would be able to suppress the induction of an 
adaptive immune response when adoptively transferred in vivo. Based on the findings revealed in 
Chapter 3 that IL-4-treated mast cells produce anti-inflammatory cytokines or their subunits, we 
therefore hypothesised that mast cells and B cells cooperate to increase the production of anti-
inflammatory cytokines, particularly IL-10, IL-13 and IL-35. 
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4.2 Materials and methods specific to this chapter 
4.2.1 Isolation, staining and quantification of mast cell-derived microvesicles 
Following 48 hr incubation with IL-4 (or left untreated), bone marrow-derived mast cells (BMMC) 
were centrifuged (300xg, 4 °C, 7 min) to pellet cells (which could then be used for other 
experiments). The supernatant was collected and further centrifuged (1,500xg, 4 °C, 20 min) to 
pellet cell debris (including apoptotic bodies). The supernatant was collected and centrifuged once 
more (16,100xg, 4 °C, 1 hr) to pellet microvesicles. These were then resuspended in cRPMI. 
Although there is no gold standard for isolating microvesicles, similar methods have been reported 
(Tang et al., 2012, Bourdonnay et al., 2015, Li et al., 2015b, Bihl et al., 2016, Dinkla et al., 2016, 
Ma et al., 2016). 
 
A small sample of the isolated microvesicles was analysed by flow cytometry (Figure 4.1). 
Microvesicles were identified using annexin V, which can bind to phosphatidylserine residues that 
are often exposed during microvesicle formation (Koopman et al., 1994). Annexin V-FITC was 
centrifuged (16,100xg, 4 °C, 1 hr) to pellet any protein aggregates that may give false positives 
when analysing subcellular fractions by flow cytometry. Microvesicles were stained with 
annexin V-FITC (1:100 dilution in 10 x annexin V binding buffer) at room temperature in the dark 
for 15 min. Microvesicles were then diluted in 1 x annexin V binding buffer and then run on the BD 
LSRFortessa or BD LSRFortessa X-10. In addition to being annexin V+, microvesicles are also 
defined as being between 0.1 and 1 µm in size. Calibrated size beads (Spherotech, Lake Forest, 
Illinois, USA) were used to assist in microvesicle identification. CountBright™ Absolute Counting 
Beads (Invitrogen, Carlsbad, CA, USA) were used to calculate the number of microvesicles present 
in cultures. For one mast cell culture, the same number of microvesicles (from untreated or IL-4-
treated mast cells) were added to B cells. These were left to incubate with B cells for 48 hr at 37 °C, 
with 5 % CO2, similarly to mast cells (Section 2.2.3).  
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Figure 4.1 – Detection and quantification of microvesicles. Microvesicles were first 
isolated by a series of centrifugations, the last one being 16,100xg for 1 hr. They were 
stained with annexin V (conjugated to FITC) for 15 min and then run on a flow cytometer. 
Size beads were run to set a size gate of 0.1 – 1 µm. The microvesicle gate was based on 
the media control. Count beads were used to calculate the volume uptaken during each 
run, to then calculate the concentration of microvesicles in each sample.
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4.2.2 Contact hypersensitivity response 
During my Honours, I established microvesicles from IL-4-treated mast cells were capable of 
activating B cells (Marsh-Wakefield, 2012). As such, it was hence of interest to determine whether 
these microvesicle-activated B cells were likewise capable of being functionally suppressive. The 
function of microvesicle-activated B cells was examined in vivo using a contact hypersensitivity 
response. This response is a model of T cell immunity, whereby a mouse is sensitised to an allergen 
(in this case DNFB) on the abdomen, and then challenged 5 days later on the ears. The level of ear 
swelling is representative of a T cell response, whereby a normal response has a large amount of ear 
swelling, whilst a decrease in swelling is a measure of a compromised response. This is commonly 
used in studies testing the suppressive nature of UV (Toews et al., 1980, De Fabo and Noonan, 
1983, El-Ghorr and Norval, 1995, Damian et al., 1999, Byrne et al., 2002, Grimbaldeston et al., 
2007). 
 
B cells were activated with microvesicles from either untreated or IL-4-treated BMMC for 48 hr. 
B cells were then centrifuged (300xg, 20 °C, 10 min) and resuspended in 5 mL cRPMI before being 
underlaid with Ficoll-Paque PREMIUM (GE Healthcare Life Sciences, Buckinghamshire, UK) and 
centrifuged at 800xg, 20 °C for 15 min with no brake. With dead cells now pelleted, live cells were 
washed with cRPMI and centrifuged (200xg, 20 °C, 10 min) before being resuspended at 15 x 106 
cells mL–1 in PBS. Each mouse was injected intravenously in the tail vein with 3 x 106 cells in 
200 µL PBS. 
 
24 hr after injection, mice were topically sensitised on their shaved abdomen with 0.5 % (v/v) 
DNFB (1-fluoro-2,4-dinitobenzene; 4:1 acetone:olive oil; 30 µL). Mice were then challenged 
5 days later, by applying 0.25 % (v/v) DNFB (15 µL) onto each ear of the mice. Absolute ear 
thickness was measured before challenge and then daily for a consecutive 5 days. 
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4.2.3 Co-immunoprecipitation assay of IL-35 
After B cells were co-cultured with mast cells or their microvesicles (or without further 
stimulation), cultured cells were centrifuged (21,000xg, 4 °C, 1 min) and the supernatant removed. 
Cells were then resuspended in 180 µL cell lysis buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 1 % 
(w/v) NP40, 1 % (v/v) Triton X-100) containing a protease inhibitor cocktail (diluted to 1.04 mM 
AEBSF, 0.8 µM aprotinin, 40 µM bestatin, 14 µM E-64, 20 µM leupeptin, 15 µM pepstatin A; 
Sigma-Aldrich) for 20 min on ice. Samples were then centrifuged (21,000xg, 4 °C, 15 min) and the 
supernatant (protein lysate) was collected and stored at –30 °C for later analysis. 
 
4.2.3.1 p35 pull-down 
Thawed protein lysates were cleared by incubating them with 1 µg of isotype antibody (rat IgG2a, 
clone eBR2a; eBioscience) together with 20 µL of protein A/G PLUS beads (Santa Cruz 
Biotechnology, Dallas, USA) for 30 min at 4 °C. This removed any non-specific binding to isotype 
antibodies or protein A/G beads. After centrifuging the beads (1,000xg, 4 °C, 5 min), 1 µg of anti-
p35 (clone C18.2; eBioscience) or 1 µg of rat IgG2a isotype antibody was added to the protein 
lysate and left to incubate at 4 °C for 1 hr. 20 µL of protein A/G PLUS beads was then added to 
samples for a further overnight incubation at 4 °C. The beads will bind the antibodies that have 
bound to p35. 
 
p35-labelled protein lysates were centrifuged (1,000xg, 4 °C, 5 min) and washed a further four 
times with 1 mL PBS. Samples were then diluted in XT reducing agent (Bio-Rad, Hercules, CA, 
USA) and Laemmli sample buffer (Bio-Rad) before being heated at 95 °C for 5 min to denature the 
proteins. Note this will denature proteins (including IL-35) into their subunits (i.e. EBI3 and p35). 
Samples were then added to a 4-20 % Mini-PROTEAN TGX precast gel (Bio-Rad) in running 
buffer (Tris/glycine/SDS buffer (Bio-Rad)), and run for 30 min at 200 V. Novex Sharp Pre-stained 
Protein Standard (Life Technologies) was used as a ladder. The gel was transferred onto a 
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hydrophobic polyvinylidene difluoride membrane (GE Healthcare) in transfer buffer (3.03 g Tris 
base, 14.4 g glycine, 10 % (v/v) methanol/MiliQ water) for 1 hr at 45 V. 
 
4.2.3.2 EBI3 co-immunoprecipitation 
Transfer membranes were washed in PBST (0.05 % (v/v) Tween-20/PBS) on a rocker at room 
temperature for 10 min before being blocked with 3 % (w/v) BSA/PBST for 30 min on a rocker at 
room temperature. Primary antibody (EBI3 was first stained, then p40 and then p35; Table 4.1) was 
then added to the membrane (diluted in 3 % (w/v) BSA/PBST at various concentrations) and left on 
the rocker in a cold room overnight. Primary antibody was poured off and retained for future stains 
and the membrane was washed in PBST for 1 hr, changing buffer every 10 min. It was then blocked 
in 5 % (w/v) skim milk powder/PBST at room temperature on a rocker for 30 min. Secondary 
antibody (anti-rat IgG, conjugated to HRP; 1/1,000 dilution in 5 % (w/v) skim milk powder/PBST) 
was then added and incubated for 1 hr at room temperature on a rocker. The membrane was then 
washed with PBST for 1 hr, changing buffer every 10 min. Equal volumes of stable peroxide 
solution and luminol/enhancer solution (SuperSignal West Pico Chemiluminescent substrate; 
Thermo Scientific, Waltham, Massachusetts, USA) was added to the membrane for 5 min. A 
ChemiDoc MP imager (Bio-Rad) was used to image the membrane. Membrane was then washed in 
stripping buffer for 20-30 min to remove excess antibody, and then washed in PBST for a further 
30 min, changing buffer every 10 min. The membrane was then stained again with anti-p40, and 
then repeated once more with antibody against p35. 
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Table 4.1 – Antibodies used for western blot. 
Target Clone Isotype Company Dilution 
EBI3 DNT27 Rat IgG2a eBioscience 1/500 
p35 C18.2* Rat IgG2a eBioscience 1/200 
p40 C15.6 Rat IgG2a eBioscience 1/200 
Rat IgG–HRP conjugated Polyclonal Goat IgG R&D Systems (HAF005) 1/1,000 
 
*Note the same clone was used for the pull-down and detection on western blot 
 
4.2.4 Detecting PAF by mass spectrometry 
Mast cells were first treated with IL-4 (or left untreated), and their microvesicles were collected. 
Mast cells were then diluted to a concentration of 1 x 106 cells mL–1 in cRPMI, whilst their 
microvesicles were left in a solution of 100 µL cRPMI. Samples were spiked with 50 nM 
deuterated-4 PAF (PAF C-16-d4; Cayman Chemical, Michigan, USA), to act as an internal 
standard. Deuterated-4 PAF is PAF (523.68 g mol–1) with 4 deuteriums added, a heavy isotope form 
of hydrogen, resulting in an additional 4 g mol–1 to the molecular weight of PAF (527.7 g mol–1). 
This allows samples to be normalised to the deuterated-4 PAF for a more accurate quantification of 
PAF. Because they have slightly different masses, it allows differentiation between the two 
molecules, but they are similar enough that they can be identified using the same LC-MS/MS 
protocol.  
 
A modified protocol from Bligh and Dyer (1959) was used to permeabilise the cells and 
microvesicles, whereby 100 µL of mast cells (or microvesicles) were added to equal parts 
chloroform and methanol (2 mL each), and then vortexed for 2 min. 1 mL chloroform was then 
added, followed by a 30 sec vortex. 1 mL of distilled water was then added with another 30 sec 
vortex. The methanol (top layer) dissolved proteins, whilst the lipids were in the chloroform 
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(bottom layer). The lipid-containing fraction was collected, and the solvents evaporated under 
vacuum at 60 °C using a Concentrator Plus (Eppendorf). The resulting dried lipid extracts were then 
resuspended in 200 µL solvent A (57:23:20 methanol:water:acetonitrile, 1 mM ammonium acetate) 
and transferred to eppendorf tubes. Lipids were centrifuged (20,817xg, 4 °C, 5 min), to pellet 
particulates that may have formed from drying. 100 µL of supernatant was then collected and added 
to mass spectrometry vials for analysis. Standard concentrations (0, 1, 5, 10, 50 nM) of carbamyl 
PAF (Enzo Life Sciences, Farmingdale, NJ, USA) were likewise spiked with 50 nM deuterated-4 
PAF, to allow quantification of PAF. Carbamyl PAF (539.4 g mol–1) is a stabilised form of PAF 
containing an additional carbamyl group. Because carbamyl PAF was used for optimising the 
parameters, the molecular weights were detected based off carbamyl PAF (539.4 g mol–1), rather 
than PAF (523.68 g mol–1). This meant the parameters may not be optimised for detecting PAF, 
which will be addressed in the discussion. 
 
Samples were run through an Agilent 1290 Infinity LC System (Agilent Technologies, Santa Clara, 
California, USA), using a ZORBAX Eclipse Plus C18 column (4.6 x 100 mm, 3.5 µm; Agilent 
Technologies), coupled to an Agilent 6400 Series Triple Quad LC/MS (Agilent Technologies). A 
triple quadrupole mass spectrometer allows identification of a precursor ion (in this case PAF), 
which is then broken apart into product ions that can be detected. This allows identification of 
specific molecules, providing differentiation from precursor ions that share the same mass. As such, 
data acquisition was performed using multiple reaction monitoring scanning in positive-ion mode, 
to select for particular precursor and product ions. The gradient ran from 50 % to 95 % solvent B 
(100 % methanol, 1 mM ammonium acetate) for the first 5 min, where it held for 5 min and then 
dropped to 50 % over the next 30 sec. Samples were run at a flow rate of 0.5 mL min–1. PAF was 
detected as a precursor ion of 539.4 g mol–1, with product ions of 184.1, 124.8 and 60 g mol–1, and a 
retention time of ~6.7 min. Deuterated-4 PAF was detected as 528.4 g mol–1, with product ions 184, 
124.8, and 86.3 g mol–1, and a retention time of ~6.9 min. Because the 184.1 g mol–1 was the most 
abundant product ion, this was used in all calculations. Between samples, a blank (containing only 
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water) was run. This helped clean the column between sample runs. PAF also has a very short half-
life (Stafforini et al., 1987, Liu et al., 2011), so to factor potential degradation that may occur 
before a particular sample is run, samples were run twice. Because there was not much of a 
difference between these two runs, only the data collected from the first run was used for analysis. 
 
Agilent MassHunter Qualitative Analysis B.07.00 software (Agilent Technologies) was used to 
analyse data, and determine peak areas where appropriate. To quantitate PAF levels, the peak area 
of carbamyl PAF was divided by the peak area of deuterated-4 PAF to develop a standard curve 
(Appendix E). Because all samples were spiked with the same level of deuterated-4 PAF (5 nM), it 
was possible to normalise samples to the internal standard to allow for a more accurate 
quantification. 
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4.3 Results 
4.3.1 Microvesicle-activated B cells decrease level of ear swelling after contact 
hypersensitivity response 
To determine whether, like mast cell-activated B cells (Leighton, 2009), microvesicle-activated 
B cells were immunosuppressive in vivo, a contact hypersensitivity response was used. A robust 
immune response will be evident by a swelling of the ear. An irritant control was also used, 
whereby mice were not sensitised, only challenged to DNFB. The increase in ear thickness in 
unsensitised irritant control mice was subtracted from the increase in ear thickness in sensitised 
mice to determine the absolute change in ear thickness as shown in Figure 4.2. The mice that 
received B cells cultured with microvesicles from IL-4-treated mast cells had significantly less 
swelling when compared to mice that received B cells cultured with microvesicles from untreated 
mast cells. 
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Figure 4.2 – Microvesicles from IL-4-treated bone marrow-derived mast cells 
activate functionally suppressive B cells. Mice had their abdomens shaved 24 hr prior 
to injection of cells. Mast cells were treated with 0.4 µg mL–1 IL-4 for 48 hr at 1 x 106
cells mL–1. Microvesicles were then collected by a series of centrifugations and cultured 
with B cells for a further 48 hr. 3 x 106 cells in PBS were then intravenously injected into 
the tail vein of mice. 24 hr after injection, mice were sensitised by applying 0.5 % (v/v) 
DNFB (1-fluoro-2,4-dinitobenzene; 4:1 acetone:olive oil; 30 µL) topically onto the 
abdomen. Mice were then challenged 5 days later, by applying 0.25 % (v/v) DNFB (15 µL) 
onto each ear of the mice. Each sample has the irritant control (only received challenge 
dose without sensitisation on abdomen) change in ear thickness subtracted from their 
original change in ear thickness to give the results shown. The results shown were taken 
24 hr after challenge. n = 5-11 mice/group from 1 independent experiment; Mann-Whitney 
test, median shown.
p = 0.0277
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4.3.2 IL-35 in supernatant of co-cultured B cells and mast cells 
IL-35 is made up of EBI3 and p35, but when EBI3 combines with p28 it forms IL-27 (Pflanz et al., 
2002). Further complicating matters is that p35 can also combine with p40 to form IL-12 
(Kobayashi et al., 1989). Therefore, to determine whether IL-35 was present in our cultures, it was 
necessary to conduct a co-immunoprecipitation assay. Anti-p35 was first used to pull-down all p35 
(both free floating and p35 that might be combined with EBI and/or p40). This pull-down was then 
followed by a western blot probing for specific subunits with different specific primary antibodies. 
This included a denaturing step to break apart proteins (including IL-35) into their subunit (i.e. 
EBI3 and p35). Figure 4.3 shows six western blots from 3 separate mast cell:B cell co-cultures 
probed for EBI3 (isotype controls are also shown). The two bands visible in all images (including 
the isotype control blots) correspond to the heavy and light chains of the original antibody used for 
the pull-down. This is due to the secondary antibody (anti-rat IgG2a-HRP conjugated) recognising 
both the heavy and light chains of the primary antibodies probing for EBI3, p35 and p40 (all rat 
IgG2a antibodies). The arrowheads indicate the co-location of positive EBI3 staining with the 
pulled down p35 and is of the expected weight (i.e. 34 kDa for EBI3). These results show that IL-35 
is present within all co-cultures. 
 
Antibodies against p40 (Figure 4.4) and p35 (Figure 4.5) were also used after the p35 pull-down to 
determine whether they too were present in the culture. While both investigations returned positive 
results, it should be noted that the same membranes were stained in the order of EBI3, p40 then 
p35, and all antibodies were of the same isotype meaning that, even though membranes were 
stripped between stains, it is possible for residual antibodies to remain attached giving false positive 
results. This is further complicated by the similar molecular weights of EBI3, p40 and p35, which 
are 34 kDa, 40 kDa and 35 kDa respectively. 
  
isotype EBI3 (34 kDa)
Figure 4.3 – Detection of IL-35 (p35+EBI3) by co-immunoprecipitation assay. Bone 
marrow-derived mast cells were first treated with 0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells 
mL–1. Cells and their microvesicles were then collected by a series of centrifugations. 
These were then co-cultured with B cells for a further 48 hr. 5 hr prior to completion, cells 
were then stimulated with PMA (50 ng mL–1), ionomycin (500 ng mL–1), LPS (10 µg mL–1) 
and brefeldin A. Cells were lysed (150 mM NaCl, 50 mM Tris (pH 8.0), 1 % (w/v) NP40,
1 % (v/v) Triton X-100, protease inhibitor cocktail), and the protein lysate was then cleared 
using an isotype antibody with protein A/G PLUS beads. A pull-down was then done using 
anti-p35. Samples were then put through an SDS PAGE, followed by a western blot 
transfer using a hydrophobic polyvinylidene difluoride (PVDF) membrane. These were 
then stained using anti-EBI3 (this figure), then anti-p40 (Figure 4.4) and finally anti-p35 
(Figure 4.5), using stripping buffer between each stain to remove residual antibody. Well 
numbers indicate: 1) Molecular weight ladder (25, 37 and 50 kDa bands labelled) 2) B cells 
alone 3) B cells + untreated mast cells 4) B cells + IL-4-treated mast cells 5) B cells + 
untreated mast cell-derived microvesicles 6) B cells + IL-4-treated mast cell-derived 
microvesicles. Each row represents a different mast cell-B cell co-culture. Arrow heads 
indicate EBI3 staining. HC heavy chain, LC light chain (of pull-down antibody). n = 3 over 2 
independent experiments.
Note the bottom right image was cut through well 1, so the image is slightly misaligned.
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isotype p40 (40 kDa)
Figure 4.4 – Detection of IL-12 (p35+p40) by co-immunoprecipitation assay. Legend 
as for Figure 4.3. Well numbers indicate: 1) Molecular weight ladder (25, 37 and 50 kDa 
bands labelled) 2) B cells alone 3) B cells + untreated mast cells 4) B cells + IL-4-treated 
mast cells 5) B cells + untreated mast cell-derived microvesicles 6) B cells + IL-4-treated 
mast cell-derived microvesicles. Each row represents a different mast cell-B cell 
co-culture. Arrow heads indicate p40 staining. HC heavy chain, LC light chain (of 
pull-down antibody). n = 3 over 2 independent experiments.
Note the bottom right image was cut through well 1, so the image is slightly misaligned. 
Also note that as the blots were stripped, the ladder became less prominent.
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isotype p35 (35 kDa)
Figure 4.5 – Detection of p35 by co-immunoprecipitation assay. Legend as for Figure 
4.3. Well numbers indicate: 1) Molecular weight ladder (25, 37 and 50 kDa bands labelled) 
2) B cells alone 3) B cells + untreated mast cells 4) B cells + IL-4-treated mast cells
5) B cells + untreated mast cell-derived microvesicles 6) B cells + IL-4-treated mast 
cell-derived microvesicles. Each row represents a different mast cell-B cell co-culture. 
Arrow heads indicate p35 staining. HC heavy chain, LC light chain (of pull-down antibody). 
n = 3 over 2 independent experiments.
Note the bottom right image was cut through well 1, so the image is slightly misaligned. 
Also note that as the blots were stripped, the ladder became less prominent.
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4.3.3 IL-4-treated mast cells alter B cell production of IL-35 subunits 
Although the co-immunoprecipitation analysis confirmed the presence of IL-35 by showing the 
binding of p35 to EBI3, this assay is unable to reliably quantitate the levels of each individual 
subunit arising from the different co-cultures. To investigate this, I performed intracellular flow 
cytometry for p28, p35, p40 and EBI3. B cells were cultured alone, with IL-4-treated (or untreated) 
mast cells, or with the respective mast cell-derived microvesicles. While B cells from all culture 
conditions produced EBI3 (Figure 4.6) there was a significant decrease in the level of EBI3 
production from B cells after co-culture with mast cells (with and without IL-4). 
 
The levels of p28 (Figure 4.7A) and p40 (Figure 4.7B) inside B cells were below the isotype control 
and hence considered negative for these subunits. In contrast, 5-10% of B cells, regardless of the 
culture conditions, had detectable levels of p35 (Figure 4.7C). There was a significant increase in 
the level of B cell-produced p35 after co-culture with mast cells (with or without IL-4). In contrast, 
culturing the B cells with mast cell-derived microvesicles did not raise the level of B cell p35. Thus, 
B cells may produce IL-35, the amount of which that can be modulated by co-culture with mast 
cells, but not their microvesicles.  
 
4.3.4 Mast cells do not alter B cell production of IL-10 or IL-13  
In Chapter 3, it was discovered that IL-4 together with B cells could increase mast cell production 
of IL-10 and IL-13. It was hence of interest to determine whether mast cells (or their microvesicles) 
in turn could also influence B cell production of IL-10 and IL-13. Data shown in Figures 4.8 and 
4.9 indicate that there was no effect of mast cells on B cell production or IL-10, or IL-13. 
  
Figure 4.6 – Untreated and IL-4-treated mast cells (but not their microvesicles) affect 
B cell cytokine production of IL-35 (and IL-27) subunit EBI3. Bone marrow-derived 
mast cells were first treated with 0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. Splenic
B cells were then isolated and cultured with either the mast cells (at a 10:1 ratio) or their 
microvesicles for a further 48 hr. 5 hr prior to completion, cells were then stimulated with 
PMA (50 ng mL–1), ionomycin (500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM). 
Samples were stained with antibodies specific for EBI3-PE by intracellular flow cytometry 
(representative flow plots are shown). Figure 3.1 shows the gating strategy used to 
differentiate B cells from mast cells. Dotted vertical lines represent the median of the 
isotype control across all groups and experiments, whereby anything less than this would 
be considered as negative for EBI3. n = 5 from 5 independent experiments; Kruskal-Wallis 
test (Dunn’s post test), median shown.
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Figure 4.7 – Untreated and IL-4-treated mast cells (but not their microvesicles) 
modulate B cell production of p35. Bone marrow-derived mast cells were first treated 
with 0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. Splenic B cells were then isolated and 
cultured with either the mast cells (at a 10:1 ratio) or their microvesicles for a further 48 hr. 
5 hr prior to completion, cells were then stimulated with PMA (50 ng mL–1), ionomycin
(500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM). Samples were stained with
(A) anti-p28-PE, (B) anti-p40-PE or (C) anti-p35-eFluor 660 antibodies for intracellular flow 
cytometry (representative flow plots are shown in Appendix D). Figure 3.1 shows the 
gating strategy used to differentiate B cells from mast cells. Dotted vertical lines represent 
the median of the isotype control across all groups and experiments, whereby anything 
less than this would be considered as negative for the subunit of interest. n = 3-5 from 3-5 
independent experiments; Kruskal-Wallis test (Dunn’s post test), median shown.
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Figure 4.8 – Neither mast cells nor their microvesicles affect B cell production of 
IL-10. Bone marrow-derived mast cells were first treated with 0.4 µg mL–1 IL-4 for 48 hr at 
1 x 106 cells mL–1. Splenic B cells were then isolated and cultured with either the mast cells 
(at a 10:1 ratio) or their microvesicles for a further 48 hr. 5 hr prior to completion, cells were 
then stimulated with PMA (50 ng mL–1), ionomycin (500 ng mL–1), LPS (10 µg mL–1), 
monensin (2 µM), anti-CD40 (10 µg mL–1) and anti-kappa (15 µg mL–1). Samples were 
stained with antibodies specific for IL-10-PE by intracellular flow cytometry (representative 
flow plots are shown). Figure 3.1 shows the gating strategy used to differentiate B cells 
from mast cells. Dotted vertical lines represent the median of the isotype control across all 
groups and experiments, whereby anything less than this would be considered as negative 
for IL-10. n = 6, from 6 independent experiments; Kruskal-Wallis test (Dunn’s post test), 
median shown.
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Figure 4.9 – Neither mast cells nor their microvesicles affect B cell production of 
IL-13. Bone marrow-derived mast cells were first treated with 0.4 µg mL–1 IL-4 for 48 hr at 
1 x 106 cells mL–1. Splenic B cells were then isolated and cultured with either the mast cells 
(at a 10:1 ratio) or their microvesicles for a further 48 hr. 5 hr prior to completion, cells were 
then stimulated with PMA (50 ng mL–1), ionomycin (500 ng mL–1), LPS (10 µg mL–1) and 
monensin (2 µM). Samples were stained with antibodies specific for IL-13-PE by 
intracellular flow cytometry (representative flow plots are shown). Figure 3.1 shows the 
gating strategy used to differentiate B cells from mast cells. Dotted vertical lines represent 
the median of the isotype control across all groups and experiments, whereby anything 
less than this would be considered as negative for IL-13. n = 6, from 6 independent 
experiments; Kruskal-Wallis test (Dunn’s post test), median shown.
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4.3.5 Microvesicle-activated B cells promote mast cell production of IL-13 
Up to this point, my results suggest that B cells are likely to be immune suppressive via a potential 
cross-talk with mast cells; analysis has so far been restricted to one-way interactions. However, it is 
possible that microvesicle-activated B cells in turn could interact with and influence the activation 
status of otherwise untreated mast cells. To investigate this, B cells were first activated with 
microvesicles from IL-4-treated mast cells and then cultured with previously untreated, fresh mast 
cells. The level of mast cell-derived IL-13 is shown in Figure 4.10. Only the B cells activated with 
microvesicles from IL-4-treated mast cells, and not the control B cells, could induce IL-13 
production in untreated mast cells. These results confirm that there is indeed an immune 
suppressive cross-talk between activated B cells and mast cells. There was no change in the level of 
mast cell-derived IL-10, EBI3, p28, p35 or p40 (data not shown). 
 
4.3.6 PAF levels were unaffected in mast cells or their microvesicles following 
IL-4 treatment 
Based off the collective data whereby IL-4-treated mast cells and their microvesicles are capable of 
activating functionally suppressive B cells, I wanted to test other molecules the mast cells (or their 
microvesicles) may be producing. PAF has been well studied in the context of UV-induced immune 
suppression (Barber et al., 1998, Walterscheid et al., 2002, Marathe et al., 2005, Wolf et al., 2006, 
Sreevidya et al., 2008, Zhang et al., 2008, Zhang et al., 2009, Sreevidya et al., 2010, Chacon-
Salinas et al., 2014), including a possible role in the activation of B cells following UV (Matsumura 
et al., 2006). During my Honours, I found I could inhibit the activation of B cells by mast cells 
when using PAF receptor antagonists (Marsh-Wakefield, 2012). As such, I was interested in 
determining whether mast cells or their microvesicles could be induced to produce PAF following 
IL-4 treatment. Figure 4.11 shows the ratio of PAF:deuterated-4 PAF. Note that all samples were 
below the limit of detection (1 nM PAF), but samples were still above the blanks (data not shown). 
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Although PAF could not be quantified, the relative levels could be analysed. There was no 
difference in the level of PAF after IL-4 treatment in mast cells or microvesicles when compared to 
their respective untreated controls. 
  
Figure 4.10 – Microvesicle-activated B cells promote mast cell production of IL-13. 
Mast cells were first treated with 0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. They then 
had their microvesicles isolated by a series of centrifugations, and then added to isolated 
splenic B cells for 48 hr. The microvesicles were washed off the B cells, which were then 
added to untreated mast cells for a further 48 hr. 5 hr prior to completion, cells were then 
stimulated with PMA (50 ng mL–1), ionomycin (500 ng mL–1), LPS (10 µg mL–1) and 
monensin (2 µM). Samples were stained with antibodies specific for IL-13-PE by 
intracellular flow cytometry (representative flow plots are shown). Dotted vertical lines 
represent the median of the isotype control across all groups and experiments, whereby 
anything less than this would be considered as negative for IL-13. n = 5-6 from 5-6 
independent experiments; Kruskal-Wallis test (Dunn’s post test), median shown.
p = 0.0449
0 10 20 30
isotype
IL-13+ mast cells (% of mast cells)
Mast cell co-culture
Untreated mast cell-derived
microvesicles + B cells
B cells
IL-4-treated mast cell-derived
microvesicles + B cells
0-10 3 10 3 10 4 10 5
0
50K
100K
150K
200K
250K
0-10 3 10 3 10 4 10 5
0
50K
100K
150K
200K
250K
0-10 3 10 3 10 4 10 5
0
50K
100K
150K
200K
250K
0-10 3 10 3 10 4 10 5
0
50K
100K
150K
200K
250K
IL-13
isotype IL-13
Mast cells +
untreated mast cell-
derived microvesicles
(+ B cells)
Mast cells +
IL-4-treated mast cell-
derived microvesicles
(+ B cells)
Fo
rw
ar
d 
Sc
at
te
r
103
Figure 4.11 – IL-4 does not affect mast cell (or microvesicle)-derived PAF. Mast cells 
were first treated with 0.4 µg mL–1 IL-4 (closed symbols) or left untreated (open symbols) 
for 48 hr at 1 x 106 cells mL–1. Microvesicles were isolated by a series of centrifugations. 
Mast cells and microvesicles had their lipids extracted by methonal/chloroform solution. 
Isolated lipids were then run on a mass spectrometer to quantify the levels of PAF. Blanks 
(water) were run between samples to remove residual lipids. (A) shows represented 
graphs indicating PAF (539.4 g mol–1) product ion 184.1 g mol–1. The highlighted peaks 
indicate the areas calculated to quantify relative abundance. (B) shows the ratio of PAF to 
the internal standard (deuterated-4 PAF).The dotted horizonal line is the limit of detection 
(1 nM standard). n = 4 from 3 independent experiments, where pairs and like symbols 
represent the same culture; Wilcoxon test; ns not significant.
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4.4 Discussion 
Our laboratory has confirmed that bone marrow-derived mast cells (BMMC) treated with IL-4 are 
capable of activating B cells that can suppress the induction of an immune response (Leighton, 
2009). In addition, during the conduct of my Honours research I discovered that microvesicles from 
these IL-4-treated mast cells were also capable of activating B cells (Marsh-Wakefield, 2012). What 
was not yet clear was whether these microvesicle-activated B cells were also capable of suppressing 
an immune response. To address this, a contact hypersensitivity response was conducted to assess 
the T cell-mediated response. It should be noted that B cells were transferred into mice prior to 
sensitisation, rather than after. A decrease in ear swelling would hence indicate a suppression of the 
induction phase, as opposed to the effector phase (which could be tested by adding B cells after 
sensitisation but before challenge). This model was previously used when testing mast cell-
activated B cells (Leighton, 2009). Matsushita et al. (2008) found depletion of B cells prior to 
induction of EAE worsened disease outcome, but conferred protection if depletion was conducted 
after induction, highlighting the potential for B cells to prevent the induction of disease. 
Considering these experiments, the model used seemed to be appropriate for this study. 
 
Mice that received B cells activated with microvesicles from IL-4-treated mast cells (prior to 
sensitisation) had significantly less ear swelling compared to mice that were injected with B cells 
cultured with microvesicles from untreated mast cells. This shows that the microvesicle-activated 
B cells are capable of suppressing the induction of an immune response. It would be interesting to 
inject these B cells after sensitisation but before challenge, to determine if they could suppress the 
effector phase, but based on the above literature I hypothesise there will be no effect on ear 
swelling. Interestingly however, when microvesicles were injected directly into the mouse they did 
not have this effect (data not shown), although these results will need to be confirmed in future 
repeats of this experiment. The lack of immune suppression by injection of microvesicles alone is 
not surprising, as I identified microvesicles based off their expression of phosphatidylserine, which 
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can act as a signal for apoptosis and can be recognised by phagocytes to induce phagocytosis 
(Fadok et al., 2001, Hoffmann et al., 2001). This in turn may prevent any immune suppression from 
occurring. Although annexin V was used for microvesicles identification, it is important to note not 
all microvesicles are positive for annexin V (Connor et al., 2010, Arraud et al., 2014). For future 
experiments dual staining annexin V alongside mast cell-specific markers (such as CD117 or 
FcεRIα) may provide more definitive identification. Injecting fluorescently labelled microvesicles 
to visualise their progression would provide insight into their interaction in vivo. The activation of 
functionally suppressive B cells is not likely due to residual IL-4 from mast cell activation, as IL-4 
would not be pelleted alongside the microvesicles. As Grimbaldeston et al. (2007) did histology 
alongside their contact hypersensitivity response assays, similar experiments could also be done to 
visualise whether B cells or mast cells are being recruited to the swelling ears (to act directly at the 
site of inflammation). It should be noted the ability of extracellular vesicles to activate regulatory 
cells has previously been reported. Szajnik et al. (2010) found exosomes from the supernatant of 
tumour cells (but not normal cells) could induce generation and enhance expansion of regulatory 
T cells. Similarly, B cells activated by exosomes from cancer patients could suppress CD8+ T cell 
proliferation in a TGF-β-dependent mechanism (Li et al., 2015b). It should be noted however that 
both these studies refer to their vesicles as “microvesicles”, but they used 100,000xg to isolate 
them. This force is likely to isolate exosomes. For comparison, my centrifugations were done at 
16,100xg. Regardless, these studies found extracellular vesicles were capable of inducing 
functionally suppressive cells, supporting my similar finding. 
 
It is also interesting to consider some pro-inflammatory effects mast cell-derived vesicles have been 
found to offer. Exosomes from mast cells have previously been shown to promote splenocyte 
proliferation and blast formation (Skokos et al., 2001), as well as increase antigen presentation by 
dendritic cells as determined by an increase in T cell production of IL-2 (Skokos et al., 2003). 
There may be different components either in or on mast cell-derived vesicles, allowing a diverse 
range of actions. It would hence also be interesting to determine how the microvesicles may be 
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interacting with the B cells, as to whether they are being internalised or being fused with the B cell 
membrane. To test this, mast cells could have their membrane fluorescently dyed such that any 
microvesicles produced (which are cell membrane-derived) would also be dyed. Using 
immunofluorescence, it would be possible to determine where on/in the B cells these microvesicles 
are targeting, which may give an indication to their mechanism of action. Although extracellular 
vesicles from mast cells have been shown to activate a diverse range of immune cells, this is the 
first report of mast cell-derived microvesicles activating functionally suppressive B cells. What is 
not yet known is how these B cells may be modulating the immune system.  
 
When investigating how these B cells may be immunosuppressive, I investigated the different 
cytokines they may be producing. Of particular interest was IL-35, a cytokine originally discovered 
within human trophoblasts, as a heterodimer made up of p35 and EBI3 (Devergne et al., 1997). In 
recent years, regulatory B cells have been found to produce IL-35 in the context of autoimmune 
diseases (Shen et al., 2014, Wang et al., 2014) as well as cancer (Pylayeva-Gupta et al., 2015), but 
the potential role of mast cells (and microvesicles) influencing B cell production of IL-35 has not 
yet been reported. Because there are no antibodies specific for IL-35, the two subunits had to be 
separately targeted. Complicating this approach is the fact that EBI3 can bind with a different 
subunit, p28, to form IL-27 (Pflanz et al., 2002). Furthermore, p35 can bind with p40 to form IL-12 
(Kobayashi et al., 1989). Therefore the only way to show EBI3 and p35 are coming together to 
form IL-35 is by performing a co-immunoprecipitation assay. Figure 4.3 shows a western blot 
against EBI3 following a p35 pull-down. Proteins made up of p35 (including IL-12 and IL-35) were 
first collected during the p35 pull-down. In turn, these proteins were then denatured to break apart 
any proteins into their subunits (i.e. any IL-35 present would be broken into EBI3 and p35). When 
these were then run on a western blot to be stained against EBI3, if IL-35 were present, a band 
against EBI3 would appear at its molecular weight of 34 kDa, not where you would expect to see 
IL-35 (78 kDa). The isotype control confirms not only the success of the p35 pull-down, but the 
specificity of the antibody for EBI3. The two bands that are present within the isotype control blot 
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represent the heavy and light chains of the antibody used for the pull-down (isotype or anti-p35). As 
the antibodies used for the pull-down were rat IgG, the secondary antibody (anti-rat IgG2a-HRP 
conjugated) recognised both the heavy and light chains, and hence can be seen on the blots. When 
targeting EBI3, there was a third band present between the heavy and light chains, but not in the 
isotype control pull-down. This confirms the presence of EBI3 in the co-immunoprecipitation 
assay. Because this was after the p35 pull-down, EBI3 was bound to p35 in the form of IL-35. EBI3 
(and hence IL-35) was detected in all the experimental groups, including B cells alone, which is 
also reflected in the intracellular staining of EBI3. This was likewise true for p35, whereby all 
B cell co-cultures had detectable p35.  
 
It should be noted however the band present in the EBI3 stain is closer to 25 kDa in weight, as 
opposed to being 34 kDa in weight. A monoclonal antibody was used to stain against EBI3 (clone 
DNT27, eBioscience), so should be specific for EBI3. Although the conformation of proteins may 
affect their appeared weight on a western blot, because there were no bands present in the isotype 
control it supports our interpretation of identifying IL-35. For repeated experiments, it would be 
worthwhile to include a positive control (recombinant murine IL-35). Running a sample without the 
pull-down would also assist in interpretation, to remove the heavy and light chains, as well as 
confirm the quality of the pull-down. By using a “softer” denaturation process, it may keep the 
pull-down antibodies whole, but still break apart the dimer proteins. This would remove the heavy 
and light chain bands, but have one larger band indicating the pull-down antibody. It is also 
important to consider how the band present within the p35 and p40 stains were in the same location 
as the EBI3 stain, even though they should be slightly different. This suggests the stripping done 
between stains was not completely efficient. As all primary antibodies used for western blot 
staining were the same isotype, the secondary antibody used would be able to react against any 
residual antibody still present from the prior stain. This would explain why the same band appears 
in all stains. Although p40 did not appear in the correct location (at 40 kDa), it may suggest it is not 
present, which is supported by the intracellular flow data. To confirm this, a positive control 
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(recombinant murine heterodimer of IL-12) would be required for any future experiments. It would 
also be worth reversing the staining process (first stain against p35, then p40 and then EBI3) to 
address any residual false positives.  
 
Although we could specifically detect IL-35 across all conditions, this method is not sensitive 
enough to quantitate small shifts in cytokine production, which is why intracellular flow cytometry 
was done on IL-35 subunits EBI3 and p35. Interestingly, I discovered that mast cells (with or 
without IL-4 treatment) significantly decreased B cell production of EBI3. In contrast, p35 was 
increased in activated B cells, with no change in p28 or p40. Others have confirmed, at least in 
human B cells, that p28, even following stimulation with anti-CD40/IL-4 is undetectable 
(Larousserie et al., 2006a). 
 
The increase in p35 production by B cells suggests they may be immunoregulatory. Work by Shen 
et al. (2014) found adoptive transfer of p35–/– B cells into mice could not protect the mice from 
EAE. This study went on to show the importance of B cell-derived IL-35 for protection from EAE 
disease. Because there was a decrease in EBI3, it is possible that p35 is acting independently from 
EBI3. Interestingly, p35 (or CDK5R1) was first identified as an activator of cyclin-dependent 
kinase 5 (Lew et al., 1994, Tsai et al., 1994). This may be important, as more recent studies have 
found inhibition of cyclin-dependent kinases to suppress development of EAE by interfering with 
T cell responses (Pareek et al., 2010, Yoshida et al., 2013). Although these latter studies suggest 
p35 may play a pro-inflammatory role, Patrick et al. (1998) found inhibition of cyclin-dependent 
kinase 5 could increase the half-life of p35 two-three fold. This may allow p35 to interact with 
EBI3 to form IL-35, and hence assist in immunoregulation. Although EBI3 was decreased in the 
B cells, it may be possible for B cell-derived p35 to interact with mast cells. It has recently been 
reported mast cells can take up exogenous IL-17, which could then be released again in an active 
form (Noordenbos et al., 2016). If a similar event can occur with other proteins, it may be possible 
the B cell-derived p35 is being taken up by the mast cells. In turn, this may form IL-35 within the 
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mast cell and contribute to immune regulation. Co-culture of mast cells and p35-deficient B cells 
could determine this possibility. 
 
In contrast to p35, the decrease in B cell production of EBI3 after co-culture with mast cells 
suggests the B cells may in fact be pro-inflammatory. B cells from pancreatic tumours have been 
found to have an increase in Ebi3 mRNA, with IL-35-producing B cells involved in cancer growth 
(Pylayeva-Gupta et al., 2015). At the same time, adoptive transfer of EBI3–/– B cells into mice have 
worsened EAE (Shen et al., 2014). There has also been a correlation between EBI3 and Foxp3, 
whereby regulatory T cells from the spleen of mice co-express Foxp3 and EBI3 (Ouyang et al., 
2011). However, mice induced to have allergic rhinitis had a decreased level of Foxp3 and EBI3 
within their regulatory T cells, but no change in number. These studies suggest the decrease in EBI3 
found in B cells after co-culture with mast cells may in fact not be immunoregulatory. At the same 
time however, human T cells have been found to not constitutively express EBI3, and even 
regulatory T cells could not be induced to express EBI3 (and hence IL-35) after CD3/CD28 
stimulation (Bardel et al., 2008). This study highlights the fact regulatory cells do not need IL-35 to 
suppress the immune system. My results found ~50 % of B cells to constitutively express EBI3, so 
the drop to ~40 % expression may not be a functionally relevant decrease. Regardless, my data 
found both mast cell- and microvesicle-activated B cells are indeed functionally suppressive, but it 
may not be the B cells that are directly suppressive, but rather a further interaction with the mast 
cells. 
 
The other cytokines of interest included IL-10 and IL-13. However, there was no significant 
difference in the level of cytokine production in any of the groups. Although all groups had 
detectable cytokine, it was surprising there was no change in IL-10 or IL-13 levels, as we 
hypothesised B cells would be the primary producers. In Chapter 3, only after co-culture with 
B cells could the IL-4-treated mast cells produce IL-10, whilst IL-4 treatment alone could promote 
mast cell IL-13 production. As there is no difference in cytokine production by B cells, it may be 
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they are suppressive via an interaction with mast cells. Lu et al. (2006) provided evidence 
regulatory T cells may act to suppress the immune system via the activation of mast cells. There is a 
lot of evidence in the literature highlighting the ability of mast cells to directly suppress the immune 
system (Hart et al., 1998, Grimbaldeston et al., 2007). This is particularly true considering the 
increased level of IL-10 production by IL-4-treated mast cells only after co-culture with B cells 
(Chapter 3). Hence, it may be the microvesicle-activated B cells are suppressing the immune system 
via mast cells. 
 
To investigate this possible cross-talk, B cells were cultured with microvesicles and then added to 
untreated mast cells. What I discovered was that only the B cells activated by microvesicles from 
IL-4-treated mast cells were capable of promoting mast cell production of IL-13. This supports my 
hypothesis that these B cells are immunosuppressive via an interaction with mast cells 
(Figure 4.12). This hypothesis is further supported by the situation that occurs following exposure 
to UV. Resident and newly recruited mast cells encounter an IL-4-rich cutaneous environment 
(Teunissen et al., 2002). The microvesicles these IL-4-treated mast cells produce are capable of 
rapidly (i.e. within 30-120 min) travelling via the lymphatics (Kunder et al., 2009) to the draining 
lymph nodes. While my in vitro studies confirm that these microvesicles can activate regulatory 
B cells, they also show that these B cells engage with mast cells, and most likely other lymph node 
cells, to mediate their suppression of immunity. Following exposure to UV, I propose that mast 
cell-derived microvesicles reach the B cell follicles prior to the migration of dermal mast cells. 
Kinetically mast cell-derived microvesicles could conceivably be priming B cells for at least 24 hr 
before the arrival of mast cells. Following their arrival in the B cell follicles of lymph nodes, mast 
cells could then collaborate with microvesicle-activated B cells, to promote immunosuppression. To 
test this hypothesis, future experiments could involve testing the immune response of mast cell-
deficient mice injected with microvesicle-activated B cells. If the microvesicle-activated B cells 
could not suppress the immune system (but could be restored through adoptive transfer of mast 
cells), this would mean mast cells are required for B cells to be immunosuppressive. Alternatively, 
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the CXCR4 antagonist AMD3100 could be used, as it inhibits UV-induced mast cell migration 
from the dermis to the skin-draining lymph nodes (Byrne et al., 2008). Because microvesicle 
formation would not be inhibited, the B cells could be phenotyped to determine whether mast cells 
were still capable of influencing B cell activation whilst remaining in the dermis. Although 
AMD3100 prevented both UV-induced immune suppression (Byrne et al., 2008) and 
carcinogenesis (Sarchio et al., 2014), it does suggest B cells require both mast cells and their 
microvesicles to be functionally suppressive. 
 
As well as this, microvesicles from IL-4-treated mast cells may be promoting B cells to produce 
microvesicles of their own that in turn influence mast cells. In fact, T cell-derived microvesicles 
have been found to directly influence mast cells. Human activated T cells have been found to 
produce microvesicles capable of promoting mast cell activity (Shefler et al., 2010), including 
production of IL-24 (Shefler et al., 2014). If B cells are likewise producing microvesicles, it would 
not be surprising if they influence mast cell cytokine production. To test this, B cells would first be 
cultured with microvesicles from IL-4-treated mast cells. The microvesicles from microvesicle-
activated B cells could then be collected and added to untreated mast cells, and then tested for 
cytokine production (particularly IL-13). To control for any residual microvesicles from the original 
IL-4-treated mast cells, microvesicles from IL-4-treated mast cells could be added directly to 
untreated mast cells. 
 
Another aspect to consider is what may be inside the IL-4-treated mast cells or their microvesicles 
to allow activation of functionally suppressive B cells. PAF anatagonist CV 3988 has been found to 
block the activation of B cells following UV exposure (Matsumura et al., 2006). I was hence 
interested in quantifying the levels of PAF within IL-4-treated mast cells and their microvesicles, 
and whether IL-4 could influence its production. Although we could not accurately quantify the 
levels of PAF (as readings were below the minimum 1 nM PAF standard), it was still possible to 
compare samples based off the internal standard, deuterated-4 PAF, because samples were all above 
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the blank controls run between samples. As such, there was no significant difference in the levels of 
PAF in IL-4-treated mast cells or their microvesicles when compared to their respective untreated 
controls. Because the half-life of PAF is so short, approximately 7-9 min in human blood/plasma 
(Stafforini et al., 1987) or 30 sec when injected into mice (Liu et al., 2011), it may be PAF is 
degrading too quickly to be quantified, particularly because each run takes at least 10.5 min. 
Although samples were run through the instrument twice (without much difference between runs), 
it still took time between extraction of cells/microvesicles, lipid preparation and running time. 
Samples could be extracted in an oxygen-free environment (such as saturating the air with 
nitrogen). It may also be important to consider the optimisation, which was done on carbamyl PAF 
(PAF with an added carabamyl group to help stabilise the lipid). Carbamyl PAF has a molecular 
weight of 538.7 g mol–1, whilst PAF is 523.68 g mol–1. This means our experiment may not be 
detecting all levels of PAF, which could explain our limited detection. For future experiments, it 
may be better to optimise using PAF rather than carabamyl PAF. Furthermore, to get an accurate 
quantification samples could be run at a higher concentration of cells/microvesicles, or run with 
more dilute standard controls (such as 100 pM PAF). One interesting observation is that the 
microvesicles (regardless of IL-4 treatment) had a greater level of PAF when compared to mast 
cells. This likewise supports our ability to detect PAF. When considering the larger amount in 
microvesicles, it reflects my observation whereby IL-4-treated mast cell-derived microvesicles were 
more capable of activating B cells than the IL-4-treated mast cells (Marsh-Wakefield, 2012). 
Furthermore, Matsumura et al. (2006) found PAF receptor was important for the activation of 
B cells following UV. It may be B cells have an upregulated level of PAF receptor, to allow 
activation by PAF within mast cell-derived microvesicles. However, it is also important to note not 
all the mast cells cultured were run through the mass spectrometer, but all of their microvesicles 
were. For future experiments, all mast cells could be collected and run, such that we could directly 
compare the level of PAF from the mast cell source and their microvesicle products. 
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The data presented thus far highlight how microvesicles from IL-4-treated mast cells can activate 
functionally suppressive B cells. In turn, these microvesicle-activated B cells promote mast cell 
production of IL-13. This may be particularly important, as Chapter 3 found IL-4-treated mast cells 
had upregulated IL-10 levels only after co-culture with B cells. Together, the data suggest a cross-
talk occurring between mast cells and B cells, resulting in immune suppression. The experiments 
thus far have used murine cells, so the next step was to determine whether human mast cells (and 
their microvesicles) could likewise activate regulatory B cells. 
  
Figure 4.12 – Proposed influence of IL-4-treated mast cells and their microvesicles 
on B cells. (1) Mast cells are first treated with IL-4. (2) IL-4-treated mast cells produce 
microvesicles. (3) Microvesicles from IL-4-treated mast cells activate B cells.
(4) Microvesicle-activated B cells in turn interact with untreated mast cells to promote their 
production of IL-13. (5) Microvesicle-activated B cells cause immune suppression via this 
cross talk with mast cells.
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Chapter 5 
HUMAN IL-4-TREATED 
MAST CELLS ACTIVATE 
B CELLS TO HAVE A 
REGULATORY PHENOTYPE 
 
The Owlsmith was a rare creature that had the power 
to leave the confinements of Hell, but chose to remain and 
feed off others’ dilemmas. They were not someone Josephine 
wanted to mess around with, but what she offered them was 
more than enough to receive their help: knowledge… 
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Chapter 5: Human IL-4-treated mast cells activate B cells 
to have a regulatory phenotype 
5.1 Introduction 
B cells with immune suppressive capacities are associated with many human conditions including 
allergy, asthma, acute inflammation, transplantation, cancer and autoimmunity (such as multiple 
sclerosis, rheumatoid arthritis, inflammatory bowel disease). CD19+ CD24hi CD38hi regulatory 
B cells within peripheral blood of systemic lupus erythematosus patients have been found to have a 
decreased regulatory capacity, as unlike those from healthy donors they fail to suppress anti-CD3-
induced CD4+ T cell production of TNF and IFN-γ (Blair et al., 2010). Patients with allergic asthma 
present with a reduced number of CD24hi CD27+ memory B cells within peripheral blood, as well 
as a decreased level of IL-10 production following lipopolysaccharide (LPS) treatment of isolated 
B cells (van der Vlugt et al., 2014). Patients suffering from common variable immunodeficiency 
(whereby there is a deficiency in serum immunoglobulins) have a decreased level of IL-10-
producing CD19+ CD24hi CD38hi B cells, with a concordant increase in the number of IFN-γ+ 
TNF-α+ CD4+ T cells (Vlkova et al., 2015). Patients with severe acute pancreatitis also have fewer 
IL-10-producing CD19+ B cells (Qiu et al., 2016). This same study used an animal model, whereby 
CD19–/– mice had worsened disease but could be restored by adoptive transfer of IL-10-producing 
B cells. It is also worth noting the effect of aging on IL-10-producing B cells. Kalampokis et al. 
(2016) found a greater level of IL-10-producing B cells within children compared to adults, whilst 
children suffering from an autoimmune disease (including juvenile idiopathic arthritis, juvenile 
dermatomyositis, systemic lupus erythematosus and mixed connective tissue disease) had a lower 
frequency and number of IL-10-producing B cells compared to their healthy counterparts. TIM-1+ 
B cells (in particular CD24+/hi CD38hi transitional B cells) have been found to be functionally 
suppressive against CD4+ T cell cytokine (IFN-γ, TNF and IL-17) production, which is impaired in 
patients suffering from systemic sclerosis (Aravena et al., 2017). Collectively these studies 
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highlight the importance of regulatory B cells (particularly IL-10-producing B cells) during various 
diseases. 
 
A protective role for B cells in multiple sclerosis (MS) is suggested by recent studies showing that 
treatment of MS patients with atacicept, a TACI-IgG fusion protein that starves B cells of the 
cytokines they need to survive (BAFF and APRIL) developed more severe disease than controls 
(Kappos et al., 2014). It has been proposed that this worsened outcome may have been due to 
atacicept inadvertently depleting APRIL-dependent, MS-protecting IL-10-producing B cells, as Hua 
et al. (2016) found APRIL could promote human peripheral blood-derived B cell production of 
IL-10 in healthy and rheumatoid arthritis patients. Needless to say, regulatory B cells in humans 
appear to have a role in multiple diseases. 
 
In contrast, the ability of B cells to suppress the immune response can be detrimental in some 
diseases, most notably cancers. Bodogai et al. (2013) found human breast tumours had tumour-
evoked regulatory B cells, which expressed low levels of CD20. When this study treated mice with 
B cell-depleting anti-CD20, it led to greater cancer progression and metastasis in mice. This was 
hypothesised to occur because tumour-evoked regulatory B cells have low CD20 expression, 
preventing the depletion of these cells following treatment. 
 
The ability to differentiate and define regulatory B cells by their phenotype is hence of interest. 
Unfortunately, to date there are no current gold standard markers for regulatory B cells (in contrast 
to regulatory T cells as CD25hi, CD127–, Foxp3+). In fact, studies have found many B cell subsets 
capable of being functionally suppressive, as highlighted in Table 1.1. For this reason, Rosser and 
Mauri (2015) propose any B cell can become regulatory, it is dependent on the environment in 
which it finds itself. Previous chapters have investigated how murine IL-4-treated mast cells (and 
their microvesicles) can activate functionally suppressive B cells. The next step was to determine 
whether human mast cells could achieve the same outcome. 
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Regulatory B cells are mostly identified and defined by their production of IL-10 (Duddy et al., 
2004). Of particular interest are the differences in phenotype of various regulatory B cell subsets, 
including evidence of both naïve (CD27–) and memory (CD27+) B cells being suppressive. An 
equivalent human subset of murine B10 cells capable of producing IL-10 (also CD24hi CD27+) have 
been identified (Iwata et al., 2011), whilst Kessel et al. (2012) have successfully isolated human 
regulatory B cells (CD25hi) using magnetic beads that in turn could decrease T cell proliferation and 
activate regulatory T cells in vitro. 
 
As IL-10 production is a defining characteristic of regulatory B cells, Stanic et al. (2015) pioneered 
a novel approach to phenotyping regulatory B cells. They transfected human peripheral blood 
B cells with human IL-10 to make them overexpress IL-10 and investigated changes in phenotype. 
This study found a decrease in anti-inflammatory cytokines (including TNF), an increase in CD25, 
CD274, GARP, CD38 and IgD expression but decreased CD19, CD27, CD80 and IgM. The same 
group were able to isolate out the IL-10-producing population of B cells to analyse their expression 
of several markers, and found it was the CD25+ CD71+ CD73– population that was responsible for 
IL-10 production, which was also the source of IgG4 (van de Veen et al., 2013). 
 
B cells from human peripheral blood have also been found to express Foxp3, a transcription factor 
commonly used to identify regulatory T cells (Noh et al., 2010). IL-21 has been found to activate 
human regulatory B cells that were capable of suppressing T cell proliferation, and even produced 
granzyme B (particularly CD5+ B cells) (Lindner et al., 2013). Human B cells expressing high 
levels of CD39 (an enzyme involved in the adenosine pathway) after stimulation with CD40L and 
IL-4 were found to produce more IL-10 and adenosine (a purine nucleoside that can inhibit effector 
T cell functions whilst activating regulatory T cells or myeloid-derived suppressor cells) (Figueiro 
et al., 2016). In turn, these CD39hi B cells suppressed T effector cell proliferation and activation in 
vitro compared to CD39– and CD39mid B cells. Expression of PD-L1 on human B cells may be 
important for regulating circulating T follicular helper cells, which correlated with BAFF receptor 
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expression, and a naïve B cell phenotype (CD19+ CD10– CD21+ CD27–) (Khan et al., 2015). Thus, 
a wide range of regulatory B cell subsets have been described, necessitating a new approach to 
characterising them. 
 
By ascertaining the phenotype, it can in turn provide evidence about what the function of the B cell 
may be. Mass cytometry provides an opportunity to dramatically expand the scope of discovery, 
allowing the potential revelation of new regulatory B cell subsets that emerge from co-culture with 
IL-4-treated mast cells or their microvesicles. This chapter hence investigates whether human IL-4-
treated mast cells (or their microvesicles) can activate phenotypically and/or functionally 
suppressive B cells. 
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5.2 Materials and methods specific to this chapter 
5.2.1 Mast cell culture and treatment 
Buffy coat was obtained from the Australian Red Cross Blood Service (approval number 
15-03NSW-21) following approval from the University of Sydney Human Ethics Committee 
(approval number 2015/174). All blood-related work was conducted under sterile conditions in a 
biosafety cabinet. The buffy coat was first diluted with an equal amount of PBS before 25 mL 
aliquots were overlayed onto 15 mL Lymphoprep (STEMCELL Technologies Australia Pty. Inc., 
Tullamarine, Australia). Cells were centrifuged (600xg, 20 °C, 30 min) with no brake. The 
mononuclear layer in the middle was isolated into new tubes and topped up with PBS. Cells were 
then centrifuged (150xg, 20 °C, 10 min) and resuspended in MACS buffer (4 mM EDTA, 0.75 % 
(v/v) BSA, PBS) to be counted. Centrifugation was repeated, and then resuspended in 600 µL 
MACS buffer with 200 µL Fc blocking reagent and 200 µL anti-CD34 MicroBeads (Miltenyi 
Biotec). Cells were left to incubate for 30 min on ice in the dark. They were then washed with 
MACS buffer and centrifuged (150xg, 20 °C, 5 min). Cells were then run through an AutoMACS 
Pro Separator (Miltenyi Biotec), using the “Possel-s” program. The CD34– cell fraction was used to 
isolate T and B cell subsets (please see Section 5.2.2). The positive fraction was centrifuged (150xg, 
20 °C, 5 min), resuspended in 24 mL cIMDM (+IL-3+SCF+IL-6; please see Section 5.2.1.1 for 
details on the media used), and 1 mL of cells were transferred into each well of two 12-well plates. 
Cells were then incubated at 37 °C in 5 % CO2. After 1 week, 1 mL fresh cIMDM 
(+IL-3+SCF+IL-6) was added to each well. At 2 weeks of culture, cell suspensions were split in 
two across two more 12-well plates. 1 mL of fresh cIMDM (+SCF+IL-6; note IL-3 no longer 
required) was added to each well. At 3 weeks of culture, cells were pooled, centrifuged (300xg, 
20 °C, 5 min) and resuspended in 15 mL cIMDM (+SCF+IL-6) before being placed into a 75 cm2 
flask. Cells were passaged weekly, for 3 weeks more at which point cIMDM (+FBS+SCF+IL-6) 
was used to allow for the final differentiation into mast cells. Mast cells were then ready to use at 9-
10 weeks after the start of the process, with each donor culture representing a single n value. 
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5.2.1.1 Human mast cell media 
Complete IMDM (cIMDM) contained IMDM (Life Technology) with 1 % (v/v) Insulin-
Transferrin-Selenium (Life Technology), 1 % (v/v) Penicillin-Streptomycin (PenStrep; Gibco), 
50 mM 2-mercaptoethanol (Sigma-Aldrich) and 35 % (v/v) BSA (bovine serum albumin; Sigma). 
The use of additional cytokines (where mentioned above) include 100 ng mL–1 SCF (Shenandoah 
Biotechnology Inc., Warwick, PA, USA), 50 ng mL–1 IL-6 (Shenandoah Biotechnology Inc.) and 
5 ng mL–1 IL-3 (ProSpec). 10 % (v/v) FBS (foetus bovine serum) was used where indicated. 
 
5.2.1.2 IL-4 treatment of mast cells 
Human mast cells were treated with 10 ng mL–1 IL-4 (Shenandoah Biotechnology Inc.) or not at 
0.3 x 106 cells in 5 mL cIMDM (+FBS+SCF+IL-6). This treatment lasted 48 hr at 37 °C with 5 % 
CO2. To control for any potential B cell-activating effects of residual IL-4, 10 ng mL–1 IL-4 was 
added to media alone before undergoing the same isolation process as for microvesicles (Section 
5.2.1.3). This “IL-4 treated media” was then added to B cells in a similar manner. 
 
5.2.1.3 Isolation of mast cell-derived microvesicles 
Following the 48 hr incubation with IL-4 (or not), mast cells were centrifuged (300xg, 4 °C, 5 min) 
to pellet cells (which could then be used for experiments involving mast cells). The supernatant was 
collected and centrifuged (1,500xg, 4 °C, 20 min) again to pellet cell debris (including apoptotic 
bodies). The supernatant was subsequently collected and centrifuged once more (16,100xg, 4 °C, 
1 hr) to pellet microvesicles. These were then resuspended in cRPMI. 
 
A small sample of the isolated microvesicles were quantified by flow cytometry (Figure 4.1). 
Microvesicles were identified using annexin V, which can bind to phosphatidylserine residues that 
are often exposed during microvesicle formation (Koopman et al., 1994). Annexin V-FITC was 
centrifuged (16,100xg, 4 °C, 1 hr) to pellet any protein aggregates that may give false positives 
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when analysing subcellular fractions by flow cytometry. Microvesicles were stained with 
annexin V-FITC (1:100 dilution in 10 x annexin V binding buffer) at room temperature in the dark 
for 15 min. Microvesicles were then diluted in 1 x annexin V binding buffer and then run on the BD 
LSRFortessa or BD LSRFortessa X-10. In addition to being annexin V+, microvesicles are also 
defined as being between 0.1 and 1 µm in size. Calibrated size beads (Spherotech, Lake Forest, 
Illinois, USA) were hence used to enhance microvesicle identification. CountBright™ Absolute 
Counting Beads (Invitrogen, Carlsbad, CA, USA) were used to calculate the number of 
microvesicles present in the cultures. For each separate mast cell culture, the same number of 
microvesicles (from untreated or IL-4-treated mast cells) were added to B cells. These were left to 
incubate with B cells for 48 hr at 37 °C, with 5 % CO2. 
 
5.2.1.4 Immunofluorescence staining of mast cells 
To confirm the successful differentiation of human CD34+ stem cells into mast cells, 
immunofluorescence staining was done. Mast cells were differentiated and then cytospun onto 
slides. Cells were fixed onto slides with 4 % paraformaldehyde for 20 min. Slides were then washed 
three times with PBS, followed by three washes with Tris buffer (50 mM Tris-HCl, pH 7.4). Slides 
were then blocked with 10 % goat serum (diluted in Tris buffer containing 0.5 % Triton X-100) for 
30 min. Slides were stained with mouse anti-human tryptase (clone G3, mouse IgG1κ isotype; 
Merck Millipore, Billerica, USA) and mouse anti-human chymase (clone B7, mouse IgG1κ isotype; 
Merck Millipore) at 5 µg mL–1 (in 0.1 % Triton, 10 % goat serum in Tris buffer) overnight at 4 °C 
in a humidified chamber. As this experiment was just to confirm the successful growth of human 
mast cells from CD34+ stem cells, I was not required to differentiate between tryptase and chymase, 
so the same species and isotype (and hence secondary antibody) were used. Control slides were 
stained with mouse IgG1κ isotype antibody conjugated to biotin (BioLegend). Slides were then 
washed twice with 0.5 % Triton X-100/Tris buffer, then once with Tris buffer. The secondary 
antibody, goat anti-mouse IgG conjugated to Alexa Fluor 488 (Invitrogen), was used a 1/500 
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dilution. Secondary antibody was stained for 2 hr at room temperature (20-24 °C). Note for this 
experiment it was not required to differentiate between tryptase- and chymase-producing cells, so 
were present on the same fluorochrome. Slides were washed with three times in 0.5 % 
Triton X-100/Tris buffer, then three more times with Tris buffer. Slides were washed once with 
distilled water prior to the addition of SlowFadeTM gold antifade mountant with DAPI (Invitrogen). 
Slides were imaged on and Olympus BX60 (Olympus, Shinjuku, Japan) with an Olympus DP72 
attachment, using the Olympus DP2-BSW software. 
 
5.2.1.5 Surface staining of mast cells for flow cytometry 
Mast cells treated for 48 hr with 10 ng mL–1 IL-4 (or not) were centrifuged (300xg, 4 °C, 5 min) 
and added to a 96-well v-bottom plate. Mast cells were then stained with anti-CD117 (clone 104D2, 
isotype mouse IgG1, conjugated to APC; 1/100 dilution; BioLegend) and/or anti-FcεRIα (clone 
AER-37, isotype mouse IgG2b, conjugated to BV510; 1/100 dilution; BioLegend) for 20 min at 
4 °C, shielded from light. 150 µL FACS buffer was added and mast cells were centrifuged (300xg, 
4 °C, 5 min). This wash was repeated with 200 µL FACS buffer. Mast cells were then transferred to 
FACS tubes through 70 µm gauze to then be run on a BD LSRII or BD LSRFortessa X-20. 
 
5.2.2 B and T cell isolation 
The CD34– fraction of peripheral blood cells was stained with anti-CD19 microbeads (Miltenyi 
Biotec) for isolation of B cells. The beads were used at 0.5 µL per 1 x 106 cells, and diluted to 20 % 
(v/v) in MACS buffer. Cells were incubated on ice for 20 min, and then washed with 10 mL 
running buffer and centrifuged (150xg, 4 °C, 5 min). Cells were resuspended in 2 mL running 
buffer and run through an AutoMACS Pro Separator (Miltenyi Biotech), using the “Possel-s” 
program. CD19+ cells were then spun down (150xg, 4 °C, 5 min) and resuspended in 10 % (v/v) 
DMSO/FBS (dimethyl sulfoxide; DMSO from Sigma) and stored in liquid nitrogen until later use 
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(i.e. once the mast cells were ready in 9-10 weeks). The CD19– cells were stained with anti-CD25 
microbeads (CD25 Microbeads II, Human; Miltenyi Biotech). These CD25 microbeads will bind to 
any activated (CD25hi) T cells as well as regulatory T cells. The steps above were repeated. The 
remaining CD19– CD25– cells were stained with anti-CD4 microbeads (Miltenyi Biotec) to isolate 
naïve helper T cells, and the steps described above were repeated. Appendix F shows the quality of 
enrichment using the microbeads. It should be noted some dendritic cells from human blood 
express CD4 (Odoherty et al., 1993), but this issue has been addressed with the relevant controls as 
described below. The potential negative effects of cryopreservation and resuscitation have recently 
been tested and found not to affect cell function (Galeano Nino et al., 2016). 
 
5.2.3 Mast cell-B cell co-culture 
Previously isolated B cells (stored safely in liquid nitrogen until needed) were thawed in a 37 °C 
waterbath. When ~half was liquefied, cells were filtered through a 70 µm sieve with 5 mL pre-
warmed cRPMI and centrifuged (300xg, 4 °C, 5 min). B cells were washed again with a further 
3 mL cRPMI to remove residual DMSO and then counted. 
 
Mast cells treated with IL-4 (or not) (Section 5.2.1.2) were added to B cells at a 1:10 ratio (mast 
cells:B cells). Mast cell-derived microvesicles (Section 5.2.1.3) were added to B cells such that the 
same number were cultured with B cells between the IL-4 and no treatment groups of each 
culture/donor. B cells were left to co-culture with either the mast cells or their microvescicles for 
48 hr at 37 °C with 5 % CO2. 
 
5.2.4 Mass cytometry 
One of the major limitations to high parametric flow cytometry panels is the ‘bleeding’ that can 
occur between fluorochromes with similar excitation and emission spectra. Mass cytometry negates 
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this limitation by using antibodies conjugated to heavy Lanthanide metal isotopes instead of 
fluorochromes. By using time-of-flight mass spectrometry, it allows specific identification of 
individual metal isotopes (and hence the conjugated antibody) without the need for compensation, 
with up to 40 parameters in a single panel. Some drawbacks of mass cytometry include the 
incineration of cells during the sample uptake (so it is not possible to sort cells by this method), as 
well as being less sensitive (as there are no “bright” metal isotopes). Hence, mass cytometry is best 
used to complement flow cytometry, rather than replace it. As there are no standard regulatory 
B cell markers, mass cytometry allowed me to identify up to 35 markers to investigate B cell 
activation status. 
 
5.2.4.1 Antibody conjugation 
Conjugation of antibodies to relevant metal isotopes was done using the Maxpar antibody labelling 
kit (Fluidigm, South San Francisco, California, USA), provided by Sydney Cytometry (the 
Advanced Cytometry Facility of the Centenary Institute and the University of Sydney). Note this kit 
did not divulge the contents of each buffer used. 
 
Polymer and metal preparation 
Polymer was brought to room temperature from storage, and then spun down in a microcentrifuge 
at maximum speed for 10 sec before being resuspended in 95 µL L-buffer and pipetting up and 
down 30 times to dissolve the polymer. 5 µL of Lanthanide metal solution was then added to the 
tube (for a final concentration of 2.5 mM). This was then incubated with the polymer at 37 °C for 
40 min, whereby the metal isotope was conjugated to the Lanthanide metal. 
 
100 µL of L-buffer was added to a 3 kDa filter, followed by the addition of the metal-loaded 
polymer. 100 µL L-buffer was used to rinse the previous tube and then added to the filter, for a final 
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volume of 300 µL, then centrifuged (12,000xg, 20 °C, 25 min). 300 µL C-buffer was then added to 
the metal-loaded polymer and then centrifuged (12,000xg, 20 °C, 30 min). 
 
Antibody preparation 
It was important that unconjugated antibodies were not in a solution that contained protein carriers 
which can interfere with the conjugation. This first step was not required for MaxPar Ready 
antibodies (BioLegend), which are already at the correct concentration of 1 µg µL–1. For those not 
at 1 µg µL–1, 300 µL R-buffer was added to a 50 kDa filter. 100 µg of antibody (up to 200 µL 
stock) was then added to the filter and centrifuged at 12,000xg, 20 °C, for 10 min. 100 µL of 4 mM 
TCEP (tris(2-carboxyethyl)phosphine; diluted in R-buffer) was added to the antibody and left to 
incubate at 37 °C for 30 min (it is critical to not go beyond this time, as TCEP can cause protein 
denaturation). 300 µL C-buffer was added to the antibody and centrifuged (12,000xg, 20 °C, 
10 min). Flow through was discarded, then 400 µL C-buffer was added and centrifuged again. 
 
Antibody conjugation to polymer-metal 
The metal-loaded polymer (from the 3 kDa filter) was resuspended in 60 µL of C-buffer, then 
transferred to the antibody (in the 50 kDa filter). 300 µL W-buffer was added to the conjugation 
mixture and centrifuged (12,000xg, 20 °C, 10 min). Flow through was discarded, and then washing 
was repeated a further three times with 400 µL W-buffer. 50 µL W-buffer was then added, and used 
to rinse the walls of the filter. The filter was then inverted into a new collection tube and 
centrifuged (1,000xg, 20 °C, 2 min). The walls of the filter were then washed again with 50 µL of 
W-buffer and centrifuged one last time. This conjugated the antibody to the metal-loaded polymer. 
 
Yield determination and storage 
Yield of antibody was determined using a Nanodrop 2000c Spectrophotometer (Thermo Scientific). 
Antibody was then diluted to a concentration of 0.5 mg mL–1 in stabilisation buffer (0.05 % (v/v) 
sodium azide, 2 mg mL–1 BSA, PBS). Conjugated antibodies were then stored at 4 °C until use. 
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5.2.4.2 Cell staining for Mass Cytometry 
4 hr prior to the end of the mast cell-B cell co-culture, cells were treated with 50 ng mL–1 phorbol 
12-myristate 13-acetate (PMA; Sigma), 0.5 µg mL–1 ionomycin (Sigma) and 5 µg mL–1 brefeldin A 
(BioLegend) to facilitate accumulation of produced cytokines inside the cells. 10 µg mL–1 CpG 
(CpG-ODN2006; InvivoGen, San Diego, USA) was also added to re-stimulate B cell production of 
IL-10, as described by Cherukuri et al. (2014). Cells were first stained in 50 µL of cisplatin 
(1/1,000 dilution in PBS) for 5 min at room temperature (20-24 °C) only. This acts as a live/dead 
marker, as cells that are dead or dying will allow platinum to enter the nucleus and bind to DNA. 
200 µL FACS buffer was added to quench the unbound cisplatin, and then the cells were 
centrifuged at 500xg, 4 °C for 5 min. Cells were then resuspended in 50 µL of a mastermix 
containing all surface-binding antibodies, and left to label the cells on ice for 30 min. 150 µL FACS 
buffer was then added followed by a centrifuge (500xg, 4 °C, 5 min). Cells were further washed 
twice using 200 µL FACS buffer. Cells were then fixed in 50 µL 4 % paraformaldehyde (PFA) for 
20 min at room temperature. 150 µL FACS buffer was added and centrifuged (800xg, 20 °C, 
5 min). Note there was a change in centrifugal force due to the change in cellular structure, as well 
as a change in temperature as cells were now fixed and did not need to be kept cold (to allow better 
clearance of non-specific intracellular antibodies in the next step). Cells were then left in 50 µL 
Foxp3 permeabilisation (perm) buffer (eBioscience Inc., San Diego, USA) for 15 min at room 
temperature. 150 µL perm buffer was added and then centrifuged (800xg, 20 °C, 5 min). Cells were 
then stained with 50 µL of mastermix containing antibodies with intracellular markers for 45 min at 
room temperature. These were then topped up with 150 µL perm buffer and centrifuged (800xg, 
20 °C, 5 min). Cells were resuspended in 200 µL perm buffer and left to sit for 10 min at room 
temperature then centrifuged (800xg, 20 °C, 5 min). This was then repeated. Cells were finally 
resuspended in 100 µL of DNA intercalator mix (1/1,000 iridium intercalator in 4 % PFA). This 
DNA intercalator stains all cells to be detected by a mass cytometer. In flow cytometry, all cells 
have a background level of fluorescence, so all cells (including unstained cells) can be detected. As 
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there is no fluorescence in mass cytometry, DNA intercalator must be used to identify all cells. 
Cells were then left in the fridge until being run on a CyTOF II (Fluidigm). 
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Table 5.1 – Antibodies used for human mass cytometry staining. 
Target Isotope Clone Isotype Company Dilution 
5-HT2A receptor 166Er Polyclonal* Rabbit IgG Novus 
Biologicals 
1/100 
ADIPOR1 141Nd EPR6626 Rabbit IgG Origene 1/100 
CD3 154Sm UCHT1 Mouse IgG1 Flow Core†  
CD4 145Nd RPA-T4 Mouse IgG1 Flow Core†  
CD19 142Nd HIB19 Mouse IgG1 Flow Core†  
CD20 147Sm 2H7 Mouse IgG2b Flow Core†  
CD23 144Nd M-L23.4 Mouse IgG1 Miltenyi Biotec 1/100 
CD24 151Eu ML5 Mouse IgG2a BioLegend 1/100 
CD25 149Sm 2A3 Mouse IgG1 Flow Core†  
CD27 155Gd L128 M-T271 Mouse IgG1 Flow Core
†  
CD38 167Er HIT2 Mouse IgG1 Flow Core†  
CD79b 153Eu CB3-2 Mouse IgG1 BioLegend 1/100 
CD80 162Dy 2D10.4 L307 Mouse IgG1 Flow Core
†  
CD86 156Gd IT2.2 Mouse IgG2b Flow Core†  
CD117 143Nd 104D2 Mouse IgG1 Flow Core†  
CD120a 158Gd REA252 Recombinant 
human IgG1 
Miltenyi Biotec 1/100 
CD120b 160Gd 3G7A02 Rat IgG2a BioLegend 1/100 
CD137L 148Nd REA254 Recombinant 
human IgG1 
Miltenyi Biotec 1/100 
CD138 168Er‡ DL-101 Mouse IgG1 Flow Core†  
CD184 (CXCR4) 175Lu 12G5 Mouse IgG2a Flow Core†  
CD210 169Tm REA239 Recombinant 
human IgG1 
Miltenyi Biotec 1/100 
CD213α1 173Yb SS12B Mouse IgG1 BioLegend 1/100 
CD213α2 176Yb REA308 Recombinant 
human IgG1 
Miltenyi Biotec 1/100 
CD267 (TACI) 159Gd 1A1 Rat IgG2a BioLegend 1/100 
CD274 (PD-L1) 161Dy 29E.2A3 Mouse IgG2b BioLegend 1/100 
CD275 (ICOSL) 150Nd 2D3 Mouse IgG2b BioLegend 1/100 
HLA-DR 174Yb L243 Mouse IgG2a Flow Core†  
IgD 146Nd/89Y IA6-2 Mouse IgG2a Flow Core†  
IgM 172Yb MHM-88 Mouse IgG1 Flow Core†  
PAF receptor 163Dy AA14 
(clone21) 
Mouse IgG2a Cayman 
Chemicals 
1/100 
S1P1 170Er MM0045-
21L9 
Mouse IgG1 Novus 
Biologicals 
1/100 
Blimp-1§ 171Yb ROS195G Mouse IgG1 BioLegend 1/50 
BLNK§ 164Dy REA240 Recombinant 
human IgG1 
Miltenyi Biotec 1/50 
Foxp3§ 168Er‡ 259D Mouse IgG1 BioLegend 1/50 
IL-10§ 165Ho JES3-9D7 Rat IgG1 BioLegend 1/50 
TNF§ 152Sm Mab11 Mouse IgG1 Flow Core†  
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* There were no monoclonal antibodies available against 5-HT2A receptor, so I had to use 
polyclonal antibodies. 
 
† Antibodies were conjugated by Sydney Cytometry. Note that all other antibodies not from them 
were conjugated by myself. 
 
‡ CD138 and Foxp3 were used in independent panels (and hence same metal isotope). 
 
§ Intracellular antigens. 
 
5.2.4.3 Mass cytometry analysis 
Samples were gated as shown in Appendix G. Note all samples prior to run are spiked with beads. 
If the detectors fluctuate during a run, samples can be normalised to these beads. It is also 
interesting to note mast cells have a higher level of cisplatin and DNA compared to B cells, 
although this has also been found in my murine mast cells (Figure 3.1). With mass cytometry, it is 
possible to have a reading of 0, meaning that figures may look different to that which present 
fluorescence cytometry data. However, the mean signal intensity is equivalent to the mean 
fluorescent intensity reported in fluorescence cytometry. Some metals have a ‘bleeding’ effect, 
similar to that of uncompensated data in flow cytometry. Appendix H highlights this effect, and 
shows why the levels of Blimp-1, CD120b and CD213α1 could not be accurately analysed. 
Appendix K summarises the changes in marker expression in transitional B cells in different co-
culture groups when compared to B cells alone. 
 
5.2.5 T cell assays 
To determine whether IL-4-treated mast cells (or their microvesicles) affect B cell function, 
autologous T cells were utilised. CD25hi cells were first isolated to remove activated/regulatory 
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T cells, followed by isolation of CD4+ cells (primarily CD4+ T cells). These CD4+ CD25– T cells 
were then used to determine whether human mast cell- and/or microvesicle-activated B cells could 
in turn suppress T cell activation (in the form of proliferation or IFN-γ production). 
 
5.2.5.1 Thawing out T cells 
T cells (CD4+ CD25– and CD25+ cells) were thawed in a 37 °C waterbath. When approximately 
half was liquefied, cells were poured into a 50 mL conical tube. 10 mL pre-warmed cRPMI was 
added drop-wise to the cells, followed by rinsing vials with a further 5 mL pre-warmed cRPMI. 
Cells were centrifuged at 150xg, 20 °C for 5 min before being resuspended in 10 mL pre-warmed 
cRPMI and added to a 25 cm2 flask. Resuscitated cells were left to recover overnight at 37 °C with 
5 % CO2 in an incubator, before use the following day. T cells were found to be more sensitive to 
resuscitation than B cells, so were left to incubate overnight prior to use. 
 
5.2.5.2 T cell suppression assays 
After overnight culture, T cells were collected and filtered through a 70 µm sieve to remove dead 
cells that can clump. Cells were further washed with 5 mL PBS (CD4+ CD25–) or cRPMI (CD25hi) 
and centrifuged (150xg, 4 °C, 5 min). PBS was used to prevent FBS interference with CellTraceTM 
Violet (CTV) Cell Proliferation Kit (Thermo Scientific) uptake. The wash was repeated and cells 
were counted. CD25hi cells were left to sit at 4 °C until use, whilst CD4+ CD25– cells were split in 
to two samples, to either sit (for cytokine staining) or stained with CTV for the proliferation assay. 
 
Staining for proliferation assay – Cells were washed with PBS to remove serum that can interfere 
with the CTV uptake. Cells were stained at 2.5 µM CTV for 20 min at 37 °C. 5 x volume cRPMI 
was then added and cells were left at 37 °C for 5 min. Cells were then centrifuged (150xg, 4 °C, 
5 min) and then washed with a further 5 mL cRPMI. 
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After the mast cell-B cell co-culture, cells were centrifuged (300xg, 4 °C, 5 min) and washed twice 
with cRPMI. Cells were then counted. 
 
CD4+ CD25– cells were co-cultured with B cells at a 1:10 ratio (CD4+ CD25– cells:B cells). Note 
mast cells were not separated from B cells, so mast cells were also present within this co-culture. 
Many studies have had successful suppression of T cell proliferation/cytokine production with a 
ratio of 1 B cell to 1 T cell (Blair et al., 2010, Kessel et al., 2012, Lindner et al., 2013, Menon et al., 
2016). Because of human variability, the final number of cells (mast cells/B cells/T cells) could 
fluctuate, but I generally ended up with more B cells than T cells for functional assays. As these 
experiments take 9-10 weeks of preparing, I did not want to waste cells, and decided to use a 
greater number of B cells. Furthermore, it was theorised a greater ratio of B cells:T cells would be 
more sensitive for detecting changes in B cell function. Controls included CD4+ cells alone 
(stimulated or unstimulated), 100 ng mL–1 hIL-10 (R&D Systems), and CD25hi cells (same ratio as 
B cells). Untreated or IL-4-treated mast cells were then added to CD4+ CD25– cells (1:1 ratio) to 
control for mast cell interaction with T cells. As well as this, microvesicle-B cell co-cultures 
(including IL-4 control group) were added to CD4+ CD25– cells alongside untreated mast cells, to 
test if there was any change in function after activation by microvesicles and then co-culture with 
mast cells. All samples were left to pre-incubate  at 37 °C, 5 % CO2, for 1 hr in a 96-well round-
bottom plate, before adding T cell Activation/Expansion Kit (human) beads (Miltenyi Biotec). 
These beads, which had anti-human CD2, anti-CD3 and anti-CD28 conjugated to them, were added 
at a ratio of 1 bead per 100 total cells (B and T cells). Samples were then left to incubate for 72 hr at 
37 °C, 5 % CO2, before assessing proliferation/cytokine production. 
 
Stimulation for cytokine staining – 5 hr prior to the end of T cell stimulation, cells were spiked with 
50 ng mL–1 PMA (Sigma), 0.5 µg mL–1 ionomycin (Sigma), 5 µg mL–1 brefeldin A (BioLegend) to 
allow intracellular flow cytometry staining of IFN-γ. 
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Antibody staining and flow cytometry 
After 72 hr, samples were centrifuged (300xg, 4 °C, 5 min) and 150 µL of supernatant was 
collected for analysis by ELISA (Section 5.2.6). Cells were then stained with relevant surface 
antibodies (Tables 5.2 and 5.3) for 20 min at 4 °C, before being washed with 150 µL FACS buffer 
and centrifuged (300xg, 4 °C, 5 min). This was repeated with a further 200 µL FACS buffer. 
Samples that were stained with CTV were then ready to run on a BD LSRFortessa X-20, whilst 
samples for cytokine staining continued as follows. 
 
Staining for intracellular cytokine – Samples were fixed with 100 µL of 4 % PFA for 20 min at 
room temperature. 100 µL perm buffer was added to cells before being centrifuged (500xg, 20 °C, 
5 min). Note there was a change in centrifugal force (as cells change morphology after fixation) and 
temperature (to allow better clearance of non-specific intracellular antibodies). Cells were then 
resuspended in 200 µL perm buffer to sit for 10 min. Samples were then stained with intracellular 
anti-IFN-γ antibodies for 30 min. 150 µL perm buffer was added to cells and were then centrifuged 
(500xg, 20 °C, 5 min). Cells were left in 100 µL perm buffer for 20 min at room temperature. Cells 
were then centrifuged (500xg, 20 °C, 5 min), and this was repeated to allow better clearance of non-
specific intracellular binding. Samples were then run on a BD LSRFortessa X-20. The gating 
strategy for T cell production of IFN-γ is shown in Appendix I. 
 
Table 5.2 – Antibodies used for human T cell proliferation flow cytometry. 
Target Fluorochrome Clone Isotype Company Dilution 
CD3 PE UCHT1 Mouse IgG1 BD Biosciences 1/100 
CD69 BV711 FN50 Mouse IgG1 BD Biosciences 1/50 
S1P1 APC 218713 Mouse IgG2b R&D Systems 1/30 
CellTraceTM Violet (equivalent to BV421 fluorochrome) 
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Table 5.3 – Antibodies used for human T cell cytokine flow cytometry. 
Target Fluorochrome Clone Isotype Company Dilution 
CD3 PE UCHT1 Mouse IgG1 BD Biosciences 1/100 
CD117 APC 104D2 Mouse IgG1 BioLegend 1/100 
IFN-γ BV421 4S.B3 Mouse IgG1 BD Biosciences 1/50 
 
5.2.5.3 Analysis of T cell proliferation 
Figure 5.1 shows the gating strategy used to differentiate between T cell divisions, based on the 
level of CTV fluorescence. Changes in surface CD69 expression, an early indicator of T cell 
activation, was also assessed. 
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Figure 5.1 – Gating strategy for human T cell proliferation. Human peripheral 
blood-derived mast cells were treated with 10 ng mL–1 IL-4 for 48 hr. Cells and 
microvesicles were then collected and co-cultured with B cells (previously frozen for each 
patient) at a 1:10 ratio mast cells:B cells for a further 48 hr. These were then co-cultured 
with CD4+ CD25– T cells for 1 hr at a 10:1 ratio B cells:T cells, followed by stimulation with 
T cell simulation beads conjugated with anti-CD2, anti-CD3, and anti-CD28 (1 bead/100 
cells) for 72 hr, followed by flow cytometry staining. The left column represents CD4+ 
CD25– T cells alone without stimulation beads added; the middle column shows CD4+ 
CD25– T cells alone with stimulation beads added; and the right column shows B cells that 
were left alone and then cultured with CD4+ CD25– T cells and stimulated. (A) shows 
previously gated single cells (Appendix A), followed by gating T cells using CD3-PE. T cell 
proliferation was measured with cell trace violet, as shown in (B/C). (B) has no gates 
applied, whilst (C) shows the same plots with the relevant gates overlaid. Each division 
was split from 0-4, as CD69– or CD69+.
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To determine the level of T cell proliferation (and hence the level of suppression), the division 
index and proliferation index were calculated using the equations below (as recommended by 
FlowJo). 
 
Equation 1 – Starting cell number 
Number of undivided cells +
number of cells in division 1
2
+
number of cells in division 2
4
+ ⋯
+
number of cells in division n
2n
 
 
Equation 2 – Total number of divisions 
(
number of cells in division 1
2
) × 1 + (
number of cells in division 2
4
) × 2 + ⋯
+ (
number of cells in division 𝑛
2𝑛
) × 𝑛 
 
Equation 3 – Number of cells that went into division 
Starting cell number (𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟏) − number of undivided cells 
 
Equation 4 – Division index 
Total number of divisions (𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐)
Starting cell number (𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟏)
 
 
Equation 5 – Proliferation index 
Total number of divisions (𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐)
Number of cells that went into division (𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑)
 
 
In short, the division index is the average number of divisions undertaken by all cells (including 
those that did not proliferate at all), whilst the proliferation index is the average number of divisions 
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undertaken by the proliferating cells. Both indices are hence useful as they provide complimentary 
evidence on the degree of T cell proliferation. 
 
5.2.6 ELISA 
Supernatants were taken from co-cultures used for T cell proliferation (Section 5.2.5.2) and stored 
at –80 °C for future analysis. Samples were used first in an IL-35 ELISA, followed by an IL-10 
ELISA. 
 
5.2.6.1 IL-35 ELISA 
A pre-coated sandwich ELISA kit (catalog number 439509, BioLegend) specific for human IL-35 
was used. This unverified kit was provided free of charge upon request, as at the time of 
experimentation it was not commercially available. Nakano et al. (2015) have previously used the 
kit, but has since been removed. The protocol provided by the manufacturer was followed. In short, 
the plate was first washed with the provided wash buffer solution. An IL-35 standard provided with 
the kit was used at the recommended concentrations (40, 20, 10, 5, 2.5, 1.25, 0.63, and 0 ng mL–1), 
in duplicate. The sample supernatants were likewise run in duplicate, either as neat (no dilution) or 
1/5 dilutions. These were added to the plate and left to incubate at room temperature (20-24 °C), 
sealed and on a rocker for 2 hr. After incubation, samples were transferred to an IL-10 ELISA plate 
(Section 5.2.6.2). The IL-35 plate was washed, and 100 µL per well of anti-Human IL-35 Detection 
Antibody (supplied) was added. This was incubated (under the same conditions) for 1 hr. The plate 
was subsequently washed, and incubated (under the same conditions) with 50 µL per well of 
Avidin-HRP solution for 30 min. The plate was washed, and then incubated with 100 µL per well 
of Substrate Solution F for 30-40 min. 100 µL per well of Stop Solution was finally added, before 
reading the absorbance (Section 5.2.6.3). 
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5.2.6.2 IL-10 ELISA 
The Human IL-10 ELISA Ready-SET-Go!® (catalog number 88-7106, eBioscience) was used to 
measure IL-10 levels. The provided protocol was used, but in short the plate was first coated with 
100 µL per well of capture antibody at 4 °C overnight. The plate was then washed with PBST 
(0.05 % (v/v) Tween-20/PBS) and then blocked with 200 µL per well of provided ELISA/ELISPOT 
Diluent for 1 hr. The plate was then washed with PBST. An IL-35 standard provided with the kit 
was used at the recommended concentrations (300, 150, 75, 37.5, 18.8, 9.4, 4.2, 2.1, and 
0 pg mL-1), in duplicate. The sample supernatants were taken from the IL-35 ELISA (Section 
5.2.6.1), and were likewise run in duplicate, either as neat (no dilution) or 1/5 dilutions. Samples 
were added to the plate, sealed and incubated overnight at 4 °C. The plate was then washed and 
100 µL per well of provided detection antibody was added and left at room temperature and sealed 
for 1 hr. Wash was repeated with PBST, and 100 µL per well of provided Avidin-HRP was added, 
then sealed at room temperature for 30 min. The plate was then washed with PBST and then 100 µL 
per well of provided TMB Solution was added and incubated at room temperature for 5-15 min. 
50 µL per well of stop solution (1 M sulphuric acid) was then added, and ready for reading. 
 
5.2.6.3 ELISA reading and analysis 
Once plates were ready, the relative absorbance was read on the Infinite® M1000 Peo (Tecan, 
Männedorf, Switzerland) using the software Tecan i-control (Tecan). Readings were taken at 450 
and 570 nm in duplicate. Data were analysed by averaging the respective readings, and then 
subtracting the 570 nm reading from the 450 nm reading for the corrected reading. The blank 
standard (0 ng mL–1) absorbance was then subtracted from the samples to give the working 
absorbance for further calculations. Appendix J shows a representative standard curve for IL-35 and 
IL-10. The limits of detection were 0.63 ng mL–1 IL-35 and 2.1 pg mL–1 IL-10. 
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5.3 Results 
5.3.1 Human IL-4-treated mast cells have downregulated CD117 expression 
but increased FcεRIα expression 
Successful differentiation of human peripheral blood CD34+ cells into mast cells after 9-10 weeks 
of culture was first confirmed by immunofluorescence staining for tryptase and chymase 
(Figure 5.2): two well established proteins produced by mast cells (Schwartz et al., 1981, Schechter 
et al., 1986). 
 
Similar to what was found with murine mast cells (Figure 3.2), activation of human mast cells with 
IL-4 led to a significant downregulation of CD117 (Figure 5.3A and C) with a concordant increase 
in FcεRIα (Figure 5.3B and D) in all 6 donors. Thus, the activation of human mast cells with IL-4 
may likewise in turn influence B cell phenotype and function. 
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Figure 5.2 – Human peripheral blood-derived mast cells express tryptase and 
chymase. Human peripheral blood CD34+ stem cells were grown in mast cell selective 
media over 9-10 weeks at which point the cells were cytospun and dual stained with 
anti-human tryptase and anti-human chymase (both directly conjugated to Alexa Fluor 488; 
green). Mouse IgG1 isotype and secondary only (no primary antibody) negative controls 
were used. DAPI staining was used to identify nuclei (blue). Yellow scale bars represent
20 µm.
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p = 0.0312 p = 0.0312
Figure 5.3 – IL-4 treatment of human mast cells alters surface marker expression of 
CD117 and FcεRIα. Mast cells were treated with 10 ng mL–1 IL-4 for 48 hr at 0.3 x 106 
cells in 5 mL. (A/B) shows the relative expression of CD117 (A) or FcεRIα (B) on 
unstained (grey), untreated (dotted line) and IL-4-treated (unbroken line) mast cells.
(C/D) show the mean fluorescent intensity of untreated (open triangles) to IL-4-treated 
(closed triangles) mast cells for CD117 or FcεRIα. Each symbol represents an individual 
donor. n = 6 from 4 independent experiments, where pairs represent the same culture; 
Wilcoxon test.
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5.3.2 Human IL-4-treated mast cells and their microvesicles preferentially 
affect transitional B cells 
Having confirmed that IL-4 activates human mast cells to assume a phenotype that is similar to that 
observed in mice, the next step was to determine whether human IL-4-treated mast cells (tMC), or 
their microvesicles (tMV), could affect B cells. HLA-DRhigh B cells (Appendix G) were first 
separated into memory (CD27+; green in Figure 5.4A) and non-memory (CD27–; purple in Figure 
5.4A) subsets. Comparing the effect of mast cell IL-4-treatment showed that there was no 
significant IL-4-driven effect on the frequency of these two B cell subsets (Figure 5.4B). However, 
incubating B cells with tMC (Figure 5.4B) did significantly alter the proportion of memory B cells 
to emerge from the co-culture compared to B cell cultured alone (Appendix K). More specifically, 
tMC significantly decreased CD27– non-memory and increased CD27+ memory B cells 
(Appendix K). 
 
CD27– non-memory B cells can be further separated into IgM– naïve, IgM+CD38+ transitional and 
IgM+CD38– subsets (Figure 5.5A). Note CD27+ memory B cells also had similar subsets 
(Figure 5.5A), but as there was no significant difference in HLA-DR expression (and other markers 
– data not shown), my analysis focused on CD27– non-memory B cells. tMC and tMV significantly 
increased the proportion of transitional (Figure 5.5B in red) and CD38– IgM+/hi B cells (Figure 5.5D 
in black), while there was a significant decrease in naïve B cells (Figure 5.5C in blue) when 
compared with their respective untreated groups (uMC and uMV respectively). Moreover, only the 
B cells cultured with tMC or tMV, but not uMC and uMV, showed significant differences to B cells 
cultured by themselves (with the exception of tMC on CD38– IgM+/hi B cells; Appendix K). 
 
The murine equivalent of HLA-DR, MHCII, has been found to be upregulated on B cells after UV 
(Byrne and Halliday, 2005, Byrne et al., 2005, Matsumura et al., 2006, Kok et al., 2016), making it 
a useful marker to identify activated B cells. Following co-culture with tMC or tMV, but not uMC 
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or uMV, CD27– non-memory B cells significantly upregulated HLA-DR (Figure 5.6A in purple). 
This tMC- and tMV-driven upregulation in B cell HLA-DR expression did not occur in CD27+ 
memory B cells (Figure 5.6B). Data is represented as a fold change in HLA-DR expression 
compared to B cells alone. 
 
Detailed analysis revealed that the effect of tMC and tMV on non-memory B cell HLA-DR 
upregulation was most profound on the CD38+ IgM+ transitional B cells (Figure 5.6D in red). 
Indeed, only transitional B cells cultured with tMC or tMV, but not uMC and uMV, had 
significantly higher HLA-DR expression compared to B cells cultured by themselves 
(Appendix K). 
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Figure 5.4 – Human IL-4-treated mast cells and their microvesicles have no effect on 
the frequency of CD27 B cell subsets. Human peripheral blood-derived mast cells were 
treated with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles were then collected and 
co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells.
(A) shows the gating strategy and definition of non-memory (CD27–) and memory (CD27+) 
B cells. (B) shows the relative frequency of non-memory and memory B cells as a fold 
change compared to B cells alone, where B cells were cultured with untreated mast cells 
(uMC) or their microvesicles (uMV), or IL-4-treated mast cells (tMC) or their microvesicles 
(tMV). The horizontal dashed line is at 1, indicating no change in expression compared to
B cells alone. n = 8 different human donors from 5 independent experiments; Wilcoxon test; 
like symbols represent same donor; ns not significant. 
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Figure 5.5 – Human IL-4-treated mast cells and their microvesicles shift the 
proportion of non-memory B cell subsets. Human peripheral blood-derived mast cells 
were treated (tMC) or not (uMC) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles 
(tMV or uMV) were then collected and co-cultured with B cells (previously frozen for each 
patient) at a 1:10 ratio mast cells:B cells for a further 48 hr. Mass cytometry was then done 
on these cells. (A) shows the gating strategy and definition of naïve (CD38–/low IgMlow), 
transitional (CD38+/hi IgMhi) and CD38– IgM+/hi B cells. (B-D) shows the relative frequency of 
(B) transitional, (C) naïve, and (D) CD38– IgM+/hi B cells as a fold change compared to B 
cells alone, where B cells were cultured with mast cells or mast cell-derived microvesicles. 
The horizontal dashed line is at 1, indicating no change in expression compared to B cells 
alone. n = 8 different human donors from 5 independent experiments; Wilcoxon test; like 
symbols represent same donor. 
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Figure 5.6 – Human IL-4-treated mast cells and their microvesicles upregulate 
HLA-DR expression on B cells, most prominently on transitional B cells but with no 
effect on memory B cells. Human peripheral blood-derived mast cells were treated (tMC) 
or not (uMC) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles (tMV or uMV) were 
then collected and co-cultured with B cells (previously frozen for each patient) at a 1:10 
ratio mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. 
This figure shows the mean mass cytometry signal intensity of HLA-DR expression of 
various B cell subsets as a fold change compared to B cells alone. The vertical dashed line is 
at 1, indicating no change in expression compared to B cells alone. n = 8 different human 
donors from 5 independent experiments; Wilcoxon test; like symbols represent same donor; 
ns not significant.
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5.3.3 Human IL-4-treated mast cells and their microvesicles alter transitional 
B cell expression of various surface receptors and molecules 
5.3.3.1 Molecules involved in antigen detection and B cell receptor signalling 
tMC and tMV preferentially affected transitional B cells, and so this subset was subjected to further 
investigation (Figures 5.7-5.19). tMV significantly increased transitional B cell expression of 
CD79b (also known as IgE), IgM and BLNK (B cell linker protein; Figure 5.7B, D and E 
respectively), when compared to B cell cultured with uMV. When compared to B cells alone, tMV 
increased expression of IgM and BLNK, with similar results for tMC with IgM (Appendix K). uMC 
induced a significant decrease in CD19 compared to B cells alone (Appendix K). There were no 
other statistically significant effects on molecules involved in antigen detection or B cell receptor 
signalling. 
  
Figure 5.7 – Human IL-4-treated mast cells and their microvesicles alter transitional 
B cell expression of various members of the B cell receptor complex. Human 
peripheral blood-derived mast cells were treated (tMC) or not (uMC) with 10 ng mL–1 IL-4 
for 48 hr. Cells and microvesicles (tMV or uMV) were then collected and co-cultured with
B cells (previously frozen for each patient) at a 1:10 ratio mast cells:B cells for a further
48 hr. Mass cytometry was then done on these cells. This figure shows the mean mass 
cytometry signal intensity of (A) CD19, (B) CD79b, (C) IgD, (D) IgM and (E) BLNK 
expression of transitional B cells as a fold change compared to B cells alone. The horizontal 
dashed line is at 1, indicating no change in expression compared to B cells alone. n = 8 
different human donors from 5 independent experiments; Wilcoxon test; like symbols 
represent same donor; ns not significant.
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5.3.3.2 Molecules involved in immune modulation 
Changes in B cell expression of co-stimulatory molecules from the B7-family, particularly CD80 
(B7-1), CD86 (B7-2) and CD274 (B7-H1 or PD-L1) can be indicative of an immunomodulatory 
function. The importance of CD80 and CD86 for UV-induced immune suppression in mice is well-
established (Ullrich et al., 1998, Ando et al., 2000), including a high expression on UV-activated 
B cells (Kok et al., 2016), whilst the PD-L1/PD-1 pathway is a mechanism by which human B cells 
can act on the immune system (Khan et al., 2015, Guan et al., 2016, Xiao et al., 2016). tMV 
significantly increased transitional B cell expression of CD80, CD86 and CD274 (Figure 5.8A, B, C 
respectively) when compared with their respective untreated groups. CD86, but not CD80 or 
CD274, was also significantly increased after B cell co-culture with tMC. When compared to 
B cells alone, mast cell-derived microvesicles, whether they were derived from uMC or tMC, 
increased expression of CD86 (Appendix K). Intriguingly, co-culture with either mast cell group, 
whether they were stimulated with IL-4 or not, significantly downregulated expression of CD274 
on transitional B cells (Appendix K). 
 
In addition to B7-family members, B cell expression of cytokine receptors can have a profound 
effect on immune outcome. Compared to uMV, tMV significantly increased transitional B cell 
expression of CD25 (IL-2 receptor α; Figure 5.9A), whilst decreasing CD184 (CXCR4; Figure 
5.9B) and CD210 (IL-10 receptor; Figure 5.9C). Co-culture with either mast cell group, whether 
they were stimulated with IL-4 or not, had no effect on any cytokine receptor investigated 
(Figure 5.9A-F). There was no significant mast cell- or microvesicle-mediated effect on transitional 
B cell expression of CD120a (TNF receptor type I; Figure 5.9D), CD213α2 (IL-13 receptor α2; 
Figure 5.9E), or CD267 (TACI; Figure 5.9F). 
  
Figure 5.8 – Human IL-4-treated mast cells and their microvesicles alter transitional 
B cell expression of various co-stimulatory molecules. Human peripheral 
blood-derived mast cells were treated (tMC) or not (uMC) with 10 ng mL–1 IL-4 for 48 hr. 
Cells and microvesicles (tMV or uMV) were then collected and co-cultured with B cells 
(previously frozen for each patient) at a 1:10 ratio mast cells:B cells for a further 48 hr. 
Mass cytometry was then done on these cells. This figure shows the mean mass 
cytometry signal intensity of (A) CD80, (B) CD86 and (C) CD274 (PD-L1) expression of 
transitional B cells as a fold change compared to B cells alone. The horizontal dashed line is 
at 1, indicating no change in expression compared to B cells alone. n = 6-8 different human 
donors from 4-5 independent experiments; Wilcoxon test; like symbols represent same 
donor; ns not significant. 
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Figure 5.9 – Human IL-4-treated mast cells and their microvesicles alter transitional 
B cell expression of CD25, CD184 and CD210, but no effect on CD120a, CD213αRU
CD267. Human peripheral blood-derived mast cells were treated (tMC) or not (uMC) with 
10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles (tMV or uMV) were then collected and 
co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio mast cells:B 
cells for a further 48 hr. Mass cytometry was then done on these cells. This figure shows 
the mean mass cytometry signal intensity of (A) CD25, (B) CD184, (C) CD210, (D) CD120a, 
(E) CD213α and (F) CD267 expression of transitional B cells as a fold change compared to 
B cells alone. The horizontal dashed line is at 1, indicating no change in expression 
compared to B cells alone. n = 6-8 different human donors from 4-5 independent 
experiments; Wilcoxon test; like symbols represent same donor; ns not significant. 
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5.3.4 Human IL-4-treated mast cells and their microvesicles upregulate 
transitional B cell production of IL-10 
Although there are currently no gold standard markers for regulatory B cells, IL-10 is still the most 
commonly associated cytokine with regulatory B cells due to its ability to induce T cell anergy 
(Groux et al., 1996). Many B cell subsets have been found to produce IL-10 (Table 1.1), so it was 
of interest to determine if there was preferential activation of a B cell subset to produce IL-10 after 
co-culture with tMC or tMV. Both tMC and tMV significantly upregulated immune modulatory 
IL-10 in transitional B cells when compared with their respective untreated groups (Figure 5.10). 
Figure 5.11 investigated the level of IL-10 expression in CD23– and CD23+ transitional B cells. 
tMC upregulated IL-10 expression on CD23+ transitional B cells when compared to CD23– 
transitional B cells. tMV upregulated IL-10 expression on CD23+ transitional B cells when 
compared to CD23– transitional B cells of the same group or their respective untreated group. 
 
In contrast, there was no significant effect on transitional B cell expression of pro-inflammatory 
TNF when comparing IL-4 treatment groups with their relevant untreated groups (Figure 5.12). 
However, there did appear to be an increase in TNF production from B cells after co-culture with 
mast cells regardless of IL-4 treatment (Appendix K). 
  
Figure 5.10 – Human IL-4-treated mast cells and their microvesicles upregulate 
transitional B cell production of IL-10. Human peripheral blood-derived mast cells were 
treated (tMC) or not (uMC) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles (tMV or 
uMV) were then collected and co-cultured with B cells (previously frozen for each patient) 
at a 1:10 ratio mast cells:B cells for a further 48 hr. Mass cytometry was then done on 
these cells. Data shows transitional B cells (defined in Figure 5.5). (A) is a representation 
of IL-10 staining on transitional B cells, including a control with no intracellular antibodies. 
Bold numbers represent the median frequency and interquartile range is in italics.
(B) shows the relative mean mass cytometry signal intensity of IL-10 as a fold change 
compared to B cells alone. The vertical dashed line is at 1, indicating no change in 
expression compared to B cells alone. n = 8 different human donors from 5 independent 
experiments; Wilcoxon test; like symbols represent same donor. 
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Figure 5.11 – Human IL-4-treated mast cells and their microvesicles upregulate IL-10 
on CD23+ transitional B cells. Human peripheral blood-derived mast cells were treated 
(or not) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles were then collected and 
co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. This 
figure shows previously gated transitional B cells (Figure 5.5). The mass cytometry signal 
intensity of IL-10 expression was then taken for CD23+ and CD23– transitional B cells.
(A) shows the results of mast cell co-culture, (B) shows the results of microvesicle co-culture. 
n = 8 different human donors from 5 independent experiments, with numbers representing 
the median; Wilcoxon test; like symbols represent same donor; ns not significant.
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Figure 5.12 – Human mast cells upregulate transitional B cell production of TNF. 
Human peripheral blood-derived mast cells were treated (tMC) or not (uMC) with 10 ng 
mL–1 IL-4 for 48 hr. Cells and microvesicles (tMV or uMV) were then collected and 
co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. Data 
shows transitional B cells (defined in Figure 5.5). (A) is a representation of TNF staining on 
transitional B cells, including a control with no intracellular antibodies. Bold numbers 
represent the median frequency and interquartile range is in italics. (B) shows the relative 
mean mass cytometry signal intensity of IL-10 as a fold change compared to B cells alone. 
The vertical dashed line is at 1, indicating no change in expression compared to B cells 
alone. n = 8 different human donors from 5 independent experiments; Wilcoxon test; like 
symbols represent same donor; ns not significant. 
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5.3.5 Transitional B cells with an immune regulatory phenotype express CD23  
My discovery that IL-10-producing transitional B cells expressed high levels of CD23 (also known 
as FcεRII) suggested that CD23 may be a useful marker of mast cell-activated B cells in humans. 
The exact role of CD23 appears to be quite diverse, particularly so due to its wide range of ligands 
including CD21 (Aubry et al., 1992), CD11b and CD11c (Lecoanet-Henchoz et al., 1995). In the 
context of B cells, it has been used to differentiate between type 1 and type 2 transitional B cells, 
whereby type 1 are CD23–, whilst type 2 are CD23+ (Loder et al., 1999). A later study found a 
difference in their response to T cell help, whereby CD23+ transitional B cells had a greater level of 
proliferation and were rescued from B cell receptor-induced apoptosis (Chung et al., 2002). In the 
context of mast cells, Roviezzo et al. (2016) found S1P induced expression of CD23 on T and 
B cells in mice, which could be reversed in mast cell-deficient mice, suggesting mast cells are 
required for B cell (and T cell) expression of CD23 in certain contexts. It was hence of interest to 
further investigate CD23 expression on transitional B cells. Indeed, when compared to B cells 
alone, co-culture with mast cells (regardless of treatment) as well as tMV, but not uMV, 
significantly upregulated CD23 expression on transitional B cells (Appendix K). Because tMV had 
the most striking effect on increasing transitional B cell CD23 expression, further phenotyping was 
done on these cells (Figure 5.14). These tMV-activated CD23+ transitional B cells were also found 
to be CD20+ (99.9 %), IgD+ (99.8 %), CD19+ (73.4 %), CD24+ (75.5 %), CD213α2low/+ (58.8 %), 
and CD13Llow/+ (53.6 %). 
 
Next, to investigate whether CD23+ transitional B cells (pink in Figures 5.15-5.19) were selectively 
altered by tMC and tMV, their surface expression of various immune regulatory molecules were 
compared with that expressed by CD23– transitional B cells, either from the same IL-4-treated 
group (orange in Figures 5.15-5.19) or from the untreated group (black in Figures 5.15-5.19). 
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tMC and tMV upregulated expression of BLNK (Figure 5.15), CD274 (Figure 5.16) and CD213α2 
(Figure 5.17) on CD23+ transitional B cells when compared to CD23– transitional B cells of the 
same group (treated or untreated). In the case of CD137L (Figure 5.18) and S1P1 (Figure 5.19), 
only tMC upregulated the expression of these molecules on CD23+ transitional B cells when 
compared to CD23– transitional B cells of the same group or uMC. 
  
Figure 5.13 – Gating strategy for identifying CD23+ and CD23– transitional B cells; 
Human IL-4-treated mast cells and their microvesicles upregulate CD23 expression 
on transitional B cells. Human peripheral blood-derived mast cells were treated (tMC) or 
not (uMC) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles (tMV or uMV) were then 
collected and co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio 
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells.
(A) Transitional B cells (defined in Figure 5.5) were further differentiated into CD23+/– 
transitional B cells as shown. Bold numbers represent the median frequency and 
interquartile range is in italics. (B) shows the mean mass cytometry signal intensity of 
CD23 expression on transitional B cells as a fold change compared to B cells alone. The 
horizontal dashed line is at 1, indicating no change in expression compared to B cells alone. 
n = 8 different human donors from 5 independent experiments; Wilcoxon test; like symbols 
represent same donor. 
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Figure 5.14 – Marker expression on CD23+ transitional B cells after co-culture with 
microvesicles from IL-4-treated mast cells. Human peripheral blood-derived mast cells 
were treated with 10 ng mL–1 IL-4 for 48 hr. Microvesicles were then collected and 
co-cultured with B cells (previously frozen for each patient) for a further 48 hr. Mass 
cytometry was then done on these cells. These figures show the relative expression level 
of previously gated CD23+ transitional B cells (defined in Figure 5.5). Grey histograms 
represent the unstained samples, whilst magenta represents samples stained with the 
underlined antibody. These figures are representative of 6-8 different human donors from 
4-5 independent experiments. Bold numbers represent the median frequency and 
interquartile range is in italics.
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Figure 5.15 – Human IL-4-treated mast cells and their microvesicles upregulate 
BLNK on CD23+ transitional B cells. Human peripheral blood-derived mast cells were 
treated (or not) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles were then collected 
and co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. This 
figure shows previously gated transitional B cells (Figure 5.5). The mass cytometry signal 
intensity of BLNK expression was then taken for CD23+ and CD23– transitional B cells.
(A) shows the results of mast cell co-culture, (B) shows the results of microvesicle co-culture. 
n = 8 different human donors from 5 independent experiments, with numbers representing 
the median; Wilcoxon test; like symbols represent same donor; ns not significant. 
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Figure 5.16 – Human IL-4-treated mast cells and their microvesicles upregulate 
CD274 (PD-L1) on CD23+ transitional B cells. Human peripheral blood-derived mast 
cells were treated (or not) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles were then 
collected and co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio 
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. This 
figure shows previously gated transitional B cells (Figure 5.5). The mass cytometry signal 
intensity of CD274 (PD-L1) expression was then taken for CD23+ and CD23– transitional
B cells. (A) shows the results of mast cell co-culture, (B) shows the results of microvesicle 
co-culture. n = 8 different human donors from 5 independent experiments, with numbers 
representing the median; Wilcoxon test; like symbols represent same donor; ns not 
significant. 
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Figure 5.17 – Human IL-4-treated mast cells and their microvesicles upregulate 
&'α on CD23+ transitional B cells. Human peripheral blood-derived mast cells were 
treated (or not) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles were then collected 
and co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. This 
figure shows previously gated transitional B cells (Figure 5.5). The mass cytometry signal 
intensity of C'α expression was then taken for CD23+ and CD23– transitional B cells. 
(A) shows the results of mast cell co-culture, (B) shows the results of microvesicle co-culture. 
n = 8 different human donors from 5 independent experiments, with numbers representing 
the median; Wilcoxon test; like symbols represent same donor; ns not significant. 
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Figure 5.18 – Human IL-4-treated mast cells (but not their microvesicles) upregulate 
CD137L on CD23+ transitional B cells. Human peripheral blood-derived mast cells were 
treated (or not) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles were then collected 
and co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. This 
figure shows previously gated transitional B cells (Figure 5.5). The mass cytometry signal 
intensity of CD137L expression was then taken for CD23+ and CD23– transitional B cells.
(A) shows the results of mast cell co-culture, (B) shows the results of microvesicle co-culture. 
n = 8 different human donors from 5 independent experiments, with numbers representing 
the median; Wilcoxon test; like symbols represent same donor; ns not significant. 
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Figure 5.19 – Human IL-4-treated mast cells (but not their microvesicles) upregulate 
S1P1 on CD23+ transitional B cells. Human peripheral blood-derived mast cells were 
treated (or not) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles were then collected 
and co-cultured with B cells (previously frozen for each patient) at a 1:10 ratio
mast cells:B cells for a further 48 hr. Mass cytometry was then done on these cells. This 
figure shows previously gated transitional B cells (Figure 5.5). The mass cytometry signal 
intensity of S1P1 expression was then taken for CD23+ and CD23– transitional B cells.
(A) shows the results of mast cell co-culture, (B) shows the results of microvesicle co-culture. 
n = 8 different human donors from 5 independent experiments, with numbers representing 
the median; Wilcoxon test; like symbols represent same donor; ns not significant. 
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5.3.6 B cells co-cultured with mast cells or their microvesicles alter T cell 
proliferation and phenotype 
Human IL-4-treated mast cells and, in some cases their microvesicles, appear to be activating 
phenotypically regulatory B cells. To determine whether these B cells could affect the activation of 
T cells, B cells were first co-cultured with mast cells or their microvesicles as described above. 
After this, the cells were co-cultured at a 10:1 ratio (B cells:T cells) with CD4+ CD25– T cells to 
determine whether they could influence T cell proliferation and production of IFN-γ. The co-culture 
was stimulated with anti-CD2, anti-CD3 and anti-CD28 to promote T cell proliferation and 
cytokine production. B cells did not have any consistent or significant effect on T cell production of 
IFN-γ. (Figure 5.20). However, B cells co-cultured with tMC did significantly increase the division 
index, but not proliferation index of T cells (Figure 5.21). The division index is the average number 
of divisions undertaken by all cells (including those that did not proliferate at all), whilst the 
proliferation index is the average number of divisions undertaken by the proliferating cells. 
Because the division index increased but not the proliferation index, it suggests the B cell-tMC co-
culture promote more T cells to divide, but does not alter the rate of proliferation by T cells that are 
undergoing proliferation. 
 
CD69 is a well-known “early activation” marker expressed by newly activated T cells. However, 
CD69 can also suppress S1P1 receptor re-expression, thereby prolonging T cell sequestration 
within lymph nodes (Shiow et al., 2006). While this gives T cells plenty of time to become 
activated by dendritic cells, it is also a means of temporary immune suppression as it can prevent 
activated T cells from migrating to sites of inflammation. Flow cytometry was conducted on the 
T cells to determine whether our B cells were capable of affecting the expression of these receptors. 
As expected, CD69 was rapidly increased on the surface of T cells activated by anti-CD2, anti-
CD3, and anti-CD28 beads (Figure 5.22). After 3 divisions, CD69 levels decrease while S1P1 
levels increase. Compared to B cells alone, there was a significant increase in the level of CD69 
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prior to any T cell division after co-culture with B cells activated by tMC but not uMC. This 
increase in CD69 prior to T cell division did not occur when T cells were incubated with B cells 
pre-stimulated with mast cell-derived microvesicles (Figure 5.23). 
 
Figure 5.24 showed that B cells co-cultured with mast cells, whether they were activated by IL-4 or 
not, had no effect on the levels of CD69 on these CD69+ T cells. However, B cells pre-cultured with 
tMV decreased the level of CD69 expression of CD69+ T cells either before or just after first 
division (Figure 5.25). These results suggest tMV-activated B cells are altering the activation of 
T cells, as their expression of CD69 is lower than that of uMV and B cells left alone at the first 
divisions. 
 
Based on data presented in earlier chapters, whereby IL-10 (Figure 3.8A) and the subunits of IL-35 
(Figures 3.9 and 3.10C) were increased after co-culture between murine IL-4-treated mast cells and 
B cells, it was hence of interest to determine whether IL-10 and or IL-35 were being produced in 
our human co-culture. Although IL-35 was un-detectable (data not shown), IL-10 was detectable in 
the tissue culture supernatants from all but one donor (Figure 5.26) and (Figure 5.27). While tMC-
stimulated B cells induced an increase in IL-10 over and above that of uMC in all cases 
(Figure 5.26), this did not reach statistical significance (p = 0.0771). There was no consistent or 
significant effect of MV on B cell-driven IL-10 changes (Figure 5.27). It was then of interest to 
determine whether B cells cultured with microvesicles could act differently when they were then 
exposed to uMC for the first time. In Chapter 4, I found murine IL-4-treated mast cell-derived 
microvesicles could activate B cells, which in turn could promote untreated mast cell production of 
IL-13 (Figure 4.10). To determine whether a similar cross-talk was occurring, B cells cultured with 
microvesicles were then co-cultured with uMC and CD4+ CD25– T cells. tMV-activated B cells co-
cultured with uMC and CD4+ CD25– T cells consistently had a greater level of IL-10 compared to 
B cells cultured with uMV (Figure 5.27). tMV-activated B cells had a significantly greater level of 
IL-10 compared to B cells alone only in the presence of uMC. As this trend was not present when 
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tMV-activated B cells were co-cultured with T cells (without the addition of uMC), it suggests 
tMV-activated B cells may require uMC to have an effect. These experiments are underpowered 
with only 3 donors. However, there was consistent upregulation in IL-10 in all 3, which provides 
some degree of confidence that the effect is real. 
  
Figure 5.20 – B cells co-cultured with mast cells or their microvesicles had no effect 
RQ7FHOOSURGXFWLRQRII)1Ȗ. Human peripheral blood-derived mast cells were treated 
(tMC) or not (uMC) with 10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles (tMV or uMV) 
were then collected and co-cultured with B cells (previously frozen for each patient) for a 
further 48 hr at a 10:1 ratio (B cells:mast cells). Cells were then washed in cRPMI before 
being added to thawed out patient CD4+ CD25– T cells (10:1 B cells:T cells) for 1 hr 
incubation, before stimulation with anti-CD2, anti-CD3, anti-CD28 beads at 1 bead/100 
cells for 72 hr. 5 hr prior to end of stimulation, cells were treated with 50 ng mL–1 PMA,
0.5 µg mL–1 ionomycin and 5 µg mL–1 brefeldin A. T cells were then stained with by 
LQWUDFHOOXODU IORZ IRU I)1-Ȗ-%9 (A) shows the gating strategy used to identify T cells. 
(B VKRZV WKH SHUFHQWDJH RI I)1-Ȗ 7 FHOOV (ZLWK UHSUHVHQWDWLYH SORWV Bold numbers 
represent the median frequency and interquartile range is in italics. n = 5 different human 
donors from 3 independent experiments; Friedman test (Dunn’s post test); like symbols 
represent same donors; ns not signficant.
I)
1
Ȗ
+  f
re
qu
en
cy
 (%
 o
f T
 c
el
ls
)
uMC tMC
Mast cells Microvesicles
B cells
alone uMV tMV
B cells
alone
0
10
20
30
40
0
5
10
15
20
T cells alone
(unstimulated)
T cells alone
(stimulated)
CD3
C
D
11
7
I)1Ȗ
C
D
3
A
B
T cells +
B cells
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
0-10 3 10 3 10 4 10 5
0
-10 3
10 3
10 4
10 5
T cells
73.1
T cells
72.7
T cells
8.46
I)1Ȗ+I)1Ȗ+ I)1Ȗ+
ns
ns
4.23 %
3.88-4.57
3.69 %
2.87-4.20
10.1 %
4.5-11.2
181
Figure 5.21 – Human IL-4-treated mast cells (but not their microvesicles) co-cultured 
with B cells increase division index of T cells (but no change in proliferation index). 
Human peripheral blood-derived mast cells were treated (tMC) or not (uMC) with
10 ng mL–1 IL-4 for 48 hr. Cells and microvesicles (tMV or uMV) were then collected and 
co-cultured with B cells (previously frozen for each patient) for a further 48 hr at a 10:1 ratio 
(B cells:mast cells). Cells were then washed in cRPMI before being added to thawed out 
patient CD4+ CD25– T cells (10:1 B cells:T cells) for 1 hr incubation, before stimulation with 
anti-CD2, anti-CD3, anti-CD28 beads at 1 bead/100 cells for 72 hr. T cells were stained 
with cell trace violet to measure proliferation as shown in (Figure 5.1), followed by analysis 
using (Equations 1-5). The two left figures show B cells cultured with mast cells, whilst the 
two right figures show B cells cultured with mast cell-derived microvesicles. The top row 
shows the division index, whilst the bottom shows the proliferation index. n = 5 different 
human donors from 3 independent experiments; Friedman test (Dunn’s post test); like 
symbols represent same donors; ns not significant.
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Figure 5.22 – Human IL-4-treated mast cells co-cultured with B cells increase CD69 
expression on T cells but have no effect on S1P1. Human peripheral blood-derived 
mast cells were treated (or not) with 10 ng mL–1 IL-4 (or not) for 48 hr and then co-cultured 
with B cells (previously frozen for each patient) for a further 48 hr, where B cells were 
cultured with untreated mast cells or IL-4-treated mast cells (10:1 B cells:mast cells). Cells 
were then washed in cRPMI before being added to thawed out patient CD4+ CD25– T cells 
(10:1 B cells:T cells) for 1 hr incubation, before stimulation with anti-CD2, anti-CD3, 
anti-CD28 beads at 1 bead/100 cells for 72 hr. T cells were stained with cell trace violet to 
measure proliferation, with a representative plot shown (A). The mean fluorescent intensity 
(MFI) was then taken for (B) CD69-BV711 and (C) S1P1-APC. n = 3-5 different human 
donors from 2-3 independent experiments; 2-way ANOVA (Turkey’s multiple comparison 
test); like symbols represent same donors; ns not significant.
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Figure 5.23 – Human IL-4-treated mast cell-derived microvesicles co-cultured with
B cells have no effect on T cell expression of CD69 or S1P1. Human peripheral 
blood-derived mast cells were treated (or not) with 10 ng mL–1 IL-4 (or not) for 48 hr. 
Microvesicles were then collected and co-cultured with B cells (previously frozen for each 
patient) for a further 48 hr, where B cells were cultured with untreated mast cell-derived 
microvesicles, or microvesicles from IL-4-treated mast cells. Cells were then washed in 
cRPMI before being added to thawed out patient CD4+ CD25– T cells (10:1 B cells:T cells) 
for 1 hr incubation, before stimulation with anti-CD2, anti-CD3, anti-CD28 beads at
1 bead/100 cells for 72 hr. T cells were stained with cell trace violet to measure 
proliferation, with a representative plot shown (A). The mean fluorescent intensity (MFI) 
was then taken for (B) CD69-BV711 and (C) S1P1-APC. n = 3-5 different human donors 
from 2-3 independent experiments; 2-way ANOVA (Turkey’s multiple comparison test); like 
symbols represent same donors.
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Figure 5.24 – Human IL-4-treated mast cells co-cultured with B cells do not affect 
CD69+ T cell expression of CD69 or S1P1. Human peripheral blood-derived mast cells 
were treated (or not) with 10 ng mL–1 IL-4 (or not) for 48 hr and then co-cultured with
B cells (previously frozen for each patient) for a further 48 hr, where B cells were cultured 
with untreated mast cells or IL-4-treated mast cells (10:1 B cells:mast cells). Cells were then 
washed in cRPMI before being added to thawed out patient CD4+ CD25– T cells (10:1
B cells:T cells) for 1 hr incubation, before stimulation with anti-CD2, anti-CD3, anti-CD28 
beads at 1 bead/100 cells for 72 hr. T cells were stained with cell trace violet to measure 
proliferation, with a representative plot shown (A). The mean fluorescent intensity (MFI) 
was then taken of CD69+ T cells for (B) CD69-BV711 and (C) S1P1-APC. n = 3-5 different 
human donors from 2-3 independent experiments; 2-way ANOVA (Turkey’s multiple 
comparison test); like symbols represent same donors.
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Figure 5.25 – Human IL-4-treated mast cell-derived microvesicles co-cultured with
B cells alter CD69+ T cell expression of CD69 and S1P1. Human peripheral 
blood-derived mast cells were treated (or not) with 10 ng mL–1 IL-4 (or not) for 48 hr. 
Microvesicles were then collected and co-cultured with B cells (previously frozen for each 
patient) for a further 48 hr, where B cells were cultured with untreated mast cell-derived 
microvesicles, or microvesicles from IL-4-treated mast cells. Cells were then washed in 
cRPMI before being added to thawed out patient CD4+ CD25– T cells (10:1 B cells:T cells) 
for 1 hr incubation, before stimulation with anti-CD2, anti-CD3, anti-CD28 beads at 1 
bead/100 cells for 72 hr. T cells were stained with cell trace violet to measure proliferation, 
with a representative plot shown (A). The mean fluorescent intensity (MFI) was then taken 
for (B) CD69-BV711 and (C) S1P1-APC. n = 3-5 different human donors from 2-3 
independent experiments; 2-way ANOVA (Turkey’s multiple comparison test); like symbols 
represent same donors; ns not significant.
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Figure 5.26 – Human IL-4-treated mast cells co-cultured with B cells and then T cells 
promote IL-10 levels. Human peripheral blood-derived mast cells were treated (tMC) or 
not (uMC) with 10 ng mL–1 IL-4 for 48 hr. Cells were then collected and co-cultured with
B cells (previously frozen for each patient) for a further 48 hr at a 10:1 ratio (B cells:mast 
cells). Cells were then washed in cRPMI before being added to thawed out patient CD4+ 
CD25– T cells (10:1 B cells:T cells) for 1 hr incubation, before stimulation with anti-CD2, 
anti-CD3, anti-CD28 beads at 1 bead/100 cells for 72 hr. Supernatant of co-cultures was 
then collected to run an ELISA against IL-10. Dotted horizontal lines represent the limit of 
detection (2.1 pg mL–1), whereby anything less is considered not to have detectable IL-10 
levels. Samples with no detectable IL-10 are not shown. n = 4 different human donors from 
2 independent experiments; Friedman test (Dunn’s post test); like symbols represent same 
donors.
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Figure 5.27 – Human IL-4-treated mast cell-derived microvesicles co-cultured with
B cells require untreated mast cells to promote IL-10 levels after co-culture with
T cells. Human peripheral blood-derived mast cells were treated (or not) with 10 ng mL–1 
IL-4 for 48 hr. Microvesicles (tMV or uMV) were then collected and co-cultured with B cells 
(previously frozen for each patient) for a further 48 hr. Cells were then washed in cRPMI 
before being added to untreated mast cells (or not) and thawed out patient CD4+ CD25–
T cells (10:1 B cells:T cells) for 1 hr incubation, before stimulation with anti-CD2, anti-CD3, 
anti-CD28 beads at 1 bead/100 cells for 72 hr. Supernatant of co-cultures was then 
collected to run an ELISA against IL-10. Dotted horizontal lines represent the limit of 
detection (2.1 pg mL–1), whereby anything less is considered not to have detectable IL-10 
levels. Samples with no detectable IL-10 are not shown. n = 3 different human donors from 
2 independent experiments; Friedman test (Dunn’s post test); like symbols represent same 
donors.
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5.4 Discussion 
My experiments involved differentiating CD34+ cells from human peripheral blood into mast cells: 
a process that took 9-10 weeks of cell culture. Long-term cultures such as this are prone to 
contamination, and are subject to donor variability (some donors had too few CD34+ cells to 
develop in to mast cells). Although there are human mast cell lines (most notably HMC-1) that do 
not require such long-term culturing, my experiments required a co-culture with autologous B and 
T cells. Furthermore, study of primary cells is more easily translated into disease contexts. B and 
T cells had to be frozen down and then resuscitated prior to use, which contributed to cell death. 
Although no model is perfect, it was deemed the most appropriate for my studies with an 
individual’s B cells after co-culture with their own mast cells. Although human variability remains 
an issue, any patterns that are consistently observed by multiple donors provide strong evidence a 
significant event is occurring. 
 
Flow cytometry and immunofluorescence staining of cytospins confirmed not only that mast cells 
could be grown from human peripheral blood CD34+ cells, but that IL-4 treatment decreased 
CD117 and increased FcHR1D expression. This IL-4-mediated effect on primary human mast cells 
is the same as that observed in murine bone-marrow-derived mast cells (Figure 3.2). As IL-4 was 
affecting our human mast cells in a similar manner to that observed in mice, it was of interest to 
determine whether human IL-4-treated mast cells (tMC) could in turn activate regulatory B cells. 
The first step was hence to investigate whether tMC (or their microvesicles, tMV) could likewise 
activate phenotypically regulatory B cells. 
 
Many subsets of B cells have been identified as regulatory (Table 1.1). Although there were no 
changes in the level of CD27+ memory or CD27– non-memory B cells, transitional B cells were the 
most prominently affected subset of CD27– non-memory B cells. The transitional B cells also 
preferentially upregulated HLA-DR after co-culture with tMC or tMV when compared to their 
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respective untreated controls (uMC and uMV). Upregulation of MHCII on B cells has been 
identified following ultraviolet (UV) exposure (Byrne and Halliday, 2005, Byrne et al., 2005, 
Matsumura et al., 2006, Kok et al., 2016), and can act as an indicator of murine B cell activation. 
Similar results were found in our murine mast cell-B cell co-culture, whereby murine IL-4-treated 
mast cells (and their microvesicles) increased B cell expression of MHCII (O'Sullivan, 2008, 
Marsh-Wakefield, 2012). Stimulation of HLA-DR on human peripheral blood B cells using 
monoclonal anti-HLA-DR (without the presence of a peptide) activated B cells to secrete IgM 
(Tabata et al., 2000). Alongside the murine data, HLA-DR expression on B cells may act as an 
indicator of human B cell activation. This result revealed transitional B cells as a key subset 
targeted by tMC and tMV. 
 
Transitional B cells, characterised by their high expression of IgM, CD38 and CD24, were first 
identified within the bone marrow of normal mice, as B cells ‘transition’ from immature to 
mature/naïve B cells (Carsetti et al., 1995). Related subsets of B cells have also been identified in 
human blood (Sims et al., 2005) and bone marrow (Agrawal et al., 2013). IgM and CD38 were used 
as this provided a clearer separation of B cell subsets. Some studies have found CD19+ CD24hi 
CD38hi transitional B cells to be immune suppressive (Blair et al., 2010, Das et al., 2012, Flores-
Borja et al., 2013, Simon et al., 2016). These are not the only subset of B cells that have been found 
to be regulatory, as highlighted by Rosser and Mauri (2015) and Table 1.1, but as our data show 
tMC and tMV are preferentially affecting CD38+/hi IgMhi transitional B cells (including HLA-DR 
upregulation). 
 
The B cell receptor complex is comprised of an immunoglobulin (of any isotype) and the 
heterodimer CD79 (made up of Igα and Igβ). It can be activated by cross-linking the 
immunoglobulins to provide further signals throughout the cell, such as proliferation (Fruman et al., 
1999) and cell survival (Lam et al., 1997). This is important when considering whether regulatory 
B cells are antigen-specific. Although Das et al. (2012) could inhibit a human CD8+ T cell antigen-
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specific (against hepatitis B virus) response using CD19+ CD24hi CD38hi B cells, it is interesting to 
consider whether regulatory B cells similarly act in an antigen-specific manner. In my experiments, 
B cells were cultured alongside autologous mast cells/microvesicles of the same donor. Any 
(phenotypically-identified) activation occurring is not likely to be in an antigen-specific manner due 
to self-tolerance. Activation is highlighted by the upregulation of IgD and IgM, which has been 
similarly reported in our murine mast cell-activated B cells (Gillis, 2010). Although there is no 
evidence of my B cells being phenotypically activated in an antigen-specific manner, the functional 
outcome of the mast cell/microvesicle-activated B cells may prove otherwise. Because CD79b (Igβ) 
expression was increased on B cells alongside IgD and IgM, the B cell receptor complex as a whole 
may increase too. This would allow easier activation of B cells via the immunoglobulins, quite 
possibly in an antigen-specific manner. This could explain how my transitional B cells were 
phenotypically but not functionally suppressive against T cell proliferation or cytokine production: 
the B cells may require activation in an antigen-specific manner to become fully activated. 
 
CD79b has been found to assist T cell receptor-induced signal transduction of B cells via MHCII 
(Lang et al., 2001), as well as B cell receptor internalisation (Gazumyan et al., 2006). These studies 
highlight the role CD79b has during antigen internalisation and presentation to T cells, so an 
increase in CD79b may contribute to both B cell and T cell activation. In contrast to the 
upregulation of CD79b, Kok et al. (2016) found it to be downregulated on UV-activated B cells. It 
is also important to note how tMC did not have this same effect. Because tMV promoted an 
increase in expression but tMC did not, this suggests that an interaction with other cells may 
modulate CD79b expression. This may explain the decrease in expression within the murine in vivo 
data. In Chapter 4, I found microvesicle-activated B cells first exposed to mast cells promoted mast 
cell production of IL-13. It may be tMV are promoting B cell expression of CD79b, but once mast 
cells arrive they decrease expression once more (which is what we see in mice). It would be 
worthwhile to phenotype tMV-activated B cells after co-culture with uMC, to see whether CD79b 
expression changes. Another experiment worth considering would involve collecting the 
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supernatant to detect any secreted antibodies; van de Veen et al. (2013) reported IgG4 expression 
within human B cells to be confined to IL-10-producing B cells. In mice, eliminating CD5– PD-L1+ 
IgA+ IL-10-producing B cells allowed CD8+ T cell-mediated eradication of oxaliplatin-treated 
tumours (Shalapour et al., 2015). By determining the presence/absence of various isotypes, it would 
give further insight in to the activation requirements and status of the B cells. 
 
B cell linker protein (BLNK) was first identified as a central linker protein that connected the B cell 
receptor-associated kinases with other signalling pathways (Fu et al., 1998). In the same year, 
SLP-65 (Wienands et al., 1998) and BASH (Goitsuka et al., 1998) were likewise identified as 
adaptor proteins involved with the B cell receptor, which were later proven to all be the same 
molecule. Mice deficient of BLNK have impaired IL-10 production from B10 cells, which leads 
them to develop more severe experimental autoimmune encephalomyelitis (EAE; animal model of 
multiple sclerosis) (Jin et al., 2013). Although this study found there was no difference in the level 
of CD1dhi CD5+ B10 cells, it does provide evidence of the importance of BLNK expression in the 
generation of IL-10-producing B cells. tMV significantly upregulated expression of BLNK on 
transitional B cells when compared to uMV. 
 
Cross-linking the B cell receptor in BLNK–/– B cells does not induce proliferation or upregulation 
of activation markers CD69 or CD86 when compared to wild type B cells (Xu, 2000). This 
unresponsiveness is due to BLNK–/– B cell inability to enter the cell cycle, as well as having a 
higher rate of spontaneous apoptosis (Tan et al., 2001). An increase in BLNK expression may 
provide a proliferation/survival signal, so rather than a shift in population (from naïve to transitional 
B cells), it may be the transitional B cells are given enhanced survival signals and do not 
progress/die, whilst the BLNKlow B cells may be dying. When considering this alongside the B cell 
receptor complex, it appears my mast cell-/microvesicle-activated B cells are being primed for 
antigen-specific activation. If this is the case, it may explain why mice given UV exposure prior to 
induction of EAE are protected (Kok et al., 2016): assuming UV is activating B cells via mast cells, 
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once these mast cell-/microvesicle-activated B cells are exposed to EAE they may be able to act in a 
functionally suppressive manner. This may also explain why it appears UV exposure at a young age 
can influence the risk of developing multiple sclerosis (MS), as McDowell et al. (2010) found the 
age of onset of MS is 2.8 years earlier for those born in winter (and hence less UV exposure) 
compared to other seasons. This explanation of regulatory B cell activation via inflammation is 
highlighted by Rosser and Mauri (2015), whereby many studies have found an increase in 
regulatory B cells in response to inflammation (Mizoguchi et al., 2002, Evans et al., 2007, Geherin 
et al., 2016). As a future experiment it would hence be interesting to culture mast cell-
/microvesicle-activated B cells with T cells alongside a specific antigen. This would give insight 
into whether the functional aspect of these B cells requires the presence of an antigen to become 
functionally activated. Alternatively, the addition of anti-IgM to cross-link the B cell receptor 
complex would also address the importance of antigen-specificity in this context. This theory is 
supported by the finding that neither mast cells nor their microvesicles (regardless of IL-4 
treatment) did not alter B cell expression of sphingosine-1-phosphate (S1P) receptor 1 (S1P1; data 
not shown). It is already known antigen stimulation (such as LPS) of B cells decrease B cell 
expression of S1P1, in turn promoting B cell migration to splenic white pulp (Cinamon et al., 
2004). The lack of S1P1 expression in my experiments indicates that the B cells may not yet be 
fully activated. 
 
Another aspect of BLNK–/– B cells is their inability to upregulate CD86 after cross-linking the 
B cell receptor complex (Xu, 2000). CD80 and CD86 have dual specificity for CD28/CTLA-4, and 
can therefore provide stimulatory or inhibitory signals through these respective receptors on T cells 
(Brunet et al., 1987, Gross et al., 1990, Linsley et al., 1994). CD86 is expressed at low levels 
basally on B cells (Freeman et al., 1993), but can be rapidly upregulated following LPS treatment 
(Hathcock et al., 1994). B cell expression of CD80 and/or CD86 has been found to co-stimulate 
T cell production of IL-2 and proliferation (Gimmi et al., 1991, Freeman et al., 1993). In contrast, 
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an increase in CD86 on immune-modulating B cells is likely to have a significant impact on the 
development of autoimmunity. Indeed, CD86+ naïve B cells are significantly higher in the blood of 
MS patients, with significantly more of these cells present during remission (Niino et al., 2009). 
CD86hi B cells in human peripheral blood are regulatory (Kessel et al., 2012), as are those murine 
regulatory B cells induced by tumours (Olkhanud et al., 2011). High CD86 expression may be 
important for B cell regulatory function, as CD19+ CD24hi CD38hi B cells from human peripheral 
blood were found to suppress Th1 cell differentiation in vitro, an event that could be reversed with 
monoclonal antibodies against CD80 and CD86 (Blair et al., 2010). Preferentially targeting CD86, 
but not CD80 with monoclonal antibodies, inhibited UV-induced immune suppression (Ullrich et 
al., 1998). The mechanism of anti-CD86 blockade appeared to involve the inhibition of suppressor 
T cell induction, as well as decreased serum IL-10 levels compared to normal levels. Murine B cells 
can be induced to express CD86 via LPS or concanavalin A (Lenschow et al., 1993), whilst human 
splenic B cells stimulated with anti-Ig also have an upregulated expression of CD86. 
 
Huang et al. (2013) found IFN-β1a treatment of human peripheral blood mononuclear cells 
increased their expression of CD86 (but decreased CD80). This IFN-E1a treatment also promoted 
B cell production of IL-10, suggesting CD86 expression on B cells is a more indicative marker of 
regulatory B cells than CD80. IL-27 can likewise increase CD86 expression on anti-µ-stimulated 
human naïve and memory B cells (Larousserie et al., 2006b). In Chapter 3, murine IL-4-treated 
mast cells upregulated their production of EBI3, a subunit of IL-27, which may contribute to the 
upregulated CD86. However, primary human peripheral blood B cells transfected to overexpress 
IL-10 had a decreased level of CD86 expression (Stanic et al., 2015). Although tMC and tMV 
promoted transitional B cell production of IL-10, as well as increasing CD86 expression, there must 
be another molecule that is preventing IL-10 from decreasing CD86 expression. 
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Exosomes from murine bone marrow-derived mast cells are capable of upregulating CD80 and 
CD86 (as well as MHCII and CD40) on immature dendritic cells, which in turn acquired potent 
antigen-presenting capacity to T cells (Skokos et al., 2003). Palm et al. (2016) found similar results 
with murine bone marrow-derived mast cells, whereby mast cells increased proliferation, blast 
formation, CD19, MHCII, CD86 and L-selectin expression on B cells, suggesting mast cells 
support optimal activation of B cells. This is similar to what was found in our human mast cells, 
whereby tMC and tMV could promote CD86 expression in B cells, and promotes my hypothesis 
mast cells are priming B cells for further activation. CD86 expression is likely to impact on the 
ability of these B cells to influence the activation and function of T cells. I found tMC (but not 
tMV) co-cultured with B cells increased the T cell division index, but did not affect the proliferation 
index. The division index represents the average number of divisions undertaken by all cells 
(including those that are not proliferating), whilst the proliferation index only considers 
proliferating cells. Although both tMC and tMV could upregulate B cell expression of CD86, only 
tMC altered T cell proliferation. This suggests CD86 may not be the primary driver of T cell-
induced proliferation. Furthermore, the IL-10 ELISA data found tMC but not tMV consistently 
increased the level of IL-10 present within the culture. CD86 could very well be playing a role in 
the T cell-B cell interaction, but it is likely other receptors are also influencing the functional 
outcome of the B cells. To test the dependence of CD86 expression on B cells to influence T cell 
proliferation, the same co-culture assay could be done in the presence of monoclonal anti-CD86 to 
inhibit its signalling, and determine whether similar effects are detected. 
 
CD86 can also be expressed on T cells (Hathcock et al., 1994), and has been found to be 
upregulated on human CD4+ and CD8+ T cells after IL-2 treatment (Paine et al., 2012). The alpha 
chain of the IL-2 receptor, CD25, is best known for its constitutive expression on regulatory T cells 
(Sakaguchi et al., 1995). Expression of CD25 allows regulatory T cells to preferentially bind IL-2 
and outcompete other T cells for any available IL-2. A subset of human regulatory B cells has been 
reported to express high levels of CD25 (Kessel et al., 2012). In this study, they were able to isolate 
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CD25hi B cells from human peripheral blood, which were found to decrease CD4+ T cell 
proliferation in vitro, as well as enhance regulatory T cell expression of Foxp3 and CTLA-4. 
Similar studies have found CD25+ regulatory B cells in both mice (Sattler et al., 2014) and humans 
(Lindner et al., 2013, van de Veen et al., 2013). I found CD25 expression to be increased on B cells 
after culture with tMV compared to uMV, but there was no such effect from tMC. It hence may be 
possible for these B cells to inhibit T cell proliferation via the uptake of IL-2. Because T cells were 
stimulated with anti-CD2, anti-CD3 and anti-CD28, it may be these B cells could not act in this 
IL-2-independent activation of T cells. To test the relevance of CD25 expression, B cells could be 
co-cultured with T cells and then stimulated with IL-2. If there was successful inhibition of T cell 
proliferation, anti-CD25 could then be added to determine whether CD25 is required for this effect. 
However, this observation of upregulated CD25 was not seen when B cells were co-cultured with 
tMC. Sattler et al. (2014) found their CD25+ regulatory B cells to also be CD23–, in contrast to my 
CD23+ transitional B cells. These may be two different subsets of regulatory B cells, which could 
explain why only tMV had an effect on B cell expression of CD25, whilst mast cells had no such 
effect. However, Hivroz et al. (1989) found IL-2 could upregulate CD23 expression on human 
B cells from patients with chronic lymphocytic leukaemia, which correlated with IL-2-induced 
proliferation of B cells. To further investigate the relevance of CD25 expression on B cells, a 
phenotypic analysis could be done on the T cells after co-culture with B cells. IL-2 can alter T cell 
expression of various markers, including an increase in CD86 (Paine et al., 2012), which may help 
explain the difference between mast cell- and microvesicle-activated B cell interactions with 
T cells. 
 
IL-2 has also been found to upregulate both PD-1 and PD-L1 on human T cells (Kinter et al., 
2008). Through an interaction with PD-1 on T cells, CD274 (programmed death ligand 1 (PD-L1); 
B7-H1) can suppress T cell activation and effector function (Wilcox et al., 2009, Starke et al., 
2010). Using monoclonal antibodies against CD274 in mice blocked CD274+ monocyte-induced 
inhibition of T cells, with improved tumour clearance (Kuang et al., 2009). Anti-CD274 worked 
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synergistically alongside IL-2 to enhance anti-viral CD8+ T cells in a mouse model of chronic 
lymphocytic choriomeningitis virus infection (West et al., 2013). In CD8+ CD25+ Foxp3+ 
regulatory T cells, TNF was found to promote CD274 expression as well as their suppressive 
capabilities against CD4+ T cell proliferation (Horwitz et al., 2013). These regulatory T cells were 
also CD120b+: the likely receptor involved in promoting an immunosuppressive effect. Although 
CD120b was included in our panel, the data was not usable due to a bleeding effect observed on this 
metal isotope (Appendix H). On B cells, CD274 expression is well characterised and known to 
endow B cells with the ability to regulate immunity (Khan et al., 2015, Guan et al., 2016). Murine 
B cells have been found to constitutively express CD274, which could be upregulated further by 
treatment with LPS or concanavalin A (Ishida et al., 2002, Yamazaki et al., 2002). When IL-10 was 
transfected into human B cells to overexpress IL-10, CD274 was upregulated on B cells (Stanic et 
al., 2015). B cell expression of CD274 has also been shown to promote Th2 cytokines IL-5 and 
IL-13 in T cells (Kubo et al., 2012). Our lab has recently found UV upregulates CD274 on murine 
B cells, which may be involved in their protective capabilities during EAE (Kok et al., 2016). I 
found tMV were capable of upregulating transitional B cell expression of CD274. Upregulation of 
CD274 on transitional B cells after co-culture with tMV is hence indicative of a mechanism by 
which they could suppress a T cell response. However, this was not the case: tMV-activated B cells 
did not influence T cell proliferation or IFN-γ production. As mentioned previously, it may be tMV 
are priming B cells for further activation before they become functional. In fact, CD19+ B cells 
from invasive breast carcinoma patients were found to activate CD4+ CD25+ Foxp3+ regulatory 
T cells when cultured alongside CD274hi MDA-MB231 cells (a breast cancer cell line), suggesting 
B cells may be activated in a CD274-dependent manner to then act on T cells (Guan et al., 2016). 
Although this study was not looking at CD274 on B cells, it does highlight the possibility of 
CD274hi B cells acting in an autocrine manner for a similar effect. 
 
In contrast to microvesicles, I discovered that human B cells cultured with mast cells (either 
untreated or IL-4-treated) had significantly reduced levels of CD274 (~10 fold lower CD274 
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expression compared to B cells cultured alone). This suggests that mast cells may be working to 
reduce B cell expression of CD274. Interestingly, these same B cells had increased expression of 
TNF. These results for CD274 downregulation in B cells are different to that observed in human 
TNF-producing monocytes (Kuang et al., 2009) and CD8+ regulatory T cells (Horwitz et al., 2013), 
which act to promote CD274 expression in an autocrine manner. Similar results were found by Ou 
et al. (2012), whereby TNF could restore monocyte CD274 expression in systemic lupus 
erythematosus patients. In contrast to this, IFN-γ but not TNF has been found to induce CD274 on 
murine mesenchymal stem cells (English et al., 2007). One possible explanation is that B cell-
derived TNF is acting on the mast cells rather than the B cells, which may explain why there was an 
increase in B cell-derived TNF after co-culture with mast cells (independent of IL-4 treatment of 
mast cells). B cells in mice are known to produce TNF, which plays an important role in controlling 
infection. Opata et al. (2013) found mice deficient of B cell-derived TNF had a greater burden of 
Pneumocystis murina compared to wild type controls, as well as a decrease in activated CD4+ 
T cells, suggesting B cell-derived TNF can play a role in the activation of T cells for clearance of 
pathogens. The ablation of CD274 expression on B cells suggest they will not be able to suppress a 
T cell response, whilst the increase in TNF may activate T cells. These changes may explain why 
tMC-activated B cells were able to promote the T cell division index: that is, more T cells are 
entering proliferation. Although this was in comparison to B cells cultured with uMC, which 
likewise had a decrease in CD274 and increased TNF production. Furthermore, there was a 
consistent increase in supernatant IL-10 levels across all donors in tMC compared to the uMC co-
cultures. Because mast cells (regardless of IL-4 treatment) had similar alterations in CD274 and 
TNF, but differences in their final IL-10 levels after co-culture with T cells, the role of this receptor 
and cytokine may not be required for B cells to have an effect. To test their relevance, monoclonal 
antibodies could target CD274/TNF receptors (or ligands), to determine whether a similar increase 
in IL-10 was present. 
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It is also worthwhile noting that B cell-derived TNF can act in an autocrine manner, as Boussiotis et 
al. (1994) found B cell-derived TNF was required for B cell receptor- and CD40-induced 
proliferation. B cell production of TNF in mice may even be important in the generation and/or 
accumulation of regulatory B cells during cancer (Schioppa et al., 2011). In human monocytes, 
TNF (as well as IL-10) can act in an autocrine manner to promote CD274 expression (Kuang et al., 
2009). In healthy humans, transitional B cells have a higher ratio of IL-10/TNF when compared to 
memory B cells, despite producing similar absolute levels of IL-10 (Cherukuri et al., 2014). These 
TNFlow IL-10hi transitional B cells were found to be immune regulatory in the context of 
suppressing T cell production of TNF and IFN-γ. Thus, IL-10 assessment alone, without taking into 
consideration the production of other cytokines like TNF, may be insufficient to determine whether 
a B cell has the potential to regulate immunity. For my studies I did not look at this ratio, as it used 
the frequency of cytokine-producing B cells for its ratio, whilst my analysis looked at the signal 
intensity. Because mass cytometry does not have “bright” metal isotopes (in comparison to flow 
cytometer, e.g. PE), it means some populations are not as clearly distinct. I hence deemed it 
appropriate to look at the signal intensity to show relative changes, rather than the frequency of 
cells, and hence did not investigate the IL-10/TNF ratio. 
 
When analysing the possible effects of TNF, it is also important to consider which receptor TNF is 
acting on. Two major receptors of TNF are TNFR1 (CD120a) and TNFR2 (CD120b). Activation of 
either receptor can have profoundly different effects, particularly in MS. CD120a is generally 
considered pro-inflammatory (Akassoglou et al., 1998), whilst CD120b has been found to promote 
remyelination and neuroprotection (Arnett et al., 2001, Fontaine et al., 2002). Here, neither mast 
cells nor their microvescicles had an effect on CD120a and it was not possible to discern CD120b 
expression due to problems with metal isotope ‘bleeding’ (Appendix H). Of potential relevance, 
TNF can increase endothelial-derived microvesicles in mice in vivo, as well as human umbilical 
vein endothelial cells in vitro via CD120a (Lee et al., 2014). Thus, it is possible that B cell-derived 
TNF is able to influence mast cell production of microvesicles that in turn continue acting on the 
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B cells for further activation. Much like the murine mast cell-B cell interaction, B cells are first 
exposed to mast cell-derived microvesicles, and then when these B cells are first introduced to mast 
cells a cross talk occurs. This may explain why B cell-derived TNF was upregulated only in the 
presence of mast cells but not microvesicles. 
 
Another member of the TNF receptor family is CD267 (transmembrane activator and calcium 
modulator and cyclophilin ligand interactor, TACI). Murine regulatory B cells have been reported 
to express CD267 (Shen et al., 2014). Human IL-10-producing B cells express more CD267 than 
IL-10– B cells (Hua et al., 2016). Furthermore, BAFF (B cell-activating factor) can promote IL-10 
production in peripheral blood-derived B cells from chronic lymphocytic leukemia patients, which 
could be inhibited in the presence of anti-CD267 (Saulep-Easton et al., 2016). My results found no 
change in CD267 expression on B cells after co-culture with mast cells or B cells. It is entirely 
possible that the mast cell-/microvesicle-activated B cells in my experiments are a different subset 
of regulatory B cells compared to those previously reported (Table 1.1). This is particularly 
relevant, as in the Saulep-Easton et al. (2016) study, their murine CD267+ B cells were likewise 
CD5+: a marker commonly used to identify B10 cells (Yanaba et al., 2008). In contrast, the B cells 
activated following UV exposure are CD5– (Kok et al., 2016), highlighting the potentially different 
subsets of regulatory B cells being activated, which may reflect differences in function. 
 
Shen et al. (2014) likewise found their murine IL-35-producing B cells to express CD267, as well 
as the chemokine receptor CXCR4 (CD184). CXCL12 is a ligand against CD184 (Bleul et al., 
1996a), and acts as a potent chemokine (Bleul et al., 1996b). In the context of UV, CD184 
expression has been found to be important for the migration of mast cells from the dermis to the 
skin-draining lymph nodes (Byrne et al., 2008, Sarchio et al., 2014). Expression of CD184 on 
B cells is important for compartmentalisation (Nie et al., 2004), whilst CXCL12 treatment 
alongside anti-IgM promotes B cell survival (Wang et al., 2009). When considering cell survival, a 
recent study found CD184 signalling was negatively affected in murine B cells deficient of IgD, but 
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could be restored when stimulated with anti-CD19 (Becker et al., 2017). As discussed, activation 
via the B cell receptor complex is capable of promoting B cell survival (Lam et al., 1997), so 
CD184 expression may contribute to these effects. In mice, B cells deficient in CD184 were found 
to accumulate within Peyer’s patches and egress more slowly (Schmidt et al., 2013), suggesting that 
CD184– B cells become trapped within lymph nodes. Furthermore, CD63 and IL-21 have been 
found to decrease B cell expression of CD184 within mice (Yoshida et al., 2011). Mast cells may 
be acting in the same way, as it was found that regardless of IL-4 treatment, mast cells significantly 
downregulated B cell expression of CD184 when compared to B cells alone. These observations in 
human cells in vitro is supported by work done in vivo during my Honours in 2012. Exposure of 
mice to seven daily doses of UV, which can induce mast cell migration away from the skin (Byrne 
et al., 2008), led to an increase in the number of B cells within the skin-draining lymph nodes and a 
concordant decrease in B cell number within distant non-draining lymph nodes (Marsh-Wakefield, 
2012). The potential entrapment of B cells may be due to a decrease in CD184 expression by 
B cells, allowing them to receive further activation signals. Once activated, these B cells may then 
exert their immune regulation in distant tissues. Indeed, we recently showed that UV-activated 
B cells were found relocated within the CNS-draining lymph nodes of UV-exposed mice protected 
from EAE development (Kok et al., 2016). 
 
Interestingly, CXCL12 has been found to redirect polarisation of Th1 cells into regulatory T cells in 
a CD184-dependent manner (Meiron et al., 2008). If a similar event could occur with B cells, the 
decrease in expression may act as a negative regulator. Alternatively, human B cells may change 
their CD184 level as they mature, as it is highest on pre-B cells, then decreases on immature 
B cells, to then increase again on mature B cells (Honczarenko et al., 1999). Furthermore, tMV 
significantly decreased the level of CD184 on B cells when compared to uMV. I hypothesise tMV 
prime B cells prior to interaction with mast cells. Chapter 4 addressed the ability of murine IL-4-
treated mast cell-derived microvesicles activating B cells, which in turn could promote mast cell 
production of IL-13 (Figure 4.10). If microvesicles are first priming B cells for further interaction 
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with mast cells, it may also explain the differences in phenotypic changes induced by mast cells and 
microvesicles. To address this possibility, a phenotypic analysis could be done on human B cells 
first cultured with tMV, and then added to uMC to determine if there were any further changes after 
being introduced to uMC. 
 
The most common marker currently used to identify regulatory B cells is IL-10. IL-10 is most well 
known for its ability to induce anergy in self-reactive T cells (Groux et al., 1996). In the context of 
UV, many studies have found IL-10 to play an important contribution to both UV-induced immune 
suppression and carcinogenesis (Rivas and Ullrich, 1992, Beissert et al., 1996, Niizeki and 
Streilein, 1997, Hart et al., 2000, Alard et al., 2001, Byrne and Halliday, 2005, Piskin et al., 2005, 
Matsumura et al., 2006, Loser et al., 2007). The importance of IL-10 and its contribution to disease 
is why a current clinical trial (NCT02731742) by the National Institutes of Health in the US is 
investigating the effects of MK-1966 (an agent that downregulates the activity of IL-10), in 
combination with SD-101 (a TLR9 agonist), in patients with advanced malignancies. B cell-derived 
IL-10 is important in many disease contexts in both mice (Fillatreau et al., 2002, Byrne and 
Halliday, 2005, Matsumura et al., 2006, Matsushita et al., 2010, Carter et al., 2011, Horikawa et al., 
2011, Carter et al., 2012, Yang et al., 2012, Rosser et al., 2014, Sattler et al., 2014, Zhang et al., 
2015, Korniotis et al., 2016) and humans (Table 1.1). The fact that tMC and tMV increased the 
level of IL-10 (when compared to their respective untreated groups) further promotes our 
hypothesis these B cells are phenotypically regulatory. This of course was despite the differences in 
phenotypic changes between mast cells and microvesicles. This may indicate CD25, CD274, TNF 
and CD184 (which had differing levels of change between mast cells and microvesicles) do not play 
a role in B cell-derived IL-10. However, regardless of the increased levels of IL-10 found after tMC 
and tMV, these activated B cells were unsuccessful in suppressing T cell proliferation. As 
discussed, I hypothesise B cells are first being primed by tMC/tMV, for further activation (possibly 
via the B cell receptor complex). This is partially reflected in the IL-10 ELISA data, whereby there 
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was no increase in IL-10 after co-culture between tMV-activated B cells and T cells, until uMC 
were added to the mix. 
 
When considering the effects of IL-10, CD210, the receptor of IL-10, can be useful. Marrella et al. 
(2015) found anti-CD210 in Rankl–/– mice decreased the frequency of regulatory B cells. In my 
context, whereby CD210 is downregulated after co-culture with tMV, the decrease in CD210 may 
act as a negative regulator to prevent over-activation of B cells. In contrast to this, CD210 has been 
found to be upregulated on UV-induced B cells, which may play a regulatory role in protecting 
mice from EAE (Kok et al., 2016). As well as this, Nova-Lamperti et al. (2016) found CD40 
engagement on human transitional B cells promoted their production of IL-10 and increased CD210 
expression. Interestingly however, the IL-10 acted in an autocrine manner decreasing their 
expression of CD86. In my experiments, the decrease in CD210 expression may prevent IL-10-
induced downregulation of CD86. To test this, IL-10 could be added to the B cells alongside tMV. 
Although there is a decrease in CD210 expression, by oversaturating the system with IL-10 it may 
counter this decrease, in turn altering CD86 expression. 
 
The large increase in transitional B cell expression of CD23 (Fcε receptor II) by tMC and tMV was 
one of the most striking findings to emerge from these studies in human cells. IL-10 itself can 
inhibit IL-4-induced upregulation of CD23 on human blood-derived monocytes (Morinobu et al., 
1996). Although this effect was not observed in B cells, it is interesting to consider as tMV had a 
more profound increase in CD23 on B cells, whilst also decreasing CD210. It may be this decrease 
in CD210 dampens the effect of IL-10 on these cells, and hence do not have their CD23 expression 
inhibited, so tMV have a more profound effect on B cell CD23 expression than tMC. An increase in 
B cell expression of CD23 can be induced by IL-4 itself (Gordon et al., 1991), although it is 
unlikely that any residual IL-4 from the mast cell cultures could be responsible for this increase in 
B cell CD23 because mast cells are washed prior to co-culture with B cells, whilst microvesicles are 
isolated by a series of centrifugations that would remove residual IL-4 in the process. However, we 
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cannot rule out a role for mast-cell derived IL-4, either via de novo IL-4-driven synthesis and 
secretion (Plaut et al., 1989) or via the capture, storage, and release of bioactive IL-4 by the mast 
cells, as has been shown for human IL-17 (Noordenbos et al., 2016). The first experiment would be 
to include neutralising anti-IL-4 in the co-culture, to determine whether any IL-4 (either mast cell-
produced or through re-packaging) is required for the activation of B cells. Then to test whether 
IL-4 were being uptaken by mast cells to then be released once in contact with B cells (or via 
packaging in microvesicles), IL-4 could be stained (such as with a fluorescent tag or a metal 
isotope). After treatment the mast cells could be imaged to determine if it was uptaken, and then 
repeated after co-culture with B cells to determine if it was released again to be taken up by the 
B cells. If IL-4 were required for B cell activation, but was not from the originally provided IL-4, it 
would indicate mast cells were producing their own IL-4. 
 
Inaoki et al. (2004) showed that there was a correlation between CD23 expression on B cells and 
increased serum IgE levels in patients with bullous pemphigold, a blister-forming skin disease, 
which may be of relevance in this context as tMC had upregulated FcεRIα expression. IL-13 has 
been found to promote CD23 expression on B cells (Onguru et al., 2011), in turn inducing IgE 
production (Defrance et al., 1994). IL-13 has also been found to induce IgG4 and IgE class 
switching by B cells independently of IL-4, as well as upregulate CD23, CD72, HLA-DR and IgM 
expression, however there was no change in CD25 or CD80 expression (Punnonen et al., 1993). 
The ability of these B cells to produce IgG4 is particularly interesting, as work by van de Veen et al. 
(2013) found IgG4-producing B cells to be regulatory. Furthermore, IL-4 can promote human B cell 
production of IgE and IgG4 (Lundgren et al., 1989), so these two isotypes may go hand-in-hand. It 
would hence be worthwhile to look at the level of IgE and IgG4 levels within our co-culture system 
by ELISA or flow cytometry. 
 
BAFF has also been found to upregulate CD23 (as well as CD21/35) expression within B cells 
(Gorelik et al., 2004), whilst TGF-β has been found to inhibit IL-4-induced upregulation of CD23 
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on human B cells (Gordon et al., 1991). The strong correlation with B cells, CD23, IgE and FcεRIα 
suggest a positive role in the context of mast cell-B cell interactions, particularly when one 
considers that MS patients have a greater level of soluble CD23 (Zaffaroni et al., 1995). Soluble 
CD23 has been found to promote proinflammatory cytokine production in human peripheral blood 
monocytes, including TNF and IFN-γ (Armant et al., 1994). Furthermore, human tonsil-derived 
B cells require soluble CD23 for both IL-4- and CD40-stimulated IgE synthesis (Cooper et al., 
2012). Soluble CD23 can also prevent apoptosis in a human pre-B acute lymphocytic leukaemia 
cell line (White et al., 1997). TNF has also been found to decrease surface expression of CD23 on 
human blood-derived monocytes, but increase soluble CD23 (Hashimoto et al., 1995), whilst IFN-γ 
decrease B cell expression of CD23 (Gordon et al., 1991), but IFN-γ with IL-4 can increase soluble 
CD23 from a human B cell line (JIJOYE) despite a decrease in membrane expression of CD23 
(Kawabe et al., 1988). It hence would be interesting to detect soluble CD23 levels within the 
supernatant of our co-cultures, to determine whether this is also affected. 
 
At the same time, Ford et al. (2006) found cleaving membrane CD23 in mice increased IgE, whilst 
Lee et al. (1987) discovered IgE inhibited the cleavage of membrane CD23, which lead to an 
increase in CD23 expression but decreased soluble CD23. It may be my B cells have undergone 
class switching to produce IgE, which may act in an autocrine manner leading to an increase in 
CD23 expression due to CD23 stabilisation (and possibly a decrease in soluble CD23). Looking at 
both surface-bound (by flow cytometry) and secreted (by ELISA) IgE levels would give insight into 
its potential role in this context. In the context of mast cells, work from Roviezzo et al. (2016) 
found S1P to induce CD23 expression on T and B cells in mice, which could be prevented in mast 
cell-deficient mice, suggesting mast cells are required for B cell (and T cell) expression of CD23 in 
certain contexts. 
 
In addition to being a receptor for IgE, CD23 can also bind CD21 (Aubry et al., 1992), CD11b and 
CD11c (Lecoanet-Henchoz et al., 1995). Dugas et al. (1996) found a range of monoclonal anti-
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CD23 clones (clone 135, MHM6 and 25) that could stimulate IL-10 production in human IL-4-
treated macrophages. It is also worth considering the two isoforms of CD23: CD23a and CD23b. 
The promoter of CD23a has been found to only be activated by IL-4, whilst the promoter for 
CD23b can also be activated by anti-µ or anti-CD40 (Ewart et al., 2002), implying different 
functional outcomes depending on the isoform being expressed. In fact, CD23a+ cells have been 
found to be important for CD23-mediated endocytosis, whilst IgE-dependent phagocytosis only 
occurs in CD23b+ cells (Yokota et al., 1992). Further work found CD23a to be constitutively 
expressed on human peripheral blood B cells, whilst CD23b could only be expressed after 
stimulation with IL-4 (Yokota et al., 1988). However, this study found CD23b could be expressed 
on peripheral blood lymphocytes in atopic patients. Interestingly, treating peripheral blood-derived 
B cells from patients with chronic lymphocytic leukaemia with anti-CD23 lead to a decrease in 
TNF-induced proliferation (Fournier et al., 1992). 
 
Type 1 and type 2 transitional B cells differ in their CD23 expression, with type 2 (but not type 1) 
being CD23+ (Loder et al., 1999). A later study found a difference in the B cell response to T cell 
help, whereby CD23+ transitional B cells had a greater level of proliferation and were rescued from 
B cell receptor-induced apoptosis (Chung et al., 2002). This observation of increased B cell survival 
supports my hypothesis, whereby tMC and tMV upregulated B cell receptor complex markers, 
possibly to select for CD23+ transitional B cells. Although type 2 transitional B cells have been 
found to be restricted to the spleen of mice (Loder et al., 1999), a phenotypically similar subset has 
been found within the peripheral blood of humans (Sims et al., 2005). Interestingly, this later study 
found a greater level of type 1 transitional B cells within the blood of systemic lupus erythematosus 
patients. The lack of CD23 expression may prevent B cell survival, which may remove potentially 
protective B cells from the patients, enhancing disease. Evans et al. (2007) found adoptive transfer 
of transitional 2-marginal zone precursor B cells could protect mice from arthritis, as they were 
increased in the spleen of naïve mice during disease remission. Alongside my phenotypic analysis 
of CD23+ transitional B cells, these may be regulatory. In contrast however, patients suffering from 
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atopic dermatitis or psoriasis have an increased level of CD23+ B cells within blood (Müller et al., 
1991). As well as this, patients allergic to grass pollen and hyposensitised (i.e. treated with small 
doses of allergen) had a decrease in the level of peripheral blood-derived CD23+ B cells (Jung et al., 
1995). A major difference between these diseases with “detrimental” CD23+ B cells to those with 
“protective” CD23+ B cells is the increase in serum IgE that can be present in atopic dermatitis, 
psoriasis (Müller et al., 1991) or allergic patients (Johansson, 1967) compared to healthy controls. It 
may be these CD23+ B cells are being over-activated by IgE, promoting B cell survival to a 
detrimental level. This is particularly relevant as Sherr et al. (1989) found activation of B cells via 
CD23 suppressed IgE synthesis, so upregulated CD23 on B cells may act as a negative regulator 
against further IgE activation. Again, it would hence be interesting to measure the level of IgE after 
co-culture to determine whether the CD23+ B cells have undergone class-switching. 
 
CD23+ transitional B cells activated by tMV were CD20+ (99.9 %) and IgD+ (99.8 %). In turn, the 
majority of these cells were CD19+ (73.4 %) and CD24+ (75.5 %). While this phenotype is entirely 
consistent with what others have shown for transitional B cells (Carsetti et al., 1995, Loder et al., 
1999, Evans et al., 2007, Newell et al., 2010, Soldevila et al., 2013, Cherukuri et al., 2014, Nova-
Lamperti et al., 2016, Simon et al., 2016, Aravena et al., 2017), it is interesting to note that the 
majority of cells (58.8 %) also expressed the high affinity IL-13 receptor (CD213α2+). IL-13 binds 
to the IL-13 receptor IL-13Rα (CD213α1) when combined with IL-4Rα (Caput et al., 1996, Hilton 
et al., 1996, Tayebi et al., 1996), but can also directly bind with even greater affinity to IL-13Rα2 
(CD213α2) (Lupardus et al., 2010). Although CD213α1 was included in my panel, the data could 
not be used due to the ‘bleeding’ of metal isotopes (Appendix H). Work from Yasunaga et al. 
(2003) found both IL-4 and IL-13 could induce de novo synthesis of CD213α2 on human bronchial 
epithelial cells in a STAT6-dependent manner. However, CD213α2 expression in turn inhibited 
STAT6-dependent IL-13 signals. Together, this study suggests CD213α2 may act as a decoy 
receptor for IL-13 in a negative feedback loop. In the context of B cells, human B cells stimulated 
through their immunoglobulin and CD40 receptors leads to an upregulation of the low affinity 
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IL-13 receptor, CD213α1, but no change in CD213α2 (Ogata et al., 1998). Considering that murine 
IL-4-treated mast cells increase their IL-13 production, it is conceivable that CD213α2 expression 
prevents activation of human B cells via IL-13. To test this, anti-CD213α2 could be incorporated 
into the co-culture system, to prevent any competitive binding IL-13 would have for CD213α2, so 
IL-13 would instead bind with CD213α1 for further cell activation. 
 
A majority of transitional B cells (53.6 %) also expressed high levels of 4-1BBL (CD137L): the 
ligand of 4-1BB (CD137). Monoclonal antibodies against CD137 promote anti-CD3-induced T cell 
proliferation (Pollok et al., 1993), with similar results found shortly after when using its ligand 
CD137L (Goodwin et al., 1993). This CD137/CD137L axis can be important during certain 
cancers, as treating human T cell leukaemia (CCRF-CEM, Jurkat) and B cell lymphoma (Raji, 
IM-9) cell lines with anti-CD137 or anti-CD137L increased the level of proliferation, survival, and 
even granted protection from anticancer drug cytotoxic effects (Palma et al., 2004). CD137L+ 
B cells have been found to increase with age, which is thought to explain the induction of CD8+ 
granzyme B+ T cells via the CD137/CD137L axis (Lee-Chang et al., 2014). In turn, these B cells in 
fact increased the anti-tumour response. The ability of the CD137/CD137L pathway to induce 
T cell proliferation and survival can hence be considered as a pro-inflammatory marker. This may 
explain why tumour-induced regulatory B cells have been found to express low levels of CD137L 
(Bodogai et al., 2013). In contrast, my results found tMV-activated CD23+ transitional B cells to 
express CD137L. However, these tMV-activated B cells were incapable of influencing T cell 
proliferation. Because tMC-activated B cells increased the division index (the average number of 
divisions taken by all cells), it would be interesting to test whether the CD137/CD137L pathway 
was playing a role. Because previous studies have used monoclonal antibodies to signal cells 
through CD137 and CD137L (Pollok et al., 1993, Palma et al., 2004, Bodogai et al., 2013), I would 
not be able to block these receptors with the same method. Instead, CD137L+ CD23+ transitional 
B cells could be sorted out from CD137L– CD23+ transitional B cells, to then culture them with 
T cells and determine whether there were any changes in the level of proliferation. Although this 
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experiment would not definitively prove the relevance of CD137L expression to induce T cell 
changes, it would be an easy first step to investigate the CD137/CD137L pathway in this context. 
 
An investigation comparing CD23– with CD23+ transitional B cells activated by tMC and tMV, 
allowed me to determine whether the changes in CD23+ transitional B cells correlated with CD23 
expression or because of the co-culture group, or if both these variables were playing a role. This 
analysis showed that CD23+ transitional B cells after co-culture with tMC or tMV increased BLNK 
expression. This is likely to be important because there is a positive correlation between BLNK and 
IL-10 production (Jin et al., 2013). Supporting this molecular link, IL-10 was found to be increased 
in the CD23+ transitional B cells after co-culture with tMC or tMV. This analytical approach also 
revealed that compared to CD23– transitional B cells, CD23+ subsets expressed significantly higher 
levels of CD274, when cultured with tMV. This was particularly intriguing because mast cells 
(regardless of IL-4 treatment) ablated B cell expression of CD274. Reconciling these two results 
suggests that CD23+ transitional B cells have a more immunoregulatory phenotype when compared 
with the CD23– subset. This is in contrast to the murine work by Sattler et al. (2014), whereby 
adoptive transfer of CD23– CD19+ B cells from mice injected with IL-33 were in turn protective in 
a mouse model of inflammatory bowel disease in an IL-10-dependent manner. I have addressed 
how there are many phenotypic variations in regulatory B cells, so it would be particularly 
interesting to sort out the CD23+ transitional B cells from CD23– transitional B cells, and repeat the 
experiments to test possible functional differences. Because the CD23+ transitional B cells have a 
further increase in BLNK, IL-10 and CD274, I hypothesise them to be more effective at suppressing 
a T cell response than CD23– transitional B cells. 
 
Interestingly similar results were observed with an upregulation of CD213α2. In the murine model 
in Chapter 3, IL-13 was found to be a potential mediator during the mast cell-B cell interaction, due 
to its upregulation in production from mast cells. IL-4 and IL-13 have been found to upregulate 
CD213α2 expression on HaCaT cells (David et al., 2001), so the upregulation suggests it may act as 
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a negative regulator of IL-13 (Yasunaga et al., 2003). It would be interesting to block CD213α2 
with monoclonal anti-CD213α2 to determine whether B cell activation is affected. 
 
The data to this point indicates that mast cell-derived microvesicles exert a stronger effect on B cell 
phenotype than the mast cells that generate them. This is consistent with data I found during my 
Honours, whereby the microvesicles had a greater effect on B cell activation than the mast cells 
(Marsh-Wakefield, 2012). One possible explanation is that the stimulatory conditions established 
with the microvesicles is higher than could be created with the mast cells. This observation was not 
always consistent however, as illustrated by the significant upregulation of CD137L on CD23+ 
transitional B cells after co-culture with tMC but not tMV. As discussed above, activation of 
CD137 on T cells by CD137L can promote T cell proliferation (Goodwin et al., 1993), tMC-
activated B cells consistently increased the T cell division index (the average number of divisions 
undertaken by all cells), but tMV-activated B cells had no such effect. The fact that CD23+ 
transitional B cells after culture with tMC have an upregulated level of CD137L, which does not 
occur with tMV, may contribute to the ability of tMC-activated B cells to promote T cell division. 
 
CD23+ transitional B cells stimulated with tMC but not tMV also increased expression of S1P1. 
The ligand S1P has a pivotal role in cellular egression from the thymus and primary lymphoid 
organs (Matloubian et al., 2004). In short, there is an S1P gradient between peripheral blood and 
lymph nodes (high to low respectively). When cells express S1P1, they are attracted to the 
periphery where there is more S1P. When S1P interacts with its receptor, S1P1 is internalised, 
whereby lymphocyte chemokine receptors (such as CCR7 and CXCR5) will drive cells towards the 
lymph nodes (with low S1P). As time progresses, S1P1 expression increases and drives 
lymphocytes back into the periphery. 
 
This data, whereby CD23+ transitional B cells stimulated with tMC (but not tMV) increased S1P1 
expression leads me to hypothesise that following an environmental stimulus (such as exposure to 
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UV radiation), microvesicles from mast cells will make first contact with lymph node B cells and 
induce multiple changes in B cell phenotype (such as downregulating S1P1 on CD23+ transitional 
B cells) and function (possibly trapping B cells within in the lymph node). It is already known 
antigen or LPS stimulation of B cells decrease B cell expression of S1P1, in turn promoting B cell 
migration to splenic white pulp (Cinamon et al., 2004), so tMV may be acting on B cells in a 
similar manner. Furthermore, B cell (and T cell) expression of CD23 can be increased with S1P, but 
did not occur in mast cell-deficient mice (Roviezzo et al., 2016), suggesting mast cells are required 
for S1P-induced expression of CD23. If tMV are inducing CD23 expression it may be in an S1P-
dependent manner, in turn decreasing S1P1 expression to trap B cells within lymph nodes prior to 
insurgence of mast cells. These microvesicle-induced changes might be targeting CD23+ 
transitional B cells directly, or they may result in selection for, preferential survival of, or retention 
of, B cells that assume a CD23+ transitional phenotype. Mast cells themselves will then arrive in the 
B cell follicles of lymph nodes (~24 hr later) (Byrne et al., 2008) to further interact with and 
influence the activation of B cells. This mast cell-B cell cross talk ultimately leads to an 
upregulation of S1P1 on the B cells which facilitates their egress from the lymph node. In this way, 
mast cells confirm the regulatory phenotype and then “licence” the newly activated regulatory 
B cells for re-circulation. 
 
Future experiments to test this hypothesis could involve co-culturing microvesicle-activated B cells 
with uMC (similar to what was done for murine cells in Chapter 4) followed by phenotypic analysis 
to determine whether S1P1 (or other markers) are in turn affected by the addition of mast cells. 
Another way to test this would be to inject microvesicles subcutaneously from IL-4-treated mast 
cells into the back of mice deficient of mast cells. A phenotypic analysis of the B cells within the 
skin-draining lymph nodes would determine if they are activated. A contact hypersensitivity 
response would determine if the mice had a suppressed immune response. Interestingly, when UV-
induced mast cell migration from the skin to the lymph nodes is blocked with the CD184 antagonist 
AMD3100 (Byrne et al., 2008), UV-immune suppression is inhibited. Thus, at least in mice, the 
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production of mast cell-derived microvesicles alone is insufficient to suppress immunity, and mast 
cells themselves must also migrate to B cells in lymph nodes in order to generate immune 
suppressive events. 
 
Initial efforts, regardless of the co-culture conditions, did not alter the ability of T cells to produce 
IFN-γ, at least under the experimental conditions used. Unfortunately, the lack of T cell-induced 
IFN-γ was likewise found in T cells that were either stimulated with anti-CD2, anti-CD3, and anti-
CD28 (median 3.69 % IFN-γ+) or left unstimulated (median 4.23 %). This lack of IFN-γ production 
may be due to the stimulation used, as it was optimised for T cell proliferation, rather than IFN-γ 
production. Although Kalampokis et al. (2016) used a similar anti-CD3 stimulation protocol for 
72 hr for T cell cytokine production, in our context the addition of anti-CD2 and anti-CD28 at 
different concentrations may not effectively be promoting T cell IFN-γ production. Furthermore, in 
this study CD40L and CpG were also added to promote B cell activation, contributing to 
suppression of IFN-γ production. Interestingly however, I found B cells alone could induce T cell 
production of IFN-γ (median 10.1 % IFN-γ+). In mice infected with Toxoplasma gondii, B cells 
have been found to induce T cell production of IFN-γ (Menard et al., 2007). It is hence surprising to 
see in my context, whereby seemingly unstimulated B cells are able to induce IFN-γ within CD4+ 
CD25– T cells. For intracellular flow cytometry, PMA, ionomycin and brefeldin A were used to 
stimulate cytokine production and to prevent its secretion. These chemicals are non-specific and 
will activate both T cells and B cells, in turn influencing B cell interaction with T cells. 
Furthermore, as discussed previously, all CD19+ B cells were added to the co-culture with T cells, 
so the promoted production of IFN-γ by T cells may be due to a particular subset of B cells, so it 
would be interesting to separate out different B cell subsets (particularly CD23+ transitional B cells) 
and repeat these assays. 
 
As expected, the anti-CD3/CD2/CD28 protocol used in these experiments did result in an increase 
in the T cell proliferation index. The proliferation index is the average number of divisions 
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undertaken by the proliferating cells. No B cell effect on the rate of already proliferating T cells 
was observed. The division index on the other hand is the average number of divisions undertaken 
by all cells (including those that did not proliferate at all). As such, the division index may provide 
a better readout of immune suppression, especially if suppression is occurring at the stage of first 
division. Contrary to predictions, B cells cultured with tMC (i.e. those with a regulatory phenotype) 
increased the division index of T cells, meaning more T cells were stimulated to enter division. 
However, there was no change in the proliferation index suggesting those T cells that were 
stimulated to proliferate did not divide more than other T cells. B cells cultured with microvesicles 
did not affect either the T cell proliferation or division index. 
 
In my experiments, mast cells were first treated with IL-4 for 48 hr, and then co-cultured with 
B cells for a further 48 hr and then added to T cells for 72 hr. The two 48 hr incubations were based 
off the murine model, and because there were detectable differences in phenotype after this time it 
was deemed appropriate. However, in the context of function it may not be an ideal amount of time. 
During my Honours, I found microvesicles from IL-4-treated mast cells were capable of altering the 
phenotype of B cells after just 24 hr (Marsh-Wakefield, 2012). For the microvesicle co-cultures, 
less time may be required to activate B cells. Furthermore, it is worth considering the pre-
incubation time between B and T cells. They were first co-cultured for 1 hr prior to stimulation of 
T cells with beads, but more time may be required for these cells to have an effect on T cell 
proliferation. In contrast however, B cells may only affect activated T cells, so co-culturing after 
T cell activation may be more appropriate. I had a ratio of 10:1 (B cells:T cells), whilst many other 
studies reported using a 1:1 ratio (Blair et al., 2010, Kessel et al., 2012, Lindner et al., 2013, Menon 
et al., 2016). Because of human variability, the final number of cells (mast cells/B cells/T cells) 
could fluctuate, but I generally ended up with more B cells than T cells for functional assays. As 
these experiments took 9-10 weeks of preparing, I did not want to waste cells, and decided to use a 
greater number of B cells. Furthermore, it was theorised a greater ratio of B cells:T cells would be 
more appropriate for identifying changes in T cell proliferation. However, many of the 
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aforementioned studies used specific purified subsets of B cells, whilst my assays included all 
CD19+ B cells. Different subsets of B cells may be competing for influence of T cells, clouding 
individual actions. It would be worthwhile to first separate out subsets of B cells and repeat these 
T cell assays to address different functions within individual B cell subsets. 
 
Another large factor to consider was the activation method of the T cells. For a suppression assay, 
the ideal level of T cell activation would be the minimum amount required for an observable effect, 
such that it is not too potent to be suppressed. For future experiments it would be worth further 
investigating other methods of T cell activation, including specific antigens, IL-2, or fewer 
antibodies (such as only using anti-CD3). 
 
An increase in the division index of T cells co-cultured with B cells activated by tMC was 
accompanied by an increase in T cell CD69 expression. Significant elevation in CD69 occurred 
before the first T cell division, suggesting that these two events may be linked. The increased 
division index (and hence an increase in proliferation of all cells) may explain this increase (or vice 
versa). If this were to be replicated in vivo, the T cells are likely to be retained within lymph nodes, 
because CD69 works, in part, to prevent S1P1 re-expression (Shiow et al., 2006). However, S1P1 
re-expression on T cells did occur, albeit around the fourth division and with a concordant decrease 
in CD69. Furthermore, S1P1 expression increased as divisions progressed, consistent with previous 
reports (Pham et al., 2008). To investigative this further, an in vitro S1P gradient could be used to 
determine whether T cell migration is impaired, as used by previous studies (Roviezzo et al., 2004). 
Interestingly, during my Honours, I found activated (CD44hi) murine T cells to be elevated in 
number within the CNS-draining lymph nodes of mice protected from EAE by exposure to UV 
(Marsh-Wakefield, 2012). Together, these data suggest that by increasing T cell CD69 expression 
(and subsequent downregulation of S1P1), mast cell-activated B cells may prevent the egress of 
activated T cells. However, mast cell-derived microvesicles alone, in the absence of mast cell 
stimulation of B cells lead to an early decrease in T cell CD69. These observations reinforce the 
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idea that mast cell-derived microvesicles prime T cells for regulation, but that the mast cells 
themselves, via a cross-talk with B cells, are required to reinforce immune suppression. It would be 
worthwhile to do a phenotypic analysis of T cells after their co-culture with B cells, to further 
evaluate induced changes within the T cells. 
 
The absence of any detectable B cell-driven effect on T cell proliferation may not necessarily 
indicate a lack of regulatory function. In my assays, I was looking at B cell function against naïve 
CD4+ CD25– T cells. It may be these mast cell- and microvesicle-activated B cells are suppressive 
against effector or previously activated T cells. To address this, I could stimulate T cells with 
antigen, or stimulate T cells prior to addition of B cells. Furthermore, I could also repeat the 
experiments with CD8+ T cells. It is also a possibility that mast cell- or microvesicle-activated 
B cells work to suppress cell-mediated immunity by promoting the development, or enhancing the 
function, of regulatory T cells, as many studies have found human regulatory B cells capable of 
promoting regulatory T cell activation and function (Kessel et al., 2012, Bodogai et al., 2013, 
Flores-Borja et al., 2013, Guan et al., 2016). Although an ELISA was done to measure the total 
level of IL-10 and IL-35 in the cultures, it would be interesting to determine whether there were any 
functional changes in the T cells after co-culture with B cells. The most obvious choice would be to 
look at CD25hi CD127– Foxp3+ regulatory T cells. 
 
Although IL-35 was undetectable in the culture supernatant, this does not rule out a possible role for 
IL-35 because the kit used may not be suitable. The human IL-35 kit used is no longer 
commercially available as the manufacturer, who supplied them to us upon request at no charge, 
cannot guarantee that it is fit for purpose. Thus, it is not possible to determine whether, like the 
mouse studies described in Chapter 4, IL-35 is involved in regulatory B cell activity. 
 
In contrast to IL-35, the majority of donor cultures had detectable levels of IL-10. Positive controls 
included T cells spiked with IL-10 and CD25hi (presumably regulatory) T cells. Both of these 
 216 
control samples had a large amount of detectable IL-10 (median > 300 pg mL–1 and 17.1 pg mL–1 
respectively), confirming that this assay was appropriate to measure IL-10 levels in the B cell-T cell 
co-cultures. Although it is not possible to identify the cellular source of IL-10, all four donors with 
detectable levels of IL-10 had a greater concentration of IL-10 when T cells were co-cultured with 
B cells activated by tMC. This is the same group that had an increase in the division index of 
T cells suggesting that mast cell-activated B cells might be promoting the proliferation of and IL-10 
secretion of regulatory T cells. No change in IL-10 was detectable in the B cell group cultured with 
microvesicles. This is also consistent with the results from the proliferation assay. Together, these 
results are somewhat unexpected as B cells activated by tMV appeared more regulatory in 
phenotype when compared to those co-cultured with tMC. However, as covered in Chapter 4, 
murine B cells activated with microvesicles from IL-4-treated mast cells were in turn capable of 
interacting with untreated mast cells to promote their production of IL-13. To determine whether a 
similar “cross-talk” between mast cells and B cells was occurring in our human cultures, B cells 
were first cultured with microvesicles and then added to T cells alongside untreated mast cells 
before stimulating the T cells. The three donors with detectable IL-10 all had demonstrably higher 
IL-10 levels when B cells had been activated by tMV. In one case, IL-10 was only detectable in this 
group. This provides strong evidence that B cells require both microvesicles and mast cells to reach 
their full potential to influence T cell proliferation and differentiation. 
 
The data presented in this chapter show how human IL-4-treated mast cells and their microvesicles 
activate phenotypically regulatory B cells. This was particularly the case for CD23+ transitional 
B cells, including upregulation of IL-10, CD274, CD25, CD86, and BLNK. However, when the 
regulatory function of these B cells were tested on T cells in vitro, I could not confirm that they 
were immune suppressive. There were B cell-induced changes in T cell proliferation, as well as an 
increase in total IL-10, suggesting B cells activated by tMC or tMV are capable of influencing 
T cells and are creating an immunomodulatory environment. I hypothesise tMC and tMV are 
priming B cells for further activation to act on the immune system (Figure 5.28). While further 
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studies, as outlined, will be needed, the data presented and discussed in this chapter does provide 
strong evidence that interactions between human mast cells, B cells and T cells are likely to have a 
profound effect on the immune response. 
 
  
Figure 5.28 – Proposed human IL-4-treated mast cell interaction with B cells via 
microvesicles. (1) Mast cells are first treated with IL-4. (2) IL-4-treated mast cells produce 
microvesicles. (3) Microvesicles from IL-4-treated mast cells activate B cells.
(4) Microvesicle-activated B cells have an upregulation of immunoregulatory markers and 
cytokines, particularly those that can promote cell survival and proliferation. (5) Mast cells 
interact with microvesicle-activated B cells to induce further phenotypic changes in B cells, 
priming them for further activation. (6) Activated B cells are exposed to an antigen to 
activate B cells to be functionally suppressive.
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Chapter 6 
 
DISCUSSION AND 
CONCLUSIONS 
 
 
The greatest of escapes are never told, because they 
are only known to the accomplished who do not plan on 
sharing. Josephine was not one to brag, and trusted The 
Owlsmith to keep their word, so although it was not the 
greatest escape, it was grand enough that no one will ever 
know how it was done… 
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Chapter 6: Discussion and conclusions 
6.1 Summary 
In Chapter 1, I hypothesised mast cells and B cells engage in a cellular cross-talk that leads to the 
generation of cells and molecules that would result in immune suppression rather than activation. 
More specifically, I hypothesised that this interaction involves the immunomodulatory cytokines 
IL-10, IL-13 and IL-35. Furthermore, I hypothesised human IL-4-treated mast cells were capable of 
activating phenotypically and functionally suppressive B cells. The following aims were proposed 
to address my hypotheses: 
 
Aim 1: To investigate the effect of IL-4 and B cells on murine mast cell phenotype and 
cytokine production. 
Aim 2: To interrogate the nature of the interaction between murine mast cells, their 
microvesicles and B cells in relation to the production of immunomodulatory 
cytokines. 
Aim 3: To determine, using mass cytometry, whether human IL-4-treated mast cells (and their 
microvesicles) influence the activation of B cells. 
 
My murine studies in Chapter 3 showed that IL-4-treated mast cells promoted IL-13 and EBI3 
production, with more cytokine upregulation after co-culture with B cells, leading to IL-10, IL-13 
and IL-35 subunit (EBI3 and p35) production. As well as this, IL-4-treated mast cells upregulated 
MHCII expression, but only after co-culture with B cells, suggesting that mast cells may be able to 
directly interact with and influence the activation state of CD4+ T cells. In Chapter 4, I found that 
microvesicles derived from IL-4-treated mast cells were capable of activating B cells that 
suppressed a contact hypersensitivity response when transferred in vivo. Contrary to my initial 
hypothesis, B cell-derived cytokines were not as strongly affected by mast cells or their 
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microvesicles, but there was detectable IL-35 within the co-culture of mast cells and B cells. 
Interestingly, microvesicle-activated B cells were capable of promoting IL-13 production by resting 
untreated mast cells when co-cultured. This suggests there is a cross talk occurring between IL-4-
treated mast cells and B cells, possibly via microvesicles. 
 
The human assays in Chapter 5 confirmed many of the changes found on murine cells, including an 
upregulation of HLA-DR, CD25, CD80, CD86 and CD274. Studies in human cells also uncovered 
a number of unique changes in B cell markers after co-culture with IL-4-treated mast cells or their 
microvesicles. All of the B cell receptor molecules investigated, including BLNK, CD79b and IgM, 
were upregulated. This increase in B cell receptor molecules may promote B cell proliferation 
and/or survival. B cells also had upregulated IL-10 expression, suggesting that mast cells and their 
microvesicles may be inducing an immunoregulatory phenotype, particularly for the CD23+ 
CD38+/hi IgMhi transitional B cell subset. However, when these B cells were cultured with 
autologous T cells there was no inhibition of proliferation. On the contrary, an increase in the 
division index (that is, an increase in proliferation by all T cells) after adding B cells was observed. 
This increase in T cell proliferation occurred alongside an upregulation of IL-10 in the culture 
supernatant. This rise in IL-10 detected by ELISA was only consistent for cultures that contained 
IL-4-treated mast cell-activated B cells, but not B cells co-cultured with untreated mast cells, after 
co-culture with T cells. Intriguingly, this increase in IL-10 was only found in microvesicle-activated 
B cells when co-cultured alongside T cells and untreated mast cells. This supports my hypothesis 
that a cross talk is occurring between the mast cells and the B cells.     
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6.2 Murine IL-4-treated mast cells interact with and influence B cell 
cytokine production in a cross talk involving microvesicles 
Treating murine mast cells with IL-4 alone increased IL-13 and EBI3 production. Whether these 
cytokine products act in an autocrine or paracrine manner remains to be determined. However, after 
co-culture with B cells these IL-4-treated mast cells were induced to upregulate IL-10 and p35. 
EBI3 combines with p35 to form IL-35 (Devergne et al., 1997), an important immunosuppressive 
cytokine that others have shown is produced by regulatory T cells (Niedbala et al., 2007, Collison 
et al., 2007) and B cells (Shen et al., 2014, Wang et al., 2014). It was most interesting that the mast 
cells rather than the B cells were the source of these immunosuppressive cytokines, as adoptive 
transfer of B cells from UV exposed mice transfer immune suppression (Byrne and Halliday, 2005, 
Matsumura et al., 2006). Although UV can likewise promote mast cell production of IL-10 
(Chacon-Salinas et al., 2011), there are currently no studies that have found mast cells to be capable 
of producing IL-35. Although my work likewise does not prove this ability, my observation of an 
increase in the subunits of IL-35 (EBI3 and p35) does suggest this as a possible product of activated 
mast cells. This could play an important role in UV-induced protection from autoimmune diseases 
such as experimental autoimmune encephalomyelitis (EAE), because B cell-derived IL-35 has been 
found to grant protection from such diseases (Shen et al., 2014, Wang et al., 2014). 
 
Whilst the potential production of immunosuppressive IL-35 by the IL-4 treated-mast cells is 
extremely interesting, the importance of mast cell-derived cytokines is questionable. My finding 
that murine B cells co-cultured with microvesicles from IL-4-treated mast cells were suppressive in 
a contact hypersensitivity response indicates that mast cell production of cytokines, independent of 
microvesicles, may not be essential. Although mast cells were absent in the activation of these 
B cells, I hypothesise a cross talk is occurring, whereby microvesicle-activated B cells interact with 
mast cells once injected in vivo. This could be tested by injecting fluorescently labelled B cells to 
determine their localisation in vivo, and whether there is any further interaction with mast cells. 
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Evidence supporting this came from the analysis of B cells co-cultured with microvesicles from 
IL-4-treated mast cells. When these B cells were mixed with untreated mast cells, they increased the 
production of IL-13, even though there were no previous interactions between these two cells. This 
may explain what is happening in vivo following exposure to immune suppressive UV. UV 
radiation increases cutaneous IL-4 (Teunissen et al., 2002) that I have shown activates mast cells to 
produce IL-13 and EBI3. More importantly, these IL-4-exposed mast cells also produce B cell-
activating microvesicles, which we know can migrate freely to skin-draining lymph nodes (Kunder 
et al., 2009). Indeed, I propose that these B cell-activating microvesicles are priming B cells in 
draining lymph nodes. A few hours later, these mast cells are recruited to the same lymph nodes 
(Byrne et al., 2008), where they are known to home to B cell areas (Byrne et al., 2008) and 
presumably interact with microvesicle-activated B cells. The ensuing cellular cross talk licenses the 
newly arrived mast cells to produce immunosuppressive cytokines, particularly IL-10 (Chacon-
Salinas et al., 2011) and, as I have shown, possibly IL-35. 
 
Supporting this hypothesis is evidence that if mast cell migration from the dermis to the skin-
draining lymph nodes is blocked with a CD184 antagonist (AMD3100), UV-induced immune 
suppression is inhibited (Byrne et al., 2008). This hypothesis implies that although dermal mast 
cells may still produce microvesicles, the mast cells still need to reach the lymph nodes to interact 
with the microvesicle-primed B cells in order for immune suppressive events to be realised. 
However, this initiates the question of what mast cells these microvesicle-activated B cells are 
interacting with if dermal mast cells are no longer being recruited to the lymph nodes. Mast cells 
are present within resting lymph nodes (Byrne et al., 2008), which could interact with microvesicle-
activated B cells once injected. However, even if B cells are being activated by microvesicles after 
AMD3100 treatment, mice are not suppressed. Vesicles from human blood can express CD184, 
which could be transferred to and therefore expressed on other cells (Kalinkovich et al., 2006). As 
my murine mast cells constitutively expressed CD184, their microvesicles may likewise express 
CD184. AMD3100 treatment may hence interfere with microvesicle formation/migration from mast 
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cells, thus preventing UV-induced immune suppression. It is also worth considering the 
methodology used during the contact hypersensitivity response. Microvesicle-activated B cells were 
injected intravenously into the tail of the mice, but we did not investigate where they migrated. It 
has recently been found that B cells can migrate to the skin after inflammation (Geherin et al., 
2016), hence, after mice are sensitised to DNFB on the abdomen, the injected microvesicle-
activated B cells may be recruited to the skin, where they may interact with dermal mast cells, as 
well as newly migrated mast cells. 
 
One way to test this would be to transfer microvesicle-activated B cells into mast cell-deficient 
mice. If these recipient mice do not have a suppressed contact hypersensitivity response then it 
would suggest that these B cells require mast cells to suppress the immune response. Conclusive 
evidence that mast cells are responsible would come from similar experiments where the recipient 
mice are reconstituted with mast cells. Furthermore, the use of mast cells derived from IL-10, IL-13 
or EBI3 knock-out mice could determine the importance of mast cell-derived cytokines in immune 
suppression by microvesicle-activated B cells. Future experiments would also include phenotyping 
B cells in UV exposed mice treated with AMD3100. If mast cell-derived microvesicles are involved 
in the activation of B cells, B cells should still have phenotypic changes following UV exposure 
independent of dermal mast cell migration. Furthermore, inhibiting microvesicle formation in vivo 
would provide insight into the requirement of microvesicles in the process of UV-induced B cell 
activation. The drug pantethine is known to prevent microvesicle formation in vivo (Penet et al., 
2008), whilst ATP-binding cassette (ABC) transporter A-1 (ABCA-1)-deficient mice likewise have 
impaired microvesicle formation (Hamon et al., 2000). To determine the importance of mast cell-
derived microvesicles, mice deficient of mast cells could be adoptively transferred with mast cells 
from ABCA-1-deficient mice. If mast cell-derived microvesicles are required, UV-induced immune 
suppression of a contact hypersensitivity response would be inhibited. In my human studies, a 
phenotypic analysis of microvesicle-activated B cells after co-culture with untreated mast cells 
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could also be undertaken. This would determine whether mast cells could then influence B cell 
phenotype after B cell activation via microvesicles. 
 
Both murine and human IL-4-treated mast cells decreased expression of CD117 but increased 
FcεRIα. These consistent cross-species changes reinforce the idea that IL-4 is a driving force in this 
response. IL-4-treated mast cells had an upregulated level of IL-13 both before and after co-culture 
with B cells. This may be important, as IL-13 can upregulate human B cell expression of CD23 
(FcεRII) (Onguru et al., 2011), a molecule that mass cytometry revealed was differentially 
expressed by human mast cell-activated B cells. Indeed, the high affinity IL-13 receptor, CD213α2 
was specifically upregulated on human CD23+ transitional B cells after co-culture with IL-4-treated 
mast cells or their microvesicles when compared with CD23– transitional B cells. However, 
CD213α2 has been shown to counterintuitively inhibit IL-13 signals (Yasunaga et al., 2003), thus 
acting as a decoy receptor. In the context of my results, mast cells may be activating B cells via 
IL-13, which in turn promotes B cell expression of CD213α2 to perform as a negative regulator of 
B cell activation. 
 
An intriguing outcome to arise from the murine mast cell-B cell experiments was the fact that IL-4-
treated mast cells upregulated MHCII, but only after co-culture with B cells. This suggests that, just 
as mast cells license the B cells to produce cytokines and express immune modulating molecules, 
the B cells in turn licence the mast cells to possibly engage with CD4+ T cells. Indeed, human mast 
cell upregulation of HLA-DR after IFN-γ stimulation influenced the activation of antigen-specific 
CD4+ T cells by promoting T cell production of IFN-γ and TNF (Suurmond et al., 2013). 
Furthermore, Lu et al. (2006) provided evidence murine regulatory T cell-derived IL-9 (a mast cell 
growth and activation factor) was important for the migration of mast cells, which contributed to 
tolerance of graft transplantation. As mast cell-deficient mice did not tolerate allograft 
transplantation (which could be restored through adoptive transfer of wild type mast cells), 
regulatory T cells may require mast cells for their ability to suppress the immune response. Whether 
 226 
HLA-DR on human mast cells is affected by IL-4 or B cells, and the functional consequence of 
such an event, remains to be determined. When considering my human B cell-T cell experiments, 
B cells activated by IL-4-treated mast cells did not suppress T cell proliferation (but rather 
promoted it). If human mast cells likewise have an increase in HLA-DR expression after co-culture 
with B cells, they may be able to directly interact with T cells. It hence may be worth co-culturing 
mast cells, B cells and T cells all at the same time, to allow immediate interaction between cells. 
This would more closely mimic in vivo, as mast cells were found interacting with B cell follicles 
following UV (Byrne et al., 2008). 
 
6.3 Human IL-4-treated mast cells activate phenotypically regulatory 
B cells that can influence T cell activity 
As murine IL-4-treated mast cells were found to activate regulatory B cells, it was hence of interest 
to determine whether human mast cells can achieve a similar effect. To that end, I showed that 
human IL-4-treated mast cells and their microvesicles were capable of activating phenotypically 
regulatory B cells. These were predominantly CD38+/hi IgMhi transitional B cells, which had notable 
increases in BLNK, HLA-DR, CD23, CD86, and IL-10. Surprisingly, this regulatory B cell 
phenotype did not translate into suppressed T cell proliferation. Indeed, co-culture with the B cells 
led to an increase in T cell division in some cases. However, this does not rule out the potential for 
the mast cell-activated B cells to be suppressive. As mentioned, B cells were found to be 
phenotypically regulatory, and it is difficult to mimic what may be occurring in vivo with a 
reductionist in vitro assay. It is highly likely that other immune cells, or their products, are required 
to have an effect on T cell proliferation. Alternatively, the B cells may be inducing a shift in T cell 
differentiation. It is equally possible that these B cells may not even act on T cells, but instead 
affect other B cells or other immune cells such as dendritic cells. In the context of UV, Langerhans 
cells have been found to be required for UV-induced immune suppression, as they activate natural 
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killer T cells within skin-draining lymph nodes to produce IL-4 (Fukunaga et al., 2010). Indeed, 
UV-activated B cells were first found to suppress dendritic cell-dependent activation of T cells 
(Byrne and Halliday, 2005). As mast cells will also migrate to the skin-draining lymph nodes 
following UV (Byrne et al., 2008), these mast cell-activated B cells may also be interacting with 
Langerhans cells to promote an immunosuppressive environment. 
 
In the human co-culture, IL-4-treated mast cells inflicted different phenotypic changes on B cells 
when compared to their microvesicles. This difference in B cell phenotype supports the hypothesis 
that mast cell-derived microvesicles may first be priming B cells for further interaction with mast 
cells. When looking at the level of IL-10 in the supernatant of the B cell-T cell co-culture, there was 
a consistent increase in overall IL-10 when B cells were pre-activated with microvesicles from 
IL-4-treated mast cells. However, this increase in IL-10 was only observed when untreated mast 
cells were also included in the co-culture. Thus, both mast cells and their microvesicles are 
important for activating immune regulatory B cells. In the murine studies I found microvesicle-
activated B cells could suppress a T cell response in vivo. Considering the collective murine and 
human data, it is very likely that these B cells in turn interact with mast cells to influence the 
environment. This could likewise be addressed by injecting microvesicle-activated B cells into mast 
cell-deficient mice, as described above. 
 
Many of the phenotypic changes observed in the human B cell co-culture involved markers that 
have been found to promote B cell survival and proliferation, including CD23 (Chung et al., 2002) 
and members of the B cell receptor complex (BLNK, CD79b, IgM) (Lam et al., 1997, Fruman et 
al., 1999). However, my experiments only investigated B cell phenotype, and not whether these 
receptors are required for activation or function of these B cells. This leads me to hypothesise that 
these B cells require additional signals to be fully activated as functionally regulatory cells: that is, 
mast cells and their microvesicles are priming a type of “pre-regulatory” B cell. Rosser and Mauri 
(2015) highlighted how previous studies have found an increase in regulatory B cells in response to 
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inflammation (Mizoguchi et al., 2002, Evans et al., 2007, Geherin et al., 2016). That is, an antigen 
is required to provide further signalling to induce regulatory B cells. This hypothesis is supported 
by the in vivo contact hypersensitivity experiments previously done, as both mast cell- (Leighton, 
2009) and now microvesicle-activated B cells were found to be suppressive. In these sets of 
experiments, B cells were added prior to sensitisation, to test the effectiveness of B cells in 
suppressing the induction of a T cell response. Indeed, murine naïve B cells have been found to not 
produce IL-10 after CD40 and B cell receptor activation unless first activated by TLR2 or TLR4 
(Lampropoulou et al., 2008). I propose that this sensitisation to antigen fully activates these B cells 
to become functionally suppressive, so upon antigen challenge the B cells are capable of 
suppressing the T cell response. Furthermore, if these B cells were injected after sensitisation they 
may not be suppressive, as they would not have been exposed to an antigen, and hence not fully 
activated. In my B cell-T cell co-cultures, B cells may require further signalling to become 
functionally suppressive. To promote B cell activation, antigen or stimulants could be included 
(such as CpG or anti-µ) to promote regulatory B cell activity. 
 
Many studies that have investigated the protective nature of B cells during EAE have injected 
B cells prior to disease induction. However, Korniotis et al. (2016) found bone marrow-derived 
cells stimulated via TLR9 generated pro-B cells that were capable of protecting mice from EAE 
after symptoms arose. These B cells have been successfully triggered (in this case with CpG), and 
can in fact attenuate established disease. To test my hypothesis of whether UV-activated B cells are 
similar to my mast cell-activated B cells but require an antigen to be fully activated, B cells from 
mice exposed to UV but also induced with EAE could be collected. These B cells would then be 
injected in to mice already induced with EAE to determine whether they could act to treat the 
disease. I hypothesise these UV-activated B cells that have been fully activated by an antigen would 
attenuate established EAE, whilst UV-activated B cells from mice that have not been induced with 
EAE will not have this effect. At the same time, it would be interesting to determine the antigen 
specificity of these B cells. Elmets et al. (1983) found lymphocytes from UV irradiated mice acted 
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in an antigen-specific manner. Mice were first exposed to UV, and then sensitised to DNFB 
antigen. Lymphocytes were then adoptively transferred into recipient mice, and then sensitised 
against DNFB or oxazolone. Recipient mice were then challenged with the same respective antigen, 
and their ear thickness was measured as a determination of an immune response. Recipient mice 
exposed to DNFB but not oxazolone had a suppressed response, indicating UV-activated 
lymphocytes act in an antigen-specific manner (Elmets et al., 1983). A similar test could be done by 
first isolating B cells from UV irradiated mice, and then repeating the contact hypersensitivity 
response with two different antigens. 
 
Another important finding by Korniotis et al. (2016) was that pro-B cells acted in an IFN-γ-, IL-10- 
and CCL19-dependent manner. CCL19 is a ligand of CCR7, so its production by B cells effectively 
trapped T cells within lymph nodes as a means of protection. UV-activated B cells could be acting 
in a similar manner, as during my Honours I found activated (CD44hi) T cells to be greater within 
the CNS-draining lymph nodes prior to disease symptoms of EAE when mice were exposed to UV 
and thus protected from disease (Marsh-Wakefield, 2012). Furthermore, I found human B cells co-
cultured with IL-4-treated mast cells increased the division index of T cells, as well as increasing 
CD69 expression early on in division. The increase in overall proliferation may explain this 
increase in CD69 expression (or vice versa). In situ, it may be these T cells would be trapped within 
their lymph node, as CD69 prevents premature S1P1 re-expression (Shiow et al., 2006). These 
human B cells may be promoting T cell activation and proliferation to keep them within the lymph 
nodes, as CD69 is increased whilst S1P1 remains decreased. Futhermore, CD69 first increased 
before division, and then decreased with each subsequent division whilst S1P1 acted conversely, 
gradually increasing with each division as CD69 decreased. If B cells are promoting T cell 
activation to prevent S1P1 re-expression (and hence trapping T cells in the lymph node), further 
phenotyping of T cells could be done to determine if there are other markers, such as CCR7 or 
CXCR3, that would promote T cell entrapment within lymph nodes. Furthermore, an in vitro S1P 
chemotaxis assay could be used to determine whether T cell migration is impaired, as used by 
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previous studies (Roviezzo et al., 2004). In short, this would involve using a transwell, whereby 
cells would be placed in the upper chamber, and S1P in the lower chamber. The cells would be left 
to incubate for a few hours to allow chemotaxis through the transwell, and the number of cells 
present within the lower chamber (due to migration via S1P) would be counted. Various 
concentrations of S1P could be used to determine whether S1P-induced migration of T cells is 
affected after co-culture with B cells. 
 
6.4 IL-13 signalling pathway may play a role in mast cell activation of 
regulatory B cells 
IL-4 alone promoted murine mast cell production of IL-13, which is likely to be a key driver of 
B cell activation. Both IL-4 (Lundgren et al., 1989) and IL-13 (Punnonen et al., 1993) can induce 
IgE and IgG4 class switching in human B cells, as well as enhance their expression of CD23 
(Kawabe et al., 1988, Yokota et al., 1988, Defrance et al., 1994). From here, IgE may provide 
further signals to mast cells. Antigen-IgE complexes have been found to induce many effects on 
mast cells, including degranulation (Pfeiffer et al., 1985), increased IL-13 mRNA (Burd et al., 
1995) and protein (Toru et al., 1998) levels, and even induce de novo expression of MHCII (Raposo 
et al., 1997). These changes are consistent with the results I have reported. As mast cell-derived 
microvesicles have been found to package cytokines including TNF (Kunder et al., 2009), I 
therefore propose that microvesicles from IL-4-treated mast cells contain IL-13, which can push 
B cells to produce IgE. Once these microvesicle-activated B cells are in the presence of mast cells, 
they can act on them via IgE (as IL-4-treated mast cells also have an increased level of FcεRIα) that 
in turn promotes mast cell production of IL-13 (possibly to activate B cells further), and possibly 
MHCII expression. It is then important to consider how IL-4-treated mast cells increased 
production of IL-10 only after co-culture with B cells, as IL-10 has been found to suppress IgE 
production but increase IgG4 within human B cells (Akdis et al., 1998, Jeannin et al., 1998). 
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Furthermore, human B cells transfected to over-express IL-10 have been found to secrete less IgE 
(Stanic et al., 2015). As IgG4-producing B cells have been found to be a key source of IL-10 (van 
de Veen et al., 2013), mast cell-derived IL-10 may promote B cell class switching into this 
regulatory subset. 
 
When considering the effects of IgE and UV, it should be noted some patients suffer from a rare 
disease known as solar urticaria, whereby patients exposed to sunlight develop a rash (Duke, 1924). 
High levels of IgE are known to contribute to allergies (Johansson, 1967), as Allen et al. (2013) 
found a correlation between vitamin D insufficiency and food allergies in infants. Not only this, 
Vickery et al. (2013) found successful immunotherapy for peanut allergy required a switch from 
IgE to IgG4. It is possible that patients who suffer from UV-related allergies have an impaired 
activation of regulatory B cells. Jeannin et al. (1998) found that if IL-10 were added after human 
B cells class switched to IgE (after 3 days of IL-4 treatment), rather than during, IL-10 would 
promote IgE levels. If mast cell-derived IL-10 is required soon after initial B cell activation to allow 
class switching to IgG4, this may explain how blocking mast cell migration with AMD3100 
prevented UV-induced immune suppression (Byrne et al., 2008). Patients that suffer from allergies 
may not be able to activate regulatory B cells in time before over-activation with IgE. To prevent 
over-activation of B cells, CD213α2 may be upregulated to act as a decoy receptor against IL-13 
(Yasunaga et al., 2003), as well as activating CD23 to suppress further IgE synthesis (Sherr et al., 
1989). It may be worth considering whether microvesicle-activated B cells would remain 
functionally suppressive if exposed to mast cells after 3 days of co-culture, to allow time for class 
switching to IgE. If these microvesicle-activated B cells are undergoing class switching to IgE, but 
kept separated from mast cells for 3 days (as opposed to 2 days), mast cell-derived IL-10 may in 
fact promote IgE synthesis over IgG4, so these B cells may no longer be regulatory. This again 
highlights the possibility of impaired activation of regulatory B cells, which may be influenced by 
mast cell migration and function. 
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In the context of multiple sclerosis (MS), IgE levels appear to be decreased in both serum (Ansari et 
al., 1976, Barsoum et al., 1977) and cerebrospinal fluid (Nerenberg et al., 1978, Greve et al., 2001). 
These decreased levels of IgE may contribute to the increased level of soluble CD23 within MS 
patients (Zaffaroni et al., 1995), as IgE can stabilise CD23 on the membrane of cells (Lee et al., 
1987). As IgE-positive cells have been found within MS lesions (Toms et al., 1990) with IgE dimer 
formation on the surface of myelin (Calenoff, 2012), it may indicate a defect in mast cell-B cell 
interactions. IgE may further activate mast cells, which in turn induce B cell class switching to 
IgG4, which is expressed by a subset of regulatory B cells (van de Veen et al., 2013). In addition, 
IL-13 can promote B cell class switching to IgG4 (Punnonen et al., 1993). Although MS patients do 
not show a change in IgG4 levels within the cerebrospinal fluid (Eickhoff et al., 1979), there 
appears to be slightly less IgG4 levels within the serum of MS patients (Greve et al., 2001), which 
may reflect impaired activation of the aforementioned IgG4-producing regulatory B cells. 
Furthermore, MS patients treated with glatiramer acetate have a push towards a Th2 response from 
a Th1 response (Miller et al., 1998), with increased levels of serum IgG4 specific for glatiramer 
acetate (Farina et al., 2002, Basile et al., 2006). It may be that glatiramer acetate is driving the 
activation of regulatory B cells, as Ireland et al. (2015) found glatiramer acetate treatment of MS 
patients promoted B cell production of IL-10. It would hence be particularly interesting to 
investigate the levels of both IgE and IgG4 in the context of murine and human in vitro assays, by 
doing an ELISA on the supernatant after the mast cell-B cell co-culture. Although my human mast 
cell- and microvesicle-activated B cells could not suppress a T cell response in these particular 
assays, I hypothesise another source (such as CpG) is required for these B cells to become 
functionally suppressive. Due to the fact B cell receptor complex markers are upregulated on 
B cells after co-culture with IL-4-treated mast cells or their microvesicles, these receptors are prone 
for activation. 
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6.5 Conclusion 
In light of the complimentary murine and human studies, together with what is already known 
regarding UV immune suppression in vivo, I propose the following (as illustrated in Figure 6.1): 
Within a few hours of exposure to an immune suppressive dose of UV, dermal mast cells are 
exposed to IL-4. These IL-4-activated mast cells produce microvesicles that find their way freely to 
the skin-draining lymph nodes where they interact with B cells. This “B cell priming” stage occurs 
prior to mast cell migration to the B cell follicles in the same lymph nodes. Upon arrival in the 
lymph nodes, activated mast cells from the skin will engage in a cross talk with microvesicle-
primed B cells: an interaction that further influences the activation status of both mast cells and 
B cells. Co-operation between the mast cells and B cells contributes to an immunosuppressive 
environment (via production of IL-10, IL-13, and possibly IL-35). I further propose that these 
B cells are not yet functionally suppressive until exposure to an antigen, upon which these “pre-
regulatory” B cells can become fully activated into regulatory B cells. Antigen engagement will 
promote B cell proliferation and survival (facilitated by mast cell- and microvesicle-induced 
upregulation of certain markers, including BLNK, CD79b, IgM and CD23), to in turn suppress the 
induction of an immune response. 
  
Figure 6.1 – Proposed in vivo activation of regulatory B cells following UV. (1) Following UV exposure, mast cells are recruited to the skin 
in an IL-4-rich environment and are activated. (2) IL-4-treated mast cells produce microvesicles that travel to the skin-draining lymph node.
(3) Microvesicles from IL-4-treated mast cells prime B cells. (4) Mast cells (either untreated or IL-4-treated) cross-talk with 
microvesicle-activated B cells to induce further phenotypic changes in B cells. (6) Primed B cells are exposed to an antigen to activate B cells 
to be functionally suppressive.
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6.6 Future directions 
An unexpected outcome from my murine studies was the discovery that mast cells rather than the 
B cells were responsible for producing immunoregulatory cytokines (including IL-10, IL-13 and the 
subunits of IL-35). Future studies that investigate whether human IL-4-treated mast cells are also 
capable of producing such cytokines after an interaction with B cells is warranted. Furthermore, 
additional assays investigating IL-35, perhaps by targeting EBI3 and p35, as well as IL-13 
production from human IL-4-treated mast cells or B cells are needed. The murine studies described 
in Chapters 3 and 4 included detailed phenotyping of the mast cells, in addition to the B cells. It 
would therefore be worthwhile determining if similar phenotypic changes are occurring in human 
IL-4-treated mast cells, particularly CD25, HLA-DR, and intracellular cytokines including IL-10, 
IL-13 and IL-35. As well as this, detecting levels of IgE and IgG4 by ELISA in both the murine and 
human assays, or in serum, would be worthwhile because of the CD23-IgE interaction, as well as 
the ability of some regulatory B cells to produce IgG4. 
 
The phenotypic analysis of human B cells showed that many molecules could play a role in the 
activation of B cells (and mast cells). To test this, we could block specific receptors and/or 
cytokines with neutralising antibodies. It is already well known that neutralising anti-IL-4 
(Shreedhar et al., 1998a) and anti-IL-10 (Beissert et al., 1996) can block UV-induced immune 
suppression in vivo. Whether downstream cytokines, particularly IL-13, are also amenable to 
neutralisation is not known. This would be a relevant follow on experiment to my studies because 
of the changes observed in both IL-13 (in the murine assays) and its receptor (in the human assays). 
Anti-IL-13 could be added during mast cell activation via IL-4 (as IL-13 was upregulated, and may 
be interacting in an autocrine/paracrine manner), as well as during the mast cell-B cell co-culture. 
This would give further insight into the importance of IL-13 in the interaction between mast cells 
and B cells. Furthermore, blocking CD23-IgE interactions would also be interesting, and would 
help determine whether this pathway of signalling is required for the activation/possible 
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maintenance of regulatory B cells. Finally, blocking CD120a/CD120b would verify the role of 
TNF, which was increased in human B cells after co-culture with mast cells (independently of IL-4 
treatment). 
 
Forming part of my conclusion is the hypothesis that antigen is needed in the final stages of 
regulatory B cell activation. However, verification of the role of B cell antigens, particularly UV-
induced lipids and oxidised proteins is still required. Therefore, another important experiment 
would involve testing the human B cell-T cell co-culture in the presence of an antigen (such as 
MOG, a glycoprotein commonly used to induce EAE in mice). Alternatively, or in concert with 
these experiments, I could include polyclonal B cell-activating reagents (such as CpG or anti-µ) to 
promote B cell activation and their suppressive capabilities. Because these reagents activate all 
B cells, and not just those of interest (particularly CD23+ transitional B cells), they were not 
included in my assays. If all B cells are activated, those that activate a T cell response may 
overshadow those with regulatory capabilities. 
 
A key finding to come out of my human studies was that individual subsets (particularly CD23+ 
transitional B cells) appeared to be particularly affected by mast cells and their microvesicles. To 
confirm the regulatory nature of these subsets will require careful sorting and further testing. This 
would include a repeat of the human T cell assays, to determine whether individual B cell subsets 
have differential effects on T cell proliferation and/or cytokine production. As well as this, it would 
be interesting to delve into the genetic make-up of subsets, by doing RNA-sequencing. This would 
allow a wide screen into any changes in the transcriptome of B cells, and provide insight into future 
experiments. 
 
In the context of MS, the real interest is developing treatment options against this disease. As such, 
further experiments investigating how the mast cells and their microvesicles are activating 
regulatory B cells are of interest. This would involve investigating what the mast cells may be 
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packaging into microvesicles, and what the mast cells themselves may be expressing that can 
provide further influence over B cell activation. My work investigated the levels of platelet-
activating factor (PAF) in murine mast cells and their microvesicles after IL-4 treatment, as both 
PAF and serotonin receptors are required for UV-induced activation of B cells in vivo (Matsumura 
et al., 2006). Although there was no noticeable difference in PAF from mast cells or their 
microvesicles after IL-4, other lipids may play a role in the activation of B cells. One such lipid is 
leukotriene B4 (LTB4), which can be produced by mast cells (Mencia-Huerta et al., 1983, Ott et al., 
2003, Weller et al., 2005), and is upregulated after UV irradiation of human fibroblasts in vitro 
(Yan et al., 2006). Regulatory B cells can be activated by LTB4 (Wejksza et al., 2013), and 
therefore mast cells may activate B cells by this mechanism. To address this, mass spectrometry 
could be done to target LTB4 levels and determine whether IL-4 treatment of mast cells affects its 
level of production. Furthermore, proteomic studies could also be implemented using mass 
spectrometry. It is possible to run a “scan” on lipids or proteins, which identifies a wide range of 
molecules based on their mass. This allows a direct comparison between untreated and IL-4-treated 
samples, and will highlight any differences. Although this does not allow identification of specific 
molecules, it does give insight into the size of these molecules, which can be identified by 
additional experiments. 
 
In addition, phenotyping B cells in untreated and treated MS patients would also be of interest, to 
determine if there are any phenotypic differences compared to healthy controls. These 
investigations may reveal less CD23 expression on B cells, as it is already known that soluble 
CD23 is increased in MS patients (Zaffaroni et al., 1995). My data provide evidence that CD23+ 
transitional B cells are phenotypically regulatory. For this to be relevant it will be important to 
assess whether this subset of B cells is impaired during MS. 
 
In the context of using cell-derived microvesicles to activate cells, it is worth considering the 
observation by Maity et al. (2015), whereby IgM receptors on B cells clustered together, but when 
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activated with a specific antigen began to move apart. If this B cell receptor clustering were a 
preferential site for microvesicle formation, it would allow B cells to transfer antigen-specific 
receptors to target cells, rather than a mix of all surface receptors. Indeed, Quah et al. (2008) found 
LPS-activated murine B cells can transfer the B cell receptor complex to bystander B cells. If 
B cells are preferentially clustering markers for release via microvesicles, it would be interesting if 
a similar event occurs in other cell types, particularly as during my Honours I found microvesicles 
from murine IL-4-treated mast cells were capable of activating functionally suppressive B cells 
(Marsh-Wakefield, 2012). It may be that mast cells express certain molecules that cluster prior to 
being released on a microvesicle. To address this, mast cells could be imaged for receptor clustering 
after IL-4 treatment, as done by Maity et al. (2015). Imaging could also be done on mast cell-
derived microvesicles, to determine whether these microvesicles likewise have clustering of the 
same receptors found on the mast cells. If this is the case, it would provide further insight into how 
IL-4-treated mast cell-derived microvesicles are capable of activating B cells. 
 
One possible method of developing treatment options involves the modification and engineering of 
vesicles. Synthetic vesicle formation involves emulsifying a soluble product (such as a protein) 
alongside a hydrophobic polymer that will encapsulate the product (such as poly(lactic-co-glycolic 
acid)) (McGinity and O'Donnell, 1997). Emulsification (such as through homogenisation) forms 
droplets containing the product. The speed of the rotor will affect droplet size, whereby an increase 
in speed will decrease droplet size. As the solvents evaporate these droplets will harden and vesicles 
can be obtained. Kheir et al. (2012) filled vesicles with oxygen to promote oxygen intake in rabbits, 
while Wang et al. (2012) engineered vesicles to progressively release IL-7 to enhance T cell levels 
in mice. Intranodal injection of vesicles into mice can even promote lymphocyte activation (Jewell 
et al., 2011), suggesting they may potentially be used to directly influence the immune system in 
diseases as a means of treatment. Nanoparticles have likewise been developed with myelin antigen 
to attenuate EAE, by reducing CNS-infiltration of encephalitogenic Th1 and Th17 cells (Hunter et 
al., 2014). Some have been produced to contain IL-10, which ameliorated and enhanced survival of 
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mice with spontaneous gastrointestinal polyposis (Chung et al., 2014). It is also worth pointing out 
the potential for stimulating T cell activation via MHCII. Clemente-Casares et al. (2016) conjugated 
MHCII to nanoparticles alongside self-antigens to promote a shift to regulatory-like T cells. These 
in turn were capable of promoting IL-10-producing B cells, but most interesting was the fact that it 
was antigen-specific, such that if an antigen against an EAE protein was used it could grant 
protection from EAE but not an animal model of rheumatoid arthritis. If the molecular mechanism 
by which IL-4-treated mast cells activate B cells were determined, it may be possible to load 
synthetic vesicles for administration to induce B cell activation and immune suppression. 
Manipulation in this way could lead to more targeted, safer and potentially more effective 
“weapons” than that provided by nature alone.  
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Appendix 
 
 
 
 
Josephine understood the importance of words and the 
sharing of knowledge, but also the limitations that come with 
them. How can words – made up of nothing more than lines 
on a piece of paper – represent and hold everything I have 
done? But as the last “i” was dotted and “t” was crossed, 
Josephine looked back at her work to realise the issue of an 
ending. It was exactly that: an ending. The finale was yet to 
come… 
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Appendix A – Basic gating strategy for cells. All flow cytometry was first gated on
(A) time for consistent uptake of cells. (B) then gated on cells, followed by (C) single cells. 
Further gating was done based on these single cells for analysis.
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Appendix B – Gating strategy for IL-4-treated mast cells of p28 and p35. Bone 
marrow-derived mast cells were first treated (or not) with 0.4 µg mL–1 IL-4 for 48 hr at
1 x 106 cells mL–1. They were then stimulated with PMA (50 ng mL–1), ionomycin
(500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM) 5 hr prior to conclusion of culture. 
Samples were then stained with (A) anti-p28-PE or (B) anti-p35-eFluor 660 antibodies for 
intracellular flow cytometry (representative flow plots are shown).
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Appendix C – Gating strategy for IL-4-treated mast cells of p28 and p35 after 
co-culture with B cells. Bone marrow-derived mast cells were first treated (or not) with 
0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. These were then co-cultured at a 1:10 ratio 
with isolated splenic B cells for 48 hr. They were then stimulated with PMA (50 ng mL–1), 
ionomycin (500 ng mL–1), LPS (10 µg mL–1) and monensin (2 µM) 5 hr prior to conclusion 
of culture. Samples were then stained with (A) anti-p28-PE or (B) anti-p35-eFluor 660 
antibodies for intracellular flow cytometry (representative flow plots are shown).
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Appendix D – Gating strategy for B cells of p28 and p35. Bone marrow-derived mast 
cells were first treated (or not) with 0.4 µg mL–1 IL-4 for 48 hr at 1 x 106 cells mL–1. These 
were then co-cultured at a 1:10 ratio with isolated splenic B cells for 48 hr. They were then 
stimulated with PMA (50 ng mL–1), ionomycin (500 ng mL–1), LPS (10 µg mL–1) and 
monensin (2 µM) 5 hr prior to conclusion of culture. Samples were then stained with
(A) anti-p28-PE or (B) anti-p35-eFluor 660 for intracellular flow cytometry (representative 
flow plots are shown).
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Appendix E – Mass spectrometry standard curve. (A) shows the relative abundance of 
deuterated-4 PAF and 1 nM carbamyl PAF. The highlighted peaks are representative of the 
area calculated to develop the standard curve (B). The R2 value is reported.
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Appendix F – Confirmation of magnetic bead separation of human B cells and
T cells from blood by flow cytometry. Human peripheral blood monocytes were first 
isolated (before). Anti-CD34 magnetic beads were used to isolate cells for human mast 
cell cultures (flow not run due to low numbers). Remaining cells were then stained with 
anti-CD19 magnetic beads to remove CD19+ cells. Then anti-CD25 and CD4 to remove
T cells. The following flow plots run in descending order of cell isolation. Each negative 
fraction was then stained with the next magnetic beads. Dot plots show purity of isolation 
compared to the negative fraction. CD25 separation also includes a histogram 
representing the level of CD25 expression from the positive (solid line) compared to the 
negative fraction (grey fill).
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Appendix G – Gating strategy for human mast cell-B cell co-culture by mass 
cytometry. Each sample is spiked with beads for normalisation in case detectors fail 
during a run. These are positive for multiple metal isotopes, and can be gated out as no 
markers are present on Ce140, shown in (A). B cells and mast cells (row B) are separated 
based on their expression of HLA-DR. Figures shown include B cells alone (first column), 
untreated mast cells alone (second column) and a co-culture of B cells with untreated mast 
cells (third column). DNA intercalator stains all cells. Note these gates can differ between 
individual samples. (C) Cisplatin is the first stain on cells, indicating live/dead cells.
(D) Single cells are determined by the level of DNA, such that doublets will express higher 
levels of DNA.
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Appendix H – ‘Bleeding’ due to metal isotopes. Samples were stained and run for mass 
cytometry. The left column shows B cells alone, whilst the right column shows B cells that 
were cultured with microvesicles from IL-4-treated mast cells. (A) shows how IgM(172Yb) 
bleeds in to Blimp-1(171Yb). The top two figures contain no intracellular antibody, whilst 
the bottom two show the addition of anti-human Blimp-1. (B) shows IgM(172Yb) bleeding 
in to CD213α(<E (C) shows CD23(144Nd) bleeding in to CD120b(160Gd). For all 
figures, the x-axis is bleeding in to the y-axis.
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Appendix I – Gating strategy for human T cell cytokine production. Human peripheral 
blood-derived mast cells were treated with 10 ng mL–1 IL-4 for 48 hr. Cells and 
microvesicles were then collected and co-cultured with B cells (previously frozen for each 
patient) at a 1:10 ratio mast cells:B cells for a further 48 hr. These were then co-cultured 
with CD4+ CD25– T cells for 1 hr at a 10:1 ratio B cells:T cells, followed by stimulation with 
T cell simulation beads conjugated with anti-CD2, anti-CD3, and anti-CD28 (1 bead/100 
cells) for 72 hr, followed by flow cytometry staining. The left column represents CD4+ 
CD25– T cells alone without stimulation beads added; the middle column shows CD4+ 
CD25– T cells alone with stimulation beads added; and the right column shows B cells that 
were left alone and then cultured with CD4+ CD25– T cells and stimulated. Cells were 
stained with anti-CD3-PE, anti-CD117-APC and IFN-Ȗ-BV421 (A) shows previously gated 
single cells (Appendix A), followed by gating T cells using CD3. (B) shows the level of 
I)1-Ȗ E\ 7 FHOOV Bold numbers represent the median frequency and interquartile range is 
in italics.
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Appendix J – ELISA standard curves. These are representative graphs of ELISA 
standard curves that were used to calculate the concentrations of IL-10 and IL-35 
production. The R2 values are reported. The limits of detection were 0.63 ng mL–1 IL-35 
and 2.1 pg mL–1 IL-10.
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Appendix K – Changes in marker expression of human transitional B cells 
compared to B cells alone. This table represents significant increases (blue), decreases 
(red) or no change (grey) in transitional B cells after co-culture with untreated mast cells 
(uMC) or their microvesicles (uMV), IL-4-treated mast cells (tMC) or their microvesicles 
(tMV), when compared to B cells alone. For those that have figures, the figure number is to 
the right of the relevant markers. n = 6-8 different human donors from 4-5 independent 
H[SHULPHQWV :LOFR[RQ WHVW 1RWH C'E C'α DQG %OLPS- DUH QRW VKRZQ GXH WR WKH 
bleeding effect (Appendix H). 
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Transitional B cells
Increase Decrease No change
Marker expression compared to B cells alone
Figure 5.6
Figure 5.7
Figure 5.8
Figure 5.9
Figure 5.10
Figure 5.12
Figure 5.13
uMC tMC uMV tMV
HLA-DR
CD19
CD79b
IgD
IgM
BLNK
CD80
CD86
CD274 (PD-L1)
CD25
CD184 (CXCR4)
CD210
CD120a
CD213a2
CD267 (TACI)
IL-10
TNF
CD23
CD20
CD24
CD137L
S1P1
CD27
CD38
CD138
CD117
ADIPOR1
CD275 (ICOSL)
PAF receptor
5-HT2A receptor
FoxP3
 289 
I’ve never been good at endings, and for something like this I think it’s best to leave it to a 
professional: 
 
“ 
There was no light, no point of reference except for the two tiny blue pinpricks sparkling in the eye 
sockets of Death himself. 
‘Well, the journey was worth taking and I saw many wonderful things on the way, including 
you, my reliable friend. Shall we go now?’ 
MADAM, WE’VE ALREADY GONE. 
” 
– The Shepherd’s Crown, Terry Pratchett 
 
 
